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Abstract 
There is accumulating evidence that reactive nitrogen species derived from nitric oxide 
metabolism are involved in cancer as they are able to damage DNA largely through oxidation 
or nitration of the guanine base. The 8-nitroguanine lesion is increasingly associated with 
cancers that result from chronic inflammation; however due to its instability, very little is known 
about this base modification. Consequently this thesis focuses upon establishing methods to 
detect and quantify the lesion and investigate enzymes potentially involved in repair systems 
directed against 8-nitroguanine in DNA. 
The approach outlined in this thesis utilises ribonucleoside analogues of the lesion which 
sufficiently stabilised the labile glycosidic bond. The 8-nitroguanine nucleosides were prepared 
prior to incorporation into the oligodeoxynucleotide sequences using the traditional 3’- to 5’-
solid-phase phosphoramidite chemistry. A number of oligodeoxynucleotides of varying lengths 
containing a single modification, and dinucleotides containing two modifications were prepared. 
A variety of reactions of the 8-nitroguanine base both in nucleosides and 
oligodeoxynucleotides have been investigated. Studies revealed a different pattern of 
alkylation for the modified base when compared to results reported in the literature for the 
natural nucleoside. Thus demonstrating the dramatic effect that nitration has on the intrinsic 
reactivity of the nucleoside. In view of the susceptibility of nitro group to reaction with thiol 
nucleophiles, displacement of the nitro group from within nucleosides and 
oligodeoxynucleotides has been achieved. In particular a fluorescent nucleophile has been 
developed which stabilises the lesion and could enable direct detection of the levels of 8-
nitroguanine in DNA. 
Using a variety of substrates prepared in this thesis, detection of the 8-nitroguanine base in 
oligodeoxynucleotides has been investigated using surface enhanced Raman spectroscopy in 
collaboration with Professor Steven Bell at Queen’s University, Belfast. The unique absorption 
profile of the 8-nitroguanine derivatives allows for signals exclusively associated with the lesion 
to be identified using this highly sensitive technique. 
The synthesis of 8-nitroguanosine triphosphate was investigated using a number of different 
approaches. Although the initial aim was not successful, the principles for the phosphorylation 
of a nucleoside have been shown. The problems encountered were attributed to the 
conformational constraints of the molecule.  
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1 Introduction 
1.1 A brief history of DNA 
The history of DNA began in 1869 when Friedrich Miescher became the first person to isolate 
a substance later to be recognised as the hereditary material1. Due to the localisation of the 
substance in the nucleus Miescher termed the compound ‘nuclein’, this later became known as 
a nucleic acid which was found to more accurately describe the nature of the compound2. 
Interest in DNA was renewed in the 1940s when Avery, MacLeod and McCarthy demonstrated 
that DNA is the carrier of genetic information3. In the following years, a number of research 
efforts revealed important details about the structure of DNA which provided the foundation 
from which Watson and Crick derived the three dimensional structure. Noteworthy 
contributions include; Chargaff’s revelation that the proportion of adenine in a nucleic acid was 
equal to the proportion of thymine and likewise, the proportions of guanine and cytosine were 
equivalent4 and the crucially important X-ray crystallography work by Rosalind Franklin and 
Maurice Wilkins that determined DNA has a regularly repeating helical structure5,6. The 
molecular structure of DNA was deciphered in 1953 by James Watson and Francis Crick7,8, 
who along with Wilkins received the Nobel prize for chemistry in 1962 for their ground breaking 
discovery. The discovery that hereditary information was contained in DNA and with the 
molecular structure now known, interest in how it could be faithfully replicated was a key 
question. A decade later in the 1960s, Holley, Khorana and Nirenberg cracked the genetic 
code9. 
The knowledge provided by these pioneers in nucleic acid research, has led to continued 
advances in the understanding of the human genome; the complete sequence of which was 
published in 200110. Examining the structure of DNA and how it functions has unlocked an 
interesting and important area of research and led the study and development of therapeutics 
and diagnostics for many diseases. 
1.2 Composition of nucleotides 
Knowledge of the structural features of nucleic acids is vital in understanding their biological 
function. In order to explore the structures derived from DNA damage and their significance, it 
is first appropriate to discuss the nomenclature, principles and key features which define 
nucleic acids.  
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The features defining the primary structure of DNA are ultimately responsible for its secondary, 
tertiary and quaternary structure. DNA is a linear polymer which encodes information through a 
series of monomers called nucleotides. A nucleotide is a repeating unit which is comprised of 
three distinct components: the sugar, the heterocyclic base and the phosphate group.  
The heterocyclic base is attached to the pentose sugar at the anomeric position via a β 
glycosidic bond; this condensation product is characterised as a nucleoside. Nucleosides 
polymerise by the formation of a phosphate ester upon phosphorylation of one of the hydroxyl 
groups of the pentose sugar. The bases are not involved in the polymerisations; hence the 
chain is held together by a sugar – phosphate backbone from which the bases extend11. The 
sugar – phosphate backbone acts as a constraint on the conformational space that is 
accessible to the base pairs2. 
1.3 The sugar 
In both RNA and DNA a pentose sugar which has been locked into a five membered furanose 
ring conformation is present. One of the two inherent structural variations between DNA and 
RNA is the substitution of a hydrogen atom with a hydroxyl group at the second carbon in the 
ring. In DNA the pentose sugar is 2-deoxy-D-ribose, whereas in RNA it is D-ribose. The 
numbering system for the sugar atoms is noted in Figure 1.1, with these being distinguished 
from those of the base atoms by a prime. 
 
Figure 1.1: The pentose sugar numbering scheme for DNA (left) and RNA (right). 
The distinctly different behaviour of the 2’-deoxyribose and ribose systems reveals information 
of critical importance to the global structure of nucleic acids and their biological function. Due 
to energetically unfavourable eclipsing interactions of adjacent bonds, the atoms in the five 
membered furanose ring cannot adopt a planar structure12. Puckering of the system reduces 
the steric conflict experienced due to eclipsed groups. The puckering of the ribose ring gives 
rise to two main structural conformations, the envelope (E) and the twist (T). In the envelope 
conformation one atom is displaced from the plane formed by the other four atoms. In the twist 
conformation two adjacent atoms are displaced from the plane formed by the other three 
atoms; one is above, one is below the plane13. 
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The pucker is described in terms of which atom in the ribose ring is displaced furthest out of 
plane. Conformations in which the atom displaced furthest from the plane resides on the same 
side as both the C5’ and the heterocyclic base are termed endo. When in the opposite 
orientation the conformation is termed exo14.  
In general, there are two principle low energy conformations which best alleviate steric conflict 
observed for all 2′-deoxyribose and ribose sugars: C3′-endo and C2′-endo (Figure 1.2). The 
terms ‘North’ (N) and ‘South’ (S) are often used to describe the C3’-endo and C2’-endo 
conformations respectively. While this terminology refers to their geographic positions on the 
pseudorotational cycle15, the notation is also representative of the shape of the chain of 4 
carbon atoms in the ring.  
 
Figure 1.2: C1’-O4’-C4’ shown in red (left) are in plane perpendicular to the paper. Simplified versions of 
the two principle sugar puckers C3’-endo (centre) and C2’-endo (right) are also shown. Note X = H or OH. 
The substitution of the hydrogen at the C2’ position in deoxyribose with a hydroxyl group in 
ribose accounts for the difference in preferred puckering modes of DNA and RNA. 
Interconversion between the various conformations of the sugar, known as pseudorotation, is 
possible due to the energy barrier separating the two preferred conformers being less than 20 
kJ mol-1 16. However the presence of substituents on both the endo and the exo face introduce 
a potential energy barrier that can oppose free pseudorotation.  
The position of the equilibrium between the two preferred conformational states is determined 
by stabilising stereoelectronic effects, the strongest of which arise from gauche interactions 
(60º dihedral angles). The gauche interaction is the tendency of X-C-C-Y containing systems, 
where X and Y are electronegative groups, to adopt a gauche conformation. In sugars, the 
stabilisation is as a result of the donation of electron density from a C-H bonding orbital to an 
adjacent C-O antibonding orbital; this can only be achieved when the bonds are in an 
antiperiplanar orientation17. There are several gauche interactions in the 2’-deoxyribose and 
ribose systems. 2′-Deoxyribose has two gauche interactions, the most important of which is 
O4′-C4′-C3′-O3′, while ribose has three additional gauche interactions most importantly O4′-
C1′-C2′-O2′ (Figure 1.3). 
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Figure 1.3: A Newman projection of C2’-endo and C3’-endo gauche interactions. 
The second and relatively weaker stabilising stereoelectronic effect which plays a role in 
determining the preferred conformational state of the sugar is an anomeric interaction18. The 
anomeric effect is applicable to chemical systems C-X-C-Y, where X has at least one set of 
lone pair electrons and Y is an electronegative atom. It describes the tendency of the lone pair 
on O4’ to orient antiperiplanar to the antibonding orbital of the C-Y bond. This geometry allows 
orbital interactions in which the lone pair on O4’ can donate into the antibonding orbital which 
is energetically favourable (Figure 1.4)17. 
 
Figure 1.4: Showing the anomeric interaction highlighted in red. 
The structurally asymmetric 2’-deoxyribose ring exhibits a preference for the C2’-endo 
conformation over the C3’-endo conformation. This preference is due to the gauche effect of 
the O4’-C4’-C3’-O3’ fragment, which is stronger than the anomeric effect. Therefore the 
dominating gauche interaction drives the pseudorotational equilibrium towards S type 
conformations19. 
In ribose however, the presence of a hydroxyl group in the 2’-position changes the situation. 
The additional gauche interaction from the O4’-C1’-C2’-O2’ counteracts the stabilisation 
provided by the O4’-C4’-C3’-O3’ fragment. Therefore based on gauche interactions alone there 
would be no preference for either the C2’-endo or C3’-endo conformation. The conformational 
behaviour can therefore be attributed to the anomeric effect in this complex system. The extra 
stabilisation provided by the anomeric effect, in which a pseudo-axial heterocyclic base 
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conformation is preferred, means that the O4’-C4’-C3’-O3’ gauche interaction predominates 
and the C3’-endo conformation is preferred20. 
1.4 The heterocyclic base 
The heterocyclic base forms the distinguishing component of nucleosides. There are five 
bases which occur naturally, three of which are common to both DNA and RNA: adenine (A), 
cytosine (C) and guanine (G). Thymine (T) and uracil (U), differing only by the absence of a 
methyl substituent, are found in DNA and RNA respectively. These bases can be categorised 
into two groups based on their structure: purines and pyrimidines. The purines, consisting of A 
and G are bicyclic molecules, whereas the pyrimidines consisting of C, T and U are smaller 
monocyclic structures. The chemical structure and numbering system for the bases according 
to the IUPAC-IUB21 are shown in Figure 1.5. Groups appended to the ring are given the same 
number as the position to which they are linked. 
 
Figure 1.5: The heterocyclic base numbering scheme for purines and pyrimidines. 
In relation to the sugar moiety, the base effectively lies in a perpendicular plane and 
approximately bisects the O4’-C1’-C2’ angle2. The base can adopt one of two main 
orientations about the glycosidic bond (Figure 1.6). The most stable and consequently most 
prevalent of these is the anti conformation. This describes the situation where the main bulk of 
the base is orientated away from the sugar ring; this reduces the steric hindrance and 
interactions which may occur between the CO and NH groups in positions 1, 2 and 6 of the 
purine ring (or 2 and 3 of the pyrimidine ring) and the sugar. In the alternative syn 
conformation, the position of the glycosidic bond is such that the base in oriented above the 
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sugar ring which can result in unfavourable steric interactions. While the syn conformation is 
less commonly observed as it tends to be somewhat higher in energy, it affords a more 
compact nucleoside which may be of biological importance22.  
 
Figure 1.6: Anti (left) and syn (right) nucleoside conformations. Note X = H or OH. 
The higher energy syn conformation can be stabilised by internal hydrogen bonding between 
the sugar and the base; this is often accompanied by changes in the sugar pucker. The barrier 
between the anti and syn conformations in deoxyribonucleosides is found to be less than 42 kJ 
mol-1 and tends to be lower with purines than with pyrimidines23. 
It has been shown that in certain cases guanine preferentially adopts the syn conformation. 
This is probably as a result of the formation of a hydrogen bond between the N2 amino group 
and the 5’-phosphate; however other stabilising interactions have been suggested23. This 
characteristic of guanine can result in formation of unusual structures in G rich sequences, 
such as in G-quadruplexes. 
Substitutions at the C8 position of a purine base can also result in destabilisation of the anti 
conformation causing the base to preferentially adopt the syn conformation24. For example, 
replacing the C8 hydrogen in guanine with a bromine atom, forming 8-bromoguanosine, 
prevents the close packing relationship with the C2’ hydrogen25. Additionally the steric 
influence of the bromine atom limits free rotation around the glycosidic bond therefore the syn 
conformation is maintained; as confirmed by X-ray crystallography26. 
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This finding is significant as the conformational preference of nucleosides and thus base 
pairing can be affected by introducing steric hindrance and hydrogen-bonding interactions to a 
nucleotide. There are various other situations in which the syn conformation is favoured that 
will be discussed in more detail later in the chapter. 
1.5 Base pairing 
The structure of DNA determined by Watson and Crick describes the pairing of bases, which is 
a crucial feature in storing, directly copying and transforming genetic information. Therefore the 
most common base pairing model encountered in nature is known as Watson-Crick base 
pairing; which was founded on the idea that adenine pairs to thymine and guanine to cytosine. 
This not only takes into account Chargaff’s rule, but also the structural parameters of the 
double-helix determined by X-ray crystallography. 
Naturally occurring bases present predominantly in their keto and amino tautomeric forms; this 
is an important requirement in the correct recognition of their respective base pairing partner. 
The hydrogen bonding involved in forming base pairs can be considered as an electrostatic 
interaction between an acidic proton and a good electron donor and play a key role in 
stabilising the secondary structure of DNA. The sp2 hybridized lone electron pairs on both the 
oxygen and nitrogen atoms of the base act as hydrogen bond acceptors, while the NH groups 
are good hydrogen bond donors. The average strength of these hydrogen bonds is between 6 
– 10 kJ mol-1 2.  
Each base pair consists of one purine and one pyrimidine. Adenine is always coupled with 
thymine in DNA and uracil in RNA via the formation of two hydrogen bonds. Guanine is always 
coupled with cytosine in both DNA and RNA forming three hydrogen bonds, making this base 
pair more thermodynamically stable2,7,27. Accordingly, these are known as complementary 
base pairs. The two pairing arrangements have similar overall shapes and fit specific 
geometric requirements, so that any sequence could be accommodated within the same 
double-helix framework. This accounts for the fact that although the Watson-Crick A:T(U) base 
pair is not favoured energetically like the G:C base pair, it is still the preferred conformation 
due to the steric constraints of the sugar phosphate backbone14. 
Karst Hoogsteen reported an alternative hydrogen bonding arrangement, based on a crystal 
structure, in which A and T formed a base pair that had a different geometry to that previously 
reported. Similarly, an alternative base pairing geometry can form between G and C using this 
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arrangement. Hoogsteen base pairs require rotation of the base about the glycosidic bond in 
order to utilise the syn face of the purine for hydrogen bonding with the anti face of the 
pyrimidine28. The Hoogsteen G:C base pair differs from that of Watson-Crick as, not only is the 
N7 imidazole nitrogen used in hydrogen bond formation, but the cytosine base requires 
protonation and only 2 hydrogen bonds are formed. Consequently the chemical properties of 
the heterocyclic bases in this model are significantly different to that of the Watson-Crick base 
pairing. 
 
Figure 1.7: Watson-Crick (top) and Hoogsteen base paring (bottom). 
Hoogsteen base pairing expands the structural and functional versatility of DNA and RNA and 
these hydrogen bonding arrangements are often found in multi stranded structures29. 
1.6 The double-helix 
The original structure of DNA, proposed by Watson and Crick in 1953 consists of two right-
handed polynucleotide strands that are coiled about the same axis7,8. Using X-ray 
crystallography data, it was determined that the helical structure repeats every 10 residues and 
the space occupied by each nucleotide in the sequence is 3.4Å. The hydrophilic sugar 
phosphate backbone is positioned on the outside of the helix and the heterocyclic bases 
project inward toward the hydrophobic centre so that they can interact with one another. The 
negatively charged phosphate groups of the backbone are mutually repulsive and contribute to 
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the rigidity of the molecule30. The two strands are arranged in an anti-parallel orientation; this 
relates to the 5'-end of one strand aligning with the 3'-end of the other strand. 
While the formation of DNA duplexes is strongly favoured by the formation of numerous 
bonding interactions, entropically the process is unfavourable due to restrictions being applied 
to the otherwise flexible backbone31. The entropic consideration is an aspect of molecular 
biology which is unavoidable. This unfavourable interaction is overcome as DNA polymerases 
pre-organise the molecule into the conformation necessary for DNA synthesis32. 
The structure of the DNA duplex is governed by a balance of non-covalent interactions in polar 
solvents. The hydrogen bonding between complementary bases discussed previously is one of 
the three important interactions which stabilise the double-helical structure. The major 
contributor to duplex stability is base stacking interactions between adjacent base pairs33,34. 
The main principles which contribute to the π-π interactions between planar DNA bases are; 
van der Waals dispersive forces (permanent dipole/induced dipole and induced dipole/induced 
dipole interactions), the permanent electrostatic effects of interacting dipoles and the 
entropically favoured exclusion of water from the hydrophobic interior of the duplex. The 
strength of the base stacking interaction is dependent on the base sequence. Purines stack 
more strongly than pyrimidines presumably due to the larger surface area and greater 
polarisabilty31. Additionally, the stabilisation conferred by solvent interactions between water 
molecules and the hydrophobic sugar phosphate backbone plays a role in the overall duplex 
stability. 
Double-helical nucleic acids exhibit two characteristic grooves known as the major and the 
minor grooves. As the names suggest the grooves are asymmetrical. These grooves are a 
result of spaces that are present between the sugar phosphate backbones of each 
polynucleotide strand2. Potential hydrogen-bond donor and acceptor atoms line both the major 
and minor grooves; therefore these regions have the potential to interact selectively with 
proteins31. 
1.7 Structural polymorphism 
DNA occurs in three major structural forms: A-DNA, B-DNA and Z-DNA. This structural 
polymorphism is dependent on its environment and occasionally its primary structure. Table 
1.1 lists some of the key defining structural parameters of the three forms of DNA helices35.  
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Parameter A-DNA B-DNA Z-DNA 
Helical Sense Right handed Right handed Left handed 
Residues per turn 11 10 12 
Axial rise (Å) 2.9 3.4 3.7 
Helical pitch (Å) 24.6 33.2 45.6 
Base tilt (º) 20 -6 7 
Twist angle (º) 32.7 36 -30 
Helix diameter (Å) 23 20 18 
Sugar pucker C3’-endo C2’-endo C3’-endo(syn) 
Table 1.1: Structural parameters of DNA Helicies2,35. 
B-DNA is the most common form and adopts the structure as first described by Watson and 
Crick. B-DNA is a right handed helix and it is the predominating form under physiological 
conditions. It has an elongated structure with a helical diameter of 20Å. The helix features a 
wide major groove with a diameter of 11.7Å (depth of 8.5Å) and a narrow minor groove 
measuring 5.7Å in width (depth of 7.5Å). A-DNA, also a right handed helix, is a broader more 
compact form with a helical diameter of 23Å. The major groove of A-DNA is comparatively slim 
with a width of 2.7Å but is far deeper than the in B-DNA with a depth of 13.5Å; naturally the 
minor groove is wide (11Å) and shallow (2.8Å) to accommodate for this2,36,37. 
Water is crucial to the conformation and hence biological functions of double-helical DNA. 
Research has shown that the number of water molecules per nucleotide must be greater than 
20 for B-DNA to be stable38. This explains why this structure is favoured under standard 
hydrated physiological conditions. Upon dehydration A-DNA is formed. The A-DNA structure is 
found in RNA irrespective of the environment and in DNA/RNA hybrids39. 
Many of the structural differences between B-DNA and A-DNA arise from the different 
conformation adopted by the deoxyribose sugar. Within B-DNA duplexes a C2’-endo pucker is 
adopted, whereas in A-DNA, the sugar conformation is generally restricted to the C3’-endo 
orientation. Consequently this conformation is favoured by RNA duplexes as additional 
stabilisation is gained by an intra-strand hydrogen bond between the O4’ of one nucleotide and 
the 2’-hydroxyl group on the next nucleotide in the sequence. This accounts for A-DNA forming 
a wider and flatter helix2. 
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The placement of each base pair with respect to the helical axis presents another major 
structural variation between A-DNA and B-DNA. In B-DNA, the base-pairs are essentially 
perpendicular the helical axis, but in A-DNA, they are displaced away from the central axis and 
closer to the major groove30,37. The base pairs are positioned 4.5Å away from the central axis 
which leaves a hollow cylindrical core 3Å in diameter. In addition, a positive tilt of 20º allows a 
van der Waals separation of 3.4Å to be maintained2.  
In 1979 a third, infrequently observed form of DNA was discovered when Rich et al. solved the 
structure of the hexamer dCGCGCG40. While the structure was in the antiparallel arrangement 
and held together by Watson and Crick base pairs, the fragment formed a left handed (Z-DNA) 
helix41. Z-DNA is thinner with an 18Å helical diameter and is more elongated in comparison to 
B-DNA. There is only one narrow, deep groove present in the structure which is equivalent to 
the minor groove in B-DNA; the major groove is not discernible37,42. The repeating unit in Z 
DNA is a dinucleotide which is in further contrast to A- and B-DNA in which the repeating unit 
is a mononucleotide43.  
It is known that the formation of Z-DNA is highly composition and base sequence dependent, 
generally being confined to alternating purine and pyrimidine sequences43. The purine bases 
are rotated about their glycosidic bond so that the base assumes the syn conformation while 
the pyrimidine bases remain in the anti conformation30. The alternating sugar pucker 
conformation in Z-DNA is unusual as purine nucleosides adopt the C3’-endo conformation 
found in A-DNA. This results in a duplex containing C3’-endo/syn purines followed by a C2’-
endo/anti pyrimidines12. 
Furthermore, these characteristics cause the phosphate backbone of the molecule to adopt a 
zig-zag arrangement, affording it the name Z-DNA. This arrangement of the duplex backbone 
causes some of the phosphate groups to be positioned closer together than in B-DNA; 
therefore there is greater electrostatic repulsion between them. Consequently, Z-DNA is highly 
stabilized by high salt concentrations35. 
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Figure 1.8: A-, B- and Z-DNA forms showing a view down the helical axis (top) and a side view of the helix 
(bottom). Helical diagrams adapted from reference 4444. 
1.8 Higher order structures 
The formation of DNA secondary structures requires specific sequence arrangements45. In the 
case of G-quadruplexes which are of interest to the scope of this thesis, the presence of a 
suitable cation also plays an important role in the stabilisation of the structure. 
In this unusual structure, four guanine bases form a co-planar array due to the formation of 
Hoogsteen type bonds46. In this arrangement each base acts as both a hydrogen bond donor 
and acceptor forming a total of 8 hydrogen bonds; represented in Figure 1.9 by dashed lines. 
This structure is known as a G-tetrad, the building block for the formation of G-quadruplexes. 
These tetrad units are stacked upon each other to form a stable G-quadruplex structure47; in 
general the stability increases with the number of units48. Formation and stability of G-
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quadruplexes is dependent on the presence of a monovalent chelating cation (typically Na+ or 
K+). The carbonyl oxygen atoms create a strong negative electrostatic potential in the centre of 
the tetrad. Cations positioned in this channel reduces the electronic repulsion between these 
atoms and overall stabilises the structure45,49. 
 
Figure 1.9: Structure of guanine tetrads (left), schematic representation of an intramolecular quadruplex 
motif (middle) and side and top view showing the position of the K+ ions in a human telomeric quadruplex 
(right) adapted from reference 4646.  
G-quadruplexes can form when four guanine rich sequences, containing two or more guanine 
residues each are in close proximity to one another45. This can either be due to intramolecular 
interactions within the same strand or intermolecular association between two or four different 
strands30,49. The quadruplexes are held together by three connecting loops arising from the 
mixed-sequence nucleotides between the guanine residues; these are not usually involved in 
the tetrads themselves48,49. 
It has been identified by computational methods, that based on G-rich patterns in the human 
genome, there are theoretically 376,000 sequences with the potential to form G-quadruplex 
structures48. Recent investigations have quantitatively shown the presence of G-quadruplexes 
and their stability in human genomic DNA using a highly specific DNA G-quadruplex 
antibody50. The large number of potential sites, the unique arrangement and the presence in 
important regions of the genome, means that G-quadruplexes are an attractive target for 
therapeutic treatments. 
Telomeres are non-coding sequences that appear at the ends of chromosomes and their role 
is to provide genomic stability and protection against gene erosion during cell division51. 
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Telomeric DNA contains thousands of tandem repeats of the sequence d(TTAGGG). It 
contains a 3’-single-stranded overhang of 100–200 nucleotides which can fold into a G-
quadruplex. Each replication results in shortening of the telomere by 50–200 bases51,52. DNA 
has a finite replicating capacity which is governed by a critical shortening of telomeric DNA; 
this causes cell death53. Telomerase is a reverse transcriptase which is responsible for 
maintaining the length of telomeres, hence making the cells that express the enzyme immortal. 
Telomerase is expressed in 80-90% of tumour cells47,51. The capability of telomeric DNA to 
form G-quadruplexes inhibits telomerase by locking the sequence into an inactive conformation 
that is no longer recognised by the enzyme47. This means that the telomeres are not 
inappropriately elongated and therefore the cell cannot become immortal. Consequently the 
development of small molecules capable of stabilising the telomeric G-quadruplex is a 
promising target for anti-cancer therapy54. 
G-quadruplexes are also highly prevalent in human gene promoter regions and are in this 
respect an emerging therapeutic target55. Their existence in the promoter region of oncogenes 
has recently been confirmed using both a G-quadruplex DNA cross-linking strategy56 and a G-
quadruplex specific probe57. Pharmacological manipulation of these structures may prove to be 
valuable for transcriptional repression of oncogenes and therefore suppression of the resultant 
oncoproteins. 
The biological properties of DNA are closely associated with its structure and alteration to the 
structure of the nucleotides, which might for example be caused by chemical modification, can 
interfere with the process of replication and transcription, leading to mutations. This thesis is 
largely concerned with a naturally occurring chemical modification of DNA that is caused by 
reactive nitrogen species that are associated with inflammation. It is therefore necessary to 
consider how these reactive species are generated and how they affect DNA. 
1.9 The physiology of inflammation 
To understand the underlying mechanisms involved in inflammation related carcinogenesis, it 
is helpful to first give a brief overview of the normal tissue response to injury. Inflammation is 
an adaptive response to any damaging condition which threatens the integrity of cellular 
homeostasis58. The mechanism can often be diverse in terms of the cell types and 
inflammatory mediators but essentially elicits the same response. Despite this complexity, the 
generic inflammatory pathway can be categorised into four key components: inducers, 
sensors, mediators and effectors (Figure 1.10)59.  
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Inducers of inflammation can be classified as either exogenous or endogenous. An example of 
an exogenous inducer is pathogen associated molecular patterns (PAMPs)60. PAMPs are 
specific structural components of invading microbial species that are not found in the host 
organism, but are essential for the pathogens physiology61. Endogenous inducers of 
inflammation are known as damage associated molecular patterns (DAMPs). These are the 
signals which are produced by the host in response to stressed, damaged or otherwise 
malfunctioning tissues59. 
Tissue-resident macrophages, dendritic cells and mast cells are classed as inflammatory 
sensors. These cells express transmembrane pattern recognition receptors (PRRs) which are 
capable of recognising and responding to PAMPs and DAMPs62. There are various types of 
PRRs, but they all possess common characteristics. PRR induced signalling ultimately results 
in the activation of transcriptions factors responsible for gene expression and the recruitment 
and synthesis of a broad range of inflammatory mediators. The nature of both the inducer and 
sensor are responsible for the different combinations and amounts of mediators produced by a 
given trigger62. 
Mediators of systemic inflammation can be classified with regards to their biochemical 
properties into seven groups: cytokines, chemokines, vasoactive amines, vasoactive peptides, 
anapylatoxins, lipid mediators and proteolytic enzymes59. The effect of the mediators is to 
locally elicit a physiological response; the tissue affected is known as the effector. 
Consequently, there is an increased blood supply at the site of inflammation and increased 
vascular permeability allowing for the recruitment of more important secretory cells (e.g. 
neutrophils, monocytes and macrophages), promotion of angiogenesis and production of 
reactive species designed to inactivate, destroy or remove an irritant63. 
 
Figure 1.10: Inflammatory Pathway Components adapted from reference 6464. 
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One mechanism by which the host signals to recruit mediators of the inflammatory response is 
through the activation of nuclear factor kappa B (NF-κB). It is well documented that NF-κB is 
rapidly activated through the PRR signalling pathway by a large range of PAMPs and 
DAMPs65. In the cytoplasm NF-κB exists in an inactive form which is regulated by IκB (inhibitor 
of NF-κB). Upstream signalling pathways activate a kinase enzyme which phosphorylates IκB 
thereby targeting it for degradation. The destruction of IκB releases NF-κB allowing it to 
translocate to the nucleus where it binds to the promoter regions of target genes and 
upregulates their transcription66,67.These genes encode a broad range of proteins including pro 
inflammatory cytokines, chemokines, cellular inhibitors of apoptosis, inducible nitric oxide 
synthase and negative regulators of NF-κB to name a few68,69. 
Acute inflammation is short lived and self-limiting63. A successful inflammatory response 
eliminates the pathogen and the host subsequently undergoes a resolution and repair phase59. 
Although there are many processes involved in the resolution of inflammation, macrophages 
are the key mediator. During the repair phase both tissue resident and recruited macrophages 
shift from producing pro-inflammatory cytokines to the expression of anti-inflammatory 
mediators such as lipoxins and resolvins. Lipoxins inhibit the recruitment of anti-microbial cells 
such as neutrophils and instead promotes the infiltration of monocytes that ingest and clear 
cellular debris in order for the cell to return to homeostasis67,70.  
In summary, inflammation is the body’s normal response to cellular injury; it is designed to 
protect from further damage, remove irritants and repair the affected tissues. However, this 
coordinated response occurs at the expense of normal cellular functions such as growth and 
reproduction. This is an unavoidable consequence of restoring homeostasis and since acute 
inflammation is generally short lived, in these circumstances, it does not cause detrimental 
effects to the host62,64. 
Acute inflammation is a tightly regulated process with a limited duration and magnitude; it has 
an integral resolution phase where the normal tissue architecture is restored71. However acute 
inflammation does not always resolve. Defects in the negative regulatory mechanisms result in 
the persistent activation of immune cells leading to the development of chronic inflammation. 
This persistent activation may be due to failure of the immune cells to remove the stimulus or 
events, such as genetic alterations, which maintain the inflammatory microenvironment 
preventing the onset of the resolution phase. The characteristics associated with chronic 
inflammation include; tissue remodelling, angiogenesis, promotion of growth and increased 
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cellular turnover67,72. These features contribute to the pathologic potential which accompanies 
chronic inflammation. 
1.10 Role of nitric oxide synthase in infection 
One of the mechanisms by which immune cells attempt to combat infection is by generating 
cytotoxic species such as nitric oxide (NO)73. This reactive nitrogen species has a multifaceted 
role in the human body; it plays a vital role in diverse biological processes, but can 
simultaneously act as a causative agent74. The role nitric oxide plays is dependent on the 
environment and which isoform of nitric oxide synthase catalyses its production75. 
There are three isoforms of the enzyme nitric oxide synthase, named according to the tissue 
type in which they were first described or their expression: the endothelial form (eNOS), the 
neuronal form (nNOS) and the inducible form (iNOS)75,76. The three isoforms are encoded by 
different genes but they display between 51-67% sequence homology75,77,78. The isoforms 
differ in their localisation, regulatory mechanisms, catalytic properties and the level of NO they 
produce. 
All NOSs are homodimers in their active form, comprising oxygenase and reductase domains. 
Various activities of these domains can be likened to those of the cytochrome p450 enzymes79. 
Calmodulin is required for the enzymatic activity and acts as an essential third subunit for all 
isoforms80. Additional requirements include the substrates molecular oxygen (O2) and L-
arginine, the cofactors nicotinamide adenine dinucleotide phosphate (NADPH), flavins and 
tetrahydrobiopterin (BH4) and the presence of an iron protoporphyrin IX (haem) group75,81. 
 
Figure 1.11: Generalised structure and function of NOS adapted from reference 8282. 
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In the presence of the essential cofactor and substrates, electrons are donated by NADPH to 
the reductase domain. These electrons are then transferred via the flavins, FAD and FMN to 
the oxygenase domain. The two domains are linked by a calmodulin (CaM) recognition site, 
without the presence of which the enzyme is inactive. In the oxygenase domain, the electrons 
interact with the haem and BH4 at the active site to reduce molecular oxygen and oxidise L-
arginine (L-Arg) to generate L-citrulline (L-Cit) and nitric oxide (NO) as products79,82. This 
process is summarised in Figure 1.11. 
Two of the isoforms, nNOS and eNOS are constitutively expressed and their activation is in 
response to increases in intracellular calcium (Ca2+) concentration. The increased 
concentration of Ca2+ induces the binding of the essential third calmodulin subunit and 
therefore leads to a transient increase in the production of NO. In contrast, the activity of iNOS 
is calcium concentration independent, as calmodulin binds to iNOS with high affinity even in at 
very low cellular Ca2+ concentrations82. iNOS expression and hence NO production, is 
principally controlled by the upregulation of transcription of the enzyme in response to 
immunoactivation; rationalising the nomenclature ‘inducible’. Typically, the iNOS enzyme 
synthesises NO continually, providing there are sufficient levels of L-arginine and other 
cofactors, until the enzyme is degraded75,77,81. 
The conversion of the substrate L-arginine to L-citrulline and NO is carried out via the two-step 
process shown in Scheme 1.1. The initial oxidation of arginine in the first step generates the 
intermediate N-hydroxyarginine, this is then further oxidised to give L-citrulline and NO76,83. 
 
Scheme 1.1: Oxidation of L-Arginine to NO and Citrulline catalysed by NOS. 
There are a number of mechanisms proposed for the transformation carried out at the active 
site of the NOS enzyme shown in Scheme 1.1, however many of these present conflicting 
views83–85. The most recent mechanism proposed is shown below. In the first step (Scheme 
1.286), the terminal oxygen of the peroxo species hydrogen bonds to L-arginine and a water 
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molecule. Heterolytic cleavage of the peroxy bond leads to the release of a water molecule and 
the formation of an oxy-ferryl species. This species then provides the oxygen atom for the 
formation of N-hydroxy-L-arginine85. 
 
Scheme 1.2: Proposed mechanism for the first oxidation step. 
In the second step of the mechanism (Scheme 1.386) the enzyme binds molecular oxygen and 
owing to the hydrogen bonding arrangement the terminal oxygen adds in to the substrate to 
give the ferric bound peroxo species. Subsequently a bond rearrangement generates citrulline 
and an additional electron transfer produces NO and water86. 
 
Scheme 1.3: Proposed mechanism for the second oxidation step. 
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1.11 Nitric oxide and its biological function 
In 1987 Ignarro et al. and Palmer et al. simultaneously identified the small molecule that 
diffuses between cells and relaxes smooth muscle tissue, originally called endothelium derived 
relaxing factor (EDRF), was in fact NO87,88. In order to discuss the physiological outcomes 
produced by NO it is first necessary to consider its chemistry. NO has 11 valence electrons; 
this mean that the highest occupied molecular orbital of the molecule contains an unpaired 
electron. Consequently NO is an uncharged, radical species. Due to its small size and 
electrical neutrality, NO is free to diffuse through cell membranes and perform its role as an 
intracellular signalling molecule89. NO is relatively stable although it reacts with other radical 
species in favour of the formation of covalent bonds. However, dimerization of NO does not 
occur readily as it is unfavourable entropically90,91. The movement of NO within the human 
body is diffusion controlled. It has a half-life of several seconds and its actions are relatively 
long range92. The distance that NO can diffuse from its releasing cell is between 100-200µm 
and it has a high diffusion coefficient of 3300µm2s-1 93. 
Although endogenous NO was originally recognised as a mediator of smooth muscle 
relaxation, it is now known that NO plays a diverse range of functions within the human body. 
The role NO plays is dependent on its environment and which enzyme catalyses its production. 
One of the primary substrates for NO is the enzyme soluble guanylate cyclase. NO binds to the 
haem cofactor in guanylate cyclase stimulating conformational changes which activate the 
catalytic domain of the enzyme. The active site catalyses the cyclisation of guanosine 
triphosphate (GTP) to form guanosine-3’,5’-cyclic monophosphate (cGMP). This then initiates 
cGMP mediated signalling cascades resulting in physiological changes within the target 
cells92,94. In the immune system, macrophages produce NO from iNOS in response to pro-
inflammatory cytokines and other mediators (e.g. NF-κB) as part of the inflammatory 
response95. In these circumstances NO can act as an antimicrobial or cytotoxic agent and its 
production is a mechanism by which the host fights infection.  
NO produced in the endothelium is responsible for smooth muscle relaxation and hence 
vasodilation, it inhibits platelet aggregation, prevents adhesion of neutrophils and platelets to 
endothelial cells and plays a role in angiogenesis. In the autonomic nervous system, neuronal 
NO acts as a non-adrenergic non-cholinergic neurotransmitter96,97. In general at lower 
concentrations (<1µM) the direct effects of NO itself predominate; this includes the effects 
produced by eNOS and nNOS as they typically produce low amounts of NO for short periods 
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of time. At higher concentrations (>1µM) such as that produced by iNOS, indirect and cytotoxic 
effects are exhibited, these will be discussed in more detail later in the chapter98. 
The role of NO in the human body is multidimensional. It can exhibit distinctly different and 
often opposing actions in similar environments. For example, in acute inflammation NO is an 
essential part of the host defence however in chronic inflammation it can be potentially toxic; 
although these effects are predominantly mediated indirectly via oxidation products rather than 
directly by NO itself90.  
1.12 Peroxynitrite 
A large proportion of the indirect effects of NO are mediated by the formation of peroxynitrite 
(ONOOˉ). The main route of its formation is the reaction between NO and superoxide. 
Superoxide is generated by a number of endogenous mechanisms; one of which is in immune 
cells (e.g. neutrophils) during a process known as an oxidative or respiratory burst. This can be 
defined as the increased oxygen consumption of immune cells during host defence. It has 
been established that the increase in oxygen consumption is a consequence of the activity of 
the enzyme NADPH oxidase. The active enzyme generates superoxide by catalysing the 
NADPH-dependent reduction of molecular oxygen shown in Scheme 1.499,100. 
 
Scheme 1.4: Generation of superoxide. 
Under normal physiological conditions, the levels of superoxide are kept low by the enzyme 
superoxide dismutase (SOD). The enzyme prevents the formation of a build-up of superoxide 
by conversion to oxygen and hydrogen peroxide101. However, in chronic inflammation, the 
simultaneous production of superoxide and high levels of NO can lead to the preferential 
formation of the powerful oxidant peroxynitrite. 
 
Scheme 1.5: Generation of peroxynitrite. 
The reaction is thermodynamically very favourable due to the formation of a covalent bond 
from two radical species; it is therefore irreversible. There are various different rate constants 
quoted for the reaction shown in Scheme 1.5, the most common of which is 6.7 x 109 M-1s-1 102. 
In comparison, the decomposition of superoxide by superoxide dismutase has a rate constant 
of ~2 x 109 M-1s-1 90,103. Consequently, in chronic inflammation the localisation and 
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concentration of NO is such that it is able to compete with endogenous superoxide dismutase 
for superoxide in order for the generation of peroxynitrite to predominate.  
Oxidative and nitrative damage caused by peroxynitrite can be attributed to one of three 
mechanisms. Firstly peroxynitrite itself can be toxic; it can react with electron rich groups 
readily oxidising both free and protein bound sulfhydryl groups104. It can irreversibly inactivate 
protein tyrosine phosphatase105, which is responsible for the regulation of signalling pathways 
that underlie an extensive range of fundamental physiological processes106. Additionally it 
induces oxidative inactivation of enzymes containing a thiolate center such as alcohol 
dehydrogenase107. 
Although peroxynitrite can itself be toxic, a large proportion of the deleterious effects observed 
are caused by secondary reaction products. These can vary depending on the local 
environment and the pH. Under physiological conditions peroxynitrite can be protonated (pKa 
6.8) to form peroxynitrous acid, which rapidly decays with a half-life of approximately 1s at 
37°C108. The decomposition products of peroxynitrous acid can be either inactive metabolites 
or toxic radicals which can participate in secondary reactions resulting in oxidative and nitrative 
damage.  
Peroxynitrous acid undergoes isomerisation adopting either the cis- or the trans-conformation 
(Scheme 1.6), this is due to the partial double bond between the nitrogen atom and the first 
peroxide oxygen109. While the cis-isomer is more stable due to hydrogen bonding, the labile 
trans-isomer is significantly more reactive110. In the trans-conformation, the peroxo bond is 
lengthened, making the molecule susceptible to degradation at this position111,112. 
Peroxynitrous acid can undergo molecular rearrangement to form nitrate but can also undergo 
homolytic decomposition of the peroxo bond to form highly reactive hydroxyl and nitrogen 
dioxide radicals in a parallel reaction (Scheme 1.6). 
 
Scheme 1.6: The reactivity of peroxynitrous acid. 
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Despite extensive research into the chemistry of peroxynitrous acid decomposition no 
consensus has emerged on its mechanism. Whilst some research supports the radical pair 
decomposition mechanism,113–115 others dispute it103. Further research in this area is 
necessary to provide unambiguous evidence to support either conclusion. 
Finally, the reaction of peroxynitrite with carbon dioxide can lead to toxic radical formation. The 
intracellular concentration of carbon dioxide is approximately 1mM, which is approximately 
10,000 times greater than the concentration of hydrogen ions, making it the most important 
modulator of peroxynitrite activity102. The peroxynitre anion reacts with carbon dioxide at a rate 
of 5.8 x 104 M-1s-1 under physiological conditions to form the nitrosoperoxycarbonate anion 
(Scheme 1.7)116,117. The nitrosoperoxycarbonate anion is highly unstable and rapidly homolysis 
of the weak peroxo bond to form carbonate and nitrogen dioxide radicals118. 
 
Scheme 1.7: Formation of carbonate and nitrogen dioxide radicals. 
The production of reactive oxygen and nitrogen species is a vital defence mechanism by which 
immune cells fight invading pathogens. However, peroxynitrite generated during chronic 
inflammation represents a major threat to the cellular components. The sustained high levels 
often results in damage to host nucleic acids, lipids, proteins and carbohydrates. Damage can 
be caused directly by peroxynitrite or indirectly by radical mediated nitration reactions, 
highlighting the multifaceted role played by NO in the human body. The inflammatory process 
triggered by infection or irritant can initiate cellular transformations that promote the 
development of cancer119. 
1.13 DNA damage caused by peroxynitrite  
Prolonged exposure of nucleic acids to reactive oxygen and nitrogen species generates 
various base modifications. This damage can lead to the initiation and advancement of 
mutagenesis and chromosomal instability120. Initial investigations into the oxidation of DNA 
were focused on the formation of strand breaks, however, now it is recognised that the 
formation of base adducts can have deleterious effects on cellular function and survival121. 
Relative to the other DNA bases, guanine represents the major target for oxidation by chemical 
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mediators of inflammation. This is attributed to it having the lowest oxidation potential (Eox = 
1.29 V vs. standard hydrogen electrode)122,123.  
A range of chemical and biological agents are capable of abstracting an electron from guanine. 
This one-electron oxidation can lead to a number of nitrated and oxidised DNA adducts shown 
in Figure 1.12.  
 
Figure 1.12: Oxidative and nitrative damage to guanine116. 
The content of the DNA sequence is also responsible for modulating the oxidation potential of 
guanine. There is evidence to show that the 5′-guanine of stacked sequences containing 
consecutive guanines oxidises more easily than an individual guanine in a sequence; hence, 
the reactivity of a guanine base in a run of guanines is significantly influenced by the 
surrounding nucleotides. Abstraction of one electron from a guanine base will induce electron 
transfer from the subsequent guanine base. Consequently, a radical cation introduced to DNA 
will migrate to the lowest energy site (if the radical is not trapped first by oxidising agents)124–
126. 
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1.14 The link between inflammation and cancer 
The observation by Rudolf Virchow in 1863 that leukocytes were present within cancerous 
lesions, provided the first link between inflammation and cancer95,127. The hypothesis that an 
inflammation promotes a cellular environment that that drives the initiation and development of 
carcinogenesis is now well documented. The tumour microenvironment is comprised of a 
complex system of cells. Inflammatory cells and their mediators have been found to comprise a 
key component of most, if not all tumours, irrespective of their cause for development69. 
The inflammatory cells provide an attractive environment for tumour growth63. They activate 
pro-tumourigenic processes leading to; the release of growth and survival factors, the 
promotion of angiogenesis, the facilitation of invasion and the increased production of reactive 
oxygen and nitrogen species that are known to induce DNA damage. These processes, among 
others, act as part of a positive amplification loop that attract additional cells in order to sustain 
the tumour microenvironment (Figure 1.13)127. 
 
Figure 1.13: Role of inflammation in tumour initiation (A) and promotion (B), adapted from reference 
127127.  
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The link between inflammation and cancer is mediated by two converging pathways: the 
extrinsic and the intrinsic. In the extrinsic pathway, pre-existing chronic inflammatory conditions 
and their associated microenvironments initiate cancer development69. Specific inflammatory 
conditions which can precede carcinogenesis at certain sites will be discussed later in the 
chapter. The intrinsic pathway is associated with tumours of which the cause is unrelated to 
any underlying inflammatory conditions128. In this pathway, cells that have undergone genetic 
alteration secrete inflammatory mediators and therefore create their own inflammatory 
microenvironment129. Regardless of which pathway elicits the inflammatory response, 
ultimately the outcome is the same.  
In 2000 the six hallmarks of cancer were defined as; self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evasion of apoptosis, unlimited replicative potential, ability 
to stimulate angiogenesis, capability for tissue invasion and metastasis128,130. The evidence 
that the inflammatory microenvironment is a key component in the development of cancer 
suggests that this may represent the seventh hallmark of cancer128,131.  
Cause Inflammatory Condition Associated Cancer 
Heliobacter pylori Gastritis Gastric cancer 
Gut pathogens Inflammatory bowel disease Colorectal cancer 
Tobacco smoke Bronchitis Bronchial lung cancer 
Hepatitis C virus Hepatitis Hepatocellular carcinoma 
Bacteria, gall bladder stones Cholecystitis Gall bladder cancer 
Tobacco, genetics, alcohol Pancreatitis Pancreatic cancer 
Epstein-Barr virus Mononucleosis Burkitts lymphoma 
Ultraviolet light Sunburn Melanoma 
Asbestos fibres Asbestosis Mesothelioma 
Gram-uropathogens Schistosomiasis (Biharzia) Bladder cancer 
Gastric acid, alcohol, tobacco Esophagitis Esophageal adenocarcinoma 
Table 1.2: Inflammatory conditions and the related cancer adapted from reference 129129. 
Evidence suggests that more than 25% of human cancers are attributable to chronic 
inflammation where DNA damage resulting from chronic inflammation is believed to be the 
mechanism120,129,132,133. In many of these cases the continued presence of an infection, 
bacteria or irritant in the affected tissue is the causative agent. A summary of inflammatory and 
pathogenic conditions that are considered to be associated with malignant transformation is 
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shown in Table 1.2129. The strongest association of chronic inflammation with malignant 
diseases is in colon carcinogenesis arising in individuals with inflammatory bowel diseases. 
Hepatitis C infection in the liver predisposes to liver carcinoma, whereas chronic Helicobacter 
pylori (H. Pylori) infection is the world’s leading cause of stomach cancer63. 
1.15 Inflammation associated cancers and DNA damage  
Since its discovery in 1983134, H. pylori has been recognised as the major cause of chronic 
gastritis and the development of gastric carcinoma. In 1994 the International Agency for 
Research on Cancer considered there to be significant evidence for the classification of H. 
pylori as a type I carcinogen in humans135. H. pylori is a spiral gram-negative bacterium which 
colonises in the stomach and is known to infect more than half of the world’s population136. It is 
considered to be the most common factor leading to infection related cancers and 5% of all 
people infected will go on to develop gastric cancer120. In 2012 gastric cancer was reported by 
the International Agency for Research on Cancer (IARC) as the 5th most prevalent cancer 
worldwide with the 3rd highest mortality137.  
H. pylori infection elicits an inflammatory response, as previously discussed; this is responsible 
for the production of inflammatory mediators, the upregulation of expression of iNOS and the 
production of reactive oxygen and nitrogen species. However, the immune system is not able 
to eliminate the bacteria which results in a sustained presence of inflammatory mediators 
leading to the development of continuous and progressive chronic inflammation138. This 
chronic inflammatory state exposes DNA to consistently high concentrations of cytotoxic 
agents which is recognised to play an important role in the initiation and progression of gastric 
cancer136.  
H. pylori has various mechanisms to evade host defence; a number of these are summarised 
in Figure 1.14. In order to be able to survive in the stomach, the bacteria produce the enzyme 
urease to catalyse the hydrolysis of urea to carbon dioxide and ammonia which neutralises the 
surrounding gastric acid138,139. NO irreversibly inhibits the respiration of H. pylori; in fact in vitro 
studies suggest that NO is capable of killing the bacteria. However this is not the case in vivo, 
H. pylori generates superoxide radicals which rapidly react with NO to form peroxynitrite. While 
peroxynitrite produces similar effects to NO and irreversibly inactivates the respiration of the 
bacteria, due to the actions of urease, it preferentially reacts with carbon dioxide which is in 
consistently high concentration in the surrounding area. It is suggested that formation of the 
nitrosoperoxycarbonate anion inhibits the bactericidal activity of peroxynitrite but as described 
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previously can decompose to free radical species which cause damage to surrounding gastric 
epithelium138,140,141. In clinical studies, both 8-nitroguanine and 8-oxoguanine have been 
observed in the nuclei and cytoplasm of gastric epithelial cells of H. pylori infected patients. 
Treatment and eradication of the infection lead to dramatically decreased levels of these DNA 
adducts142,143.  
 
Figure 1.14: The defence mechanisms against oxidative stress taken from reference 138138. 
Based on the GLOBOCAN 2012 estimates, liver cancer is the sixth most frequently diagnosed 
cancer, and is the second leading cause of cancer-related deaths worldwide137. Hepatocellular 
carcinoma (HCC) is the most common primary liver cancer, accounting for between 70-85% of 
cases144. Infection with the Hepatitis C virus (HCV) is a significant predisposing factor in the 
development of HCC. While the pathogenic mechanism underlying the evolution from HCV to 
HCC is not well defined, the multistage progression is summarised below. 
In between 70-80% of individuals infected with HCV, the acute phase is asymptomatic despite 
triggering an immune mediated inflammatory response. While 15-25% of patients will clear the 
infection, in the vast majority of cases, the disease will become chronic. Chronic hepatitis C 
(CHC) is characterised by the presence of HCV RNA in the blood 6 months after the onset of 
the acute infection145. Failure of the immune response to clear the infection leads to chronic 
inflammation; 20-40% of individuals develop liver cirrhosis and 4-6% progress to HCC after 10-
40 years of infection. HCV is a single stranded RNA virus that does not integrate into the host 
genome, therefore the chronic inflammatory environment it elicits is considered a major 
contributing factor to the development of carcinogenesis144. 
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The reactive oxygen and nitrogen species released from activated immune cells as a 
consequence of chronic inflammation can interact with nucleic acids leading to mutations and 
malignant transformation143,146. To determine the extent of DNA damage resulting from HCV, 
the formation of the DNA adducts 8-nitroguanine and 8-oxoguanine in the liver of patients with 
CHC before and after treatment has been analysed. Both 8-nitroguanine and 8-oxguanine 
formation was apparent in the nucleus of hepatocytes in patients with CHC. The number of 
hepatocytes identified containing the DNA adducts increased with the degree of inflammation 
of the liver. Furthermore, upon treatment, the accumulation of 8-nitroguanine and 8-
oxoguanine base modifications in the liver decreased147. Together these findings support the 
conclusion that oxidative and nitrative DNA damage are an important contributing factor to 
HCV associated HCC. 
Cigarette smoking is a well-established risk factor in cancer development. The precise 
mechanisms for this transformation remain to be defined, however the connection between 
lung cancer, tobacco smoke and inflammation are unquestioned. Lung cancer is the leading 
cause of cancer related deaths worldwide137. It has been estimated that cigarette smoking can 
be attributed to 90% of lung cancer incidence in men and 70 to 80% in women148. 
Approximately 5000 chemical compounds are released during the combustion of tobacco149. 
These chemicals have cytotoxic, mutagenic and carcinogenic properties. 
Continued exposure to cigarette smoke can foster an environment that induces chronic 
inflammation which can lead to carcinogenesis. The gas phase of cigarette smoke contains 
high concentrations of nitric oxide; estimated figures range from 300-600μg per cigarette150–152. 
This exogenous source of nitric oxide can directly, or as a consequence of secondary reaction 
products, lead to oxidative and nitrative DNA damage. In addition, the components of cigarette 
smoke are known to activate several inflammatory signalling cascades, including the NF-κB 
pathway. As previously discussed, this transcription factor is responsible for the expression of 
inflammatory genes, the release of a number of inflammatory mediators and ultimately the 
production of reactive oxygen and nitrogen species153,154. These converging pathways both 
result in the formation of DNA adducts and contribute to the pathogenesis of lung cancer. 
Various studies have been carried out to quantify the oxidative and nitrative products of DNA 
damage caused by cigarette smoke. Smoking has been shown to greatly increase the amount 
of 8-nitroguanine found in urine by between 6-69 fold when compared to non-smokers. The 
increase in the levels of 8-oxodeoxyguanosine was modest in comparison with amounts 
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between 9-50% higher155. Hsieh et al. determined the levels of 8-nitroguanine in DNA 
extracted from peripheral lymphocyte of tobacco smokers and compared the results to that of 
non-smoking healthy controls. The DNA from the healthy control volunteers contained trace 
levels of the DNA adduct, whereas the levels were significantly higher in cigarette 
smokers116,151. 
1.16 8-Oxoguanine 
It has been estimated that approximately 20,000 mutagenic lesion are formed in each 
mammalian cell per day156. Exposure to reactive oxygen and nitrogen species is considered to 
be major factor contributing to DNA damage. However the high fidelity of DNA replication is 
maintained by a combination of proofreading and repair mechanisms. 
One of the most abundant and extensively studied oxidative DNA lesions is 8-oxoguanine. By 
its chemical incorporation into DNA, it has been possible to gain in depth information about this 
lesion and how it may be a factor in carcinogenesis. The formation of 8-oxoguanine was first 
reported in 1984 as a result of the treatment of DNA with ascorbic acid157. In vivo the addition 
of a hydroxyl radical to the C8 position of guanine forms a radical adduct which can be 
oxidised to yield 8-oxoguanine158. The additional presence of a carbonyl group at the C8 
position and a hydrogen atom at the N7 position significantly changes the bases properties 
with respect to guanine and alters the efficiency and fidelity of transcription. 8-Oxoguanine can 
adopt a number of different tautomeric structures; the predominant forms are shown in Figure 
1.15. Computational methods suggest that in the aqueous phase the keto form is the most 
stable tautomer and hence it is most likely that this species contributes to the mutagenesis of 
8-oxoguanine159. The estimated daily level of 8-oxoguanine formed is approximately 103 
lesions per cell in tissues at homeostasis; however this can be as high as 105 lesions per cell 
in cancerous tissues160.  
 
Figure 1.15: Keto-enol tautomerisation of 8-oxoguanine. 
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The primary structural basis for the mutagenicity of 8-oxoguanine is its ability to form base 
pairs with both cytosine and adenine. This requires rotation of the base about the glycosidic 
bond relative to the sugar moiety. The oxygen atom at the C8 position can result in 
destabilisation of the anti-conformation causing the base to preferentially adopt a syn 
orientation24. This can be attributed to the steric clash between the C8 substituent and the 
sugar-phosphate backbone; the syn-conformation best alleviates these unfavourable steric 
interactions161. The conformation of the 8-oxoguanine glycosidic bond in DNA is dependent on 
its base pairing partner which is determined by the polymerase replicating the DNA. 
While 8-oxoguanine can form a stable Watson-Crick base pair with cytosine, it can pair with 
comparable stability to adenine162. When pairing to cytosine, 8-oxoguanine adopts the 
unfavourable anti conformation. Despite forming three hydrogen bonds this base pair is 
destabilised in comparison to the corresponding natural G:C base pair. The protonated 
nitrogen in the N7 of position of 8-oxoguanine creates an additional hydrogen bond donor. 
Consequently in the syn orientation, 8-oxoguanine can functionally mimic thymine and form a 
Hoogsteen base pair with adenine. If cytosine is incorporated opposite the lesion, 
complementary base pairing is maintained ensuring faithful DNA replication and therefore 
there is no mutation as a result of oxidative DNA damage. Conversely, if adenine is 
incorporated opposite 8-oxoguanine in subsequent DNA replication the lesion would be 
recognised as a thymine instead of guanine; this is known as a G→T transversion. These 
seeming small changes to the DNA sequence can cause mutagenesis24,163,164.  
 
Figure 1.16: Base pairing of 8-oxoguanine. 
The defence mechanisms against mutagenesis caused by 8-oxoguanine have been 
extensively studied. Three key enzymes have been identified that reduce the mutagenic 
potential of 8-oxoguanine. These fall into two categories, those that prevent the incorporation 
of the oxidised nucleotide into DNA and those that are involved in the repair of the lesion165. 
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The accuracy of the recognition and repair processes plays a critical role in determining the 
consequences of oxidative DNA damage. 
MutT (hMTH1 in humans) is responsible for preventing the misincorporation of 8-oxoguanine 
nucleotides opposite adenine by DNA and RNA polymerases. The enzyme is a triphosphatase 
that hydrolyses 8-oxo-dGTP in the nucleotide pool to the corresponding monophosphate and 
pryrophosphate, thus eliminating it as a potential DNA synthesis precursor166. The structural 
basis for this specificity is the presence of a hydrogen bond between the N7 hydrogen and an 
oxygen atom in the substrate binding site of the enzyme. Additionally, 8-oxoguanine is 
discriminated from guanine nucleotides by the syn conformation of the glycosidic bond which is 
preferential for the 8-oxoguanine mononucleotide. MutT exhibits high substrate specificity for 
8-oxoguanine nucleotides, although it is known to hydrolyse several other oxidised purine 
nucleosides167. 
8-Oxoguanine can be repaired by the base excision repair (BER) pathway; this can be initiated 
by DNA glycosylate/β-lyase OGG1. This enzyme is responsible for the removal of 8-
oxoguanine from DNA when it is paired opposite cytosine, in order to restore the G:C base pair 
and to ensure faithful replication in subsequent DNA synthesis. OGG1 can recognise and bind 
to 8-oxoguanine while it is stacked within the double-helix165. Initially hydrogen bond formation 
between the 8-oxoguanine base and the enzyme destabilise the base pairing with cytosine. 
This promotes rotation of the modified base into the active site of the enzyme; both the 
extruded base and the double-helix are stabilised by key residues of the protein. The 
hydrolysis of the glycosidic bond is catalysed by the enzyme to leave an apurinic site in the 
DNA168. 
The OGG1 enzyme possesses a high degree of substrate specificity. When guanine is located 
in the active site of the enzyme, despite being positioned in approximately the same position 
as 8-oxoguanine, OGG1 does not catalyse base excision169. OGG1 is the enzyme primarily 
responsible for repairing 8-oxoG once it has been formed in, or been incorporated into DNA. 
However, if for some reason OGG1 does not remove the lesion, a second enzyme excises the 
mispaired adenine base in order to promote incorporation of the correct base pair.  
The enzyme adenine DNA glycosylase, known and MutY in bacteria and hMYH in humans is 
responsible for removing an inappropriately paired adenine base from DNA if replication has 
already taken place. The enzyme recognises the mismatch by an extensive array of hydrogen 
bonds which engage every face of the 8-oxoguanine base. An important factor in this 
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recognition is the unique C-terminal domain of MutY, without which the enzyme cannot 
discriminate for the mismatch of adenine with 8-oxoguanine170. The enzyme rotates the base 
out of the helix by inducing bending and distortion. The extruded adenine base is inserted into 
the binding site in the catalytic domain of the enzyme. MutY then removes the base via 
hydrolysis of the glycosidic bond163,171. As previously mentioned, to mispair with adenine, the 
glycosidic bond of 8-oxoguanine adopts the syn conformation. Interestingly crystal structures of 
the bound MutY-DNA complex show that 8-oxoguanine is rotated about the glycosidic bond 
into the anti orientation. This rotation would cause a unfavourable steric interaction providing 
the driving force to expel adenine from the helix170. 
Subsequent steps involve further processing by various different proteins in the base excision 
repair pathway (AP endonuclease, DNA polymerase, DNA ligase). This corrects the DNA 
sequence by template-directed insertion of nucleotides to restore the original G:C pair166. 
Mutations in any of the genes in DNA repair pathway play an important role in the development 
of carcinogenesis172. Despite the actions of these repair enzymes, some oxidatively damaged 
bases remain unrepaired. These can potentially be detected by DNA polymerases during 
replication. 
DNA synthesis opposite 8-oxoguanine is problematic because the lesion can evade 
proofreading mechanisms which can lead to mutagenesis. Two of the many mechanisms by 
which it can avoid detection are detailed below. To facilitate base pairing between 8-
oxoguanine and cytosine, the DNA strand adopts a kinked configuration. This prevents 
unfavourable steric interactions between the C8 substituent of 8-oxoguanine and the sugar 
phosphate backbone, but induces a conformational change in the enzyme. Distortion of the 
active site functions to identify mismatched base pairs and suspends DNA replication. When 
paired to adenine, 8-oxoguanine adopts the sterically favoured syn conformation. In this 
orientation, the mismatch geometrically resembles that of a conventional Watson-Crick base 
pair. Therefore the 8-oxoguanine adenine base pair is able to occupy the active site without 
distorting the protein thus evading this method of error detection173,174.  
High fidelity polymerase enzymes consist of a number of key sites that consecutive bases 
occupy. After incorporation, the new base pair moves to a post-insertion site where hydrogen 
bonds are formed between residues on the enzyme and universal hydrogen bond acceptors in 
the minor groove of the DNA. Failure to form these hydrogen bonds leads to recognition of the 
mismatched base pair which stalls the polymerase. When 8-oxoguanine adopts the syn 
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conformation, the C8 substituent is projected into the minor groove of the helix. The oxygen 
atom acts as a hydrogen bond acceptor and effectively mimics the N3 of an undamaged purine 
in the anti-configuration. Consequently, it provides feedback to the enzyme concerning the 
geometry of the minor groove. As the oxidative damage enables 8-oxoguanine to interact 
appropriately with these donors, the lesion does not trigger proofreading functions and is 
considered as an undamaged nucleoside175. 
Much of what is known about 8-oxoguanine has been established by chemically incorporating 
the modification into DNA; it has been possible to gain in depth information about how the 
lesion may be a factor in carcinogenesis. This includes details of how the modification 
influences the structure of the DNA duplex, how the lesion is recognised in vivo and which 
enzymes are involved in its repair.  
1.17 8-Oxoguanine as a biomarker of disease 
The National Institutes of Health define a biomarker as ‘a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention’176. Biomarkers are used 
for the early detection of a disease before the development of clinical symptoms. They are 
based on the concept that accumulation of a particular precursor is directly proportional to 
mutagenic potential177. Ideally the marker must be detectable in samples from easily 
accessible proxy tissues178. Understanding the relationship between measurable biological 
molecules or processes and how they influence the development of diseases plays an 
important role in rational drug design. 
The presence of 8-oxoguanine is often exploited as a cellular biomarker to indicate the extent 
of oxidative stress and the potential for carcinogenesis. It is relatively easily formed, is 
mutagenic and is measurable by a variety of methods179. Validated biomarkers of oxidative 
DNA damage such as 8-oxoguanine, could provide an approach to early detection and 
prevention strategies for diseases associated with oxidative stress180. 
1.18 8-Nitroguanine 
8-Nitroguanine is readily identified following damage by reactive oxygen and nitrogen species 
and is of particular interest with regard to this thesis. In order to gain a comprehensive 
understanding of how this lesion can be a factor in carcinogenesis it is essential to be able to 
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synthesise and examine oligonucleotides containing the modification; however, until recently 
this was not been possible.  
8-Nitrodeoxyguanosine (8-NO2-dG) undergoes rapid hydrolysis of the glycosidic bond to give 
the free 8-nitroguanine base, leaving an abasic site in the DNA (Scheme 1.8). Under 
physiological conditions 8-nitrodeoxyguanosine has a half-life of 1-4 hours126,181. However it 
has been found that 8-nitroguanine in RNA is significantly more stable with only 5% 
depurination occurring within 6 hours182. The increased stability can be attributed to the 
additional C2’ hydroxyl group characteristic of the ribose sugar. The hydroxyl group 
destabilises the oxonium ion intermediate making the hydrolysis process less favourable. 
 
Scheme 1.8: Hydrolysis of the glycosidic bond. 
8-Nitrodeoxyguanosine has been shown to have a high miscoding frequency. This may be due 
to the lesion itself causing miscoding or its ability to form apurinic sites in DNA183. Abasic sites 
are one of the most frequently encountered DNA lesions, they are generated via a number of 
mechanisms and their mutagenic effects have been extensively studied184,185. Abasic sites are 
predominantly recognised by the enzyme AP endonuclease186. The AP endonuclease initiates 
a repair cascade involving a concerted effort of the enzymes in the base excision repair 
pathway. Briefly, after recognition of the lesion, the proteins excise the damaged nucleotides 
and subsequently replace the damaged moiety with an undamaged nucleotide which restores 
the original DNA sequence185–187. 
Abasic sites that remain undetected challenge DNA polymerases to incorporate a nucleotide 
without a template strand to copy. These lesions are known to inhibit the progress of high 
fidelity DNA polymerases responsible for catalysing the majority of DNA synthesis175. In order 
to bypass the abasic site, the sequential actions of two error prone DNA polymerases are 
required. The enzymes Pol δ and Rev1 are involved in the insertion of a nucleotide opposite an 
abasic site; however these DNA polymerase cannot catalyse translesion synthesis. DNA 
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polymerase δ is required in order to extend from nucleosides incorporated opposite the 
lesion188,189. 
Translesion synthesis favours the incorporation of adenine opposite the abasic site leading to 
G→T transversions; this preference is known as the ‘A rule’ of mutagenicity188. It has been 
suggested that adenine is incorporated opposite an abasic site as this does not confer any 
distortion to the double-helical structure of B-DNA188. Additionally the melting temperature of 
the duplex containing this base pair is the same as that of a T:A base pair in the same 
duplex190. The use of error prone polymerases in this bypass mechanism, may contribute 
further to extensive point mutations191. 
Interestingly, it has been reported that 8-nitroguanine nucleosides and nucleotides can be 
directly involved in the generation of oxidative stress; this provides an alternative mechanism 
by which the lesion can lead to mutagenesis192. As described previously, NOS utilises NADPH 
as an electron donor to facilitate the production of nitric oxide. In the presence of 8-
nitroguanine, the electron transfer can become disorganised causing 8-nitroguanosine to be 
reduced forming an 8-nitroguanosine radical (Figure 1.17)193. This electron is then transferred 
to molecular oxygen in a redox cycling reaction which reforms 8-nitroguanosine and generates 
superoxide116. This process is pathophysiologically significant because superoxide and its 
secondary reaction products, such as peroxynitrite, can lead to further cellular damage which 
can contribute to carcinogenesis. 
 
Figure 1.17: Mechanism of superoxide production stimulated by 8-nitroguanosine. Adapted from 
reference 193193 
A large proportion of what is currently known about the 8-nitroguanine lesion has been recently 
established by Bhamra et al. However, the miscoding properties of 8-nitroguanine were 
previously explored by Suzuki et al. An oligonucleotide was prepared by photochemical 
synthesis which contained a single 8-nitrodeoxyguanosine residue.  
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The oligodeoxynucleotide containing the 8-nitroguanine lesion was then used as template in 
primer extension reactions in order to study polymerisation past the 8-nitroguanine base. This 
involved treatment of the photochemically nitrated oligodeoxynucleotide, primed with a 5’-
labelled short complementary sequence, with variable amounts of DNA polymerases α, β, ε 
and κ in the presence of four deoxyribonucleotide triphosphates. Synthesis catalysed by 
polymerases α and β was blocked to a certain extent, one base prior to, or opposite the 8-
nitroguanine residue. Of the polymerases that were able to extend past the lesion, cytosine 
was preferentially incorporated opposite 8-nitroguanine, nevertheless misincorporation of both 
adenine and guanine was observed. Extension of the primers past the lesion by polymerases ε 
and κ was more efficient, but exhibited a high miscoding frequency and broad miscoding 
specificity. Direct incorporations of adenine and cytosine were observed along with less 
significant amounts of guanine and cytosine; in addition one and two base deletions were 
detected183.  
The evidence presented by Suzuki et al. suggests that 8-nitroguanine can be mispaired with 
adenine in mammalian cells, directly inducing a G→T transversion. They propose that adenine 
is incorporated opposite the lesion by forming complementary hydrogen bonds with the 
Hoogsteen face of 8-nitroguanine in the syn conformation. However the experiments were 
conducted using a template-primer system that readily releases the 8-nitroguanine base, so it 
is also possible the polymerases are in fact placing adenine opposite an abasic site which 
cause the same transversion mutation187,194. 
The scope of this procedure is limited by a number of factors. Firstly this method is not suitable 
for preparing oligodeoxynucleotides which contain more than one guanine base. Secondly, the 
yield of the oligodeoxynucleotides containing the photochemically nitrated nucleoside was only 
~3% of the initial concentration195. Furthermore, the deoxyribose sugar moiety renders the 
lesion highly susceptible to hydrolysis of the glycosidic bond. Despite some structural 
information being obtained using oligomers synthesised by this procedure, the extremely low 
yields and instability meant this was not the ideal method to determine the physicochemical 
properties of the lesion. 
As chemically incorporating 8-nitrodeoxyguanosine into oligonucleotides is impractical, 
generation of a suitable hydrolytically stable mimic of this nucleotide was required to explore 
the chemical and biological effect of the modification. The approach established by Bhamra et 
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al. in the first phase of the project utilised a 2’-O-methyl analogue of 8-nitroguanine that could 
be chemically incorporated into oligodeoxynucleotides.  
The synthesis of 8-nitroguanosine and its 2’-fluoro and 5’-azido analogues, considered suitable 
for biochemical research, has been described by Saito et al. The hydrolytic stability of these 
analogues was assessed and half-lives of 72 and 4.5 days were established for the 2’-fluoro 
and 5’-azido derivatives respectively196. Using this methodology, it was envisioned that the use 
of an electronegative 2’-O-methyl substituent would stabilise the labile glycosidic bond and 
hence minimise depurination to allow for chemical incorporation into oligodeoxynucleotides.  
2’-O-Methyl nucleosides have been extensively investigated in comparison to the 
ribonucleoside and other 2’-modified analogues. Introducing a 2’-O-methyl substituent to the 
nucleoside has a significant effect on the conformation of the sugar. As mentioned previously, 
the substitution of the hydrogen at the C2’ position with a hydroxyl group accounts for the 
difference in preferred puckering modes of DNA and RNA. Hence, in addition to stabilising the 
glycosidic bond, substitution with an electronegative group at the 2’-position shows a strong 
preference to adopt the C3’-endo conformation of RNA197. The conformational bias imposed on 
the sugar pucker by the 2’-substituent is relative to the electronegativity of the substituent197–
199. 
Replacement of the 2’-hydrogen by a fluorine atom may be considered a more suitable mimic 
as it does not cause significant steric perturbations to the shape of the molecule. However, 
despite the 2’-fluoro nucleosides being isoteric to their DNA equivalents, the electronegativity 
of the substituent would cause these derivatives to adopt a sugar conformation that is 
increasingly detached from the of the C2’-endo conformation of DNA194,198. 
The 2’-O-methyl analogue was readily available and its use is advantageous in that the 2’-
position of the nucleoside does not require additional protection. The incorporation of a 2’-O-
methyl substituent allowed for analysis of the chemical and biological properties of the 
stabilised 8-nitroguanine analogue to be obtained. 
The physicochemical data previously obtained by Bhamra et al. confirms that 8-nitro-2’-O-
methylguanosine adopts a syn conformation about the glycosidic bond. The evidence for this 
comes from characteristic shifts in the NMR spectrum of the nucleoside upon adopting the syn 
conformation200,201. A significant upfield shift in the 2’-carbon signal of 8-nitro-2’-O-
methylguanosine was exhibited with respect to the unmodified 2’-O-methylguanosine. 
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Furthermore a downfield shift in the signals corresponding to H2’, C1’, C3’ and C4’ were also 
observed. Analogous data was obtained for 8-bromo-2’-O-methylguanosine, which is known to 
adopt the syn conformation, and this was consistent with that of the nitro analogue (Table 
1.3)194. It has been proposed that the upfield shift of the C2’ signal is a consequence of the 
proximity of the lone pair of electrons on the N3 atoms with the C-H bond at the C2’ position200. 
The downfield shift observed for the signal corresponding to the H1’ proton is seemingly a 
feature which is unique to the 8-nitroguanine analogues. The spatial orientation of the H1’ 
proton in relation to the nitro group in the syn conformation is proposed to be the basis for 
this194. 
Nucleoside H1’ H2’ C1’ C2’ C3’ C4’ 
2’-O-Me-G 5.82 4.28 85.85 82.73 68.66 84.32 
8-Br-2’-O-Me-G 5.79 4.78 88.01 79.79 69.27 86.67 
8-NO2-2’-O-Me-G 6.32 4.68 89.12 80.88 69.55 86.20 
Table 1.3: NMR data for studies on the conformation of 8-nitro-2’-O-methylguanosine, taken from 
reference 194194 
The pKa of the atoms in a nucleic acid can be used as a measure to determine how it will 
interact with and behave towards other molecules. The strength of the hydrogen bonds which 
are formed between complementary base pairs can be correlated to the relative pKa values of 
the donor and acceptor atoms of the bases. When modifications lead to deviations in the pKa 
of a nucleobase, the bonding geometry and base pairing properties are altered accordingly. 
Hence, this may be an indication of the potential mutagenicity of a lesion202–204. 
Nucleosides containing the 8-nitroguanine modification have a distinctive UV absorption at 
approximately 390nm. This enabled the determination of the pKa for the deprotonation of N1 by 
analysing the changes in this UV absorption as a function of pH. pKa values of 8.4 and 8.3 
were calculated for 8-nitroguanosine and 8-nitro-2’-O-methylguanosine respectively. The data 
establishes that the nucleosides containing the 8-nitro moiety are significantly more acidic than 
guanosine and 2’-O-methylguanosine which have pKa values of 9.4 and 9.5 respectively. 
These results reflect the electron withdrawing capacity of the nitro group194. 
An accurate indication of oligodeoxynucleotide stability can be obtained by measuring the UV 
absorbance of a DNA duplex at regular intervals as a function of increasing temperature. Upon 
the formation of a duplex, base stacking is accompanied by a reduction in the absorbance 
when compared to the corresponding unhybridised strands. The interaction between the π 
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electrons on neighbouring bases reduces the transition dipoles, hence reducing the ability of 
the system to absorb light. This results in a reduced UV absorbance of the duplex, which upon 
dissociation of the two strands is reversed. The thermal melting temperature (Tm) is the 
temperature at which 50% of the mixture exists as a single stand and 50% exists in the duplex 
formation2,205. 
Thermal melting studies of duplexes containing the stabilised 8-nitroguanine analogue were 
performed. The formation of a number of duplexes in which each of the DNA nucleobases are 
paired with the modified base allows for information on the base pairing preferences to be 
obtained. The results indicated that there is significant destabilisation of the duplex upon 
pairing 8-nitroguanine with cytosine. The base pair formed between 8-nitroguanine and a 
guanine base appears to form the most stable duplex on the basis of it having the highest Tm 
temperature. However, it is likely that in vivo DNA polymerases would discriminate against this 
pairing due to the poor geometric fit within the helical structure. The 8-nitro moiety seemingly 
had no effect on the stability of the pairing with adenine or thymine194. 
Further to this, primer extension studies were performed to examine the mutagenic potential of 
the lesion. Two different polymerases were studied; the polymerase AMV-RT, chosen due to 
its ability to extend past the 2’-O-methyl modification and DNA polymerase β, chosen to 
provide a direct comparison to previously published results. AMV-RT paired deoxycytidine 
predominantly opposite the 8-nitro-2’-O-methylguanosine analogue, forming a fully extended 
product. Conversely polymerase β preferentially inserted deoxyadenosine as opposed to 
deoxycytidine in a ratio of 2:1 and the primers were not fully extended. Extension past the 
lesion was significantly impaired in both cases. Although the 2’-O-methyl substituent may be a 
factor in this, control experiments established that it did not significantly affect the specificity of 
the enzyme194. 
While the conclusions drawn from primer extension reactions with polymerase β were in 
agreement with those previously stated by Suzuki et al.183, the level of incorporation opposite 
the lesion was not. There are a number of aspects of the systems that may be responsible for 
the difference seen between the two studies including: the model of the lesion, the pH and the 
primer extension reaction construct. 
The use of running start and standing start reactions can be used to determine the efficiencies 
and specificities of nucleotide insertion opposite a lesion with respect to a particular DNA 
polymerase. A standing start, used by Bhamra et al., is defined as a reaction where the first 
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nucleotide to be incorporated is opposite the position of interest on the template strand. In 
comparison, Suzuki et al. utilised a running start primer extension which requires the 
polymerase to incorporate one or more nucleotides prior to reaching the position of interest206. 
Both primer template systems have their own merits, but might account for the observed 
variations. 
As previously shown for abasic sites, the sequential actions of more than one polymerase can 
be required to insert a nucleotide opposite a lesion. Therefore, using this reasoning, it is 
possible that bypass of the 8-nitroguanine lesion could efficiently be carried out in vivo by one 
or more of the other 14 DNA polymerases the human genome encodes207. 
Overall these findings demonstrate the potential value of further investigation into recognition 
and repair of this lesion. Oligodeoxynucleotides containing the 8-nitroguanine modification are 
not widely prepared and studied due to the inherent difficulty in their preparation. Recent 
results from Bhamra et al. have enabled the incorporation of a suitable model of 8-
nitrodeoxyguanosine into chemically synthesised DNA. In terms of sugar conformation, the 2’-
O-methyl analogue populates a configuration closer to that of RNA as opposed to DNA. 
Nevertheless this is considered a suitable mimic for the scope of this thesis. Not only may 8-
nitroguanine function as an endogenous mutagen, but it may also serve as a biomarker for 
inflammation related carcinogenesis. 8-Nitroguanine is already considered a marker for 
inflammation and nitrative stress147, but as the link between sustained production of reactive 
nitrogen species and the initiation and progression of cancer is strengthened, it is possible that 
the lesion itself could be exploited as a biomarker for inflammation related cancers. 
1.19 Projects aims 
It is clear that the 8-nitroguanine lesion plays an important role in mutagenesis, carcinogenesis 
and is also associated with a poor prognosis of the cancer191. To obtain a more detailed 
understanding of these effects, it is apparent that new and sensitive methods are required to 
detect the lesion. A major aim of this thesis is to study the reactions of the 8-nitroguanine 
modification to understand how it differs from guanine and to develop new methods for its 
detection. Additionally this work initiates studies aimed at investigating whether mechanisms 
exist to repair this lesion. 
More specifically the following studies have been undertaken: 
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 Synthesis of oligodeoxynucleotides containing the 8-nitroguanine modification 
(Chapter 2). 
 Reactions of 8-nitroguanine nucleosides and oligodeoxynucleotides (Chapter 3). 
 Detection of the 8-nitroguanine lesion using surface enhanced (resonance) Raman 
spectroscopy (Chapter 4). 
 Studies towards the synthesis of 8-nitroguanosine triphosphate to investigate repair by 
MutT (Chapter 5). 
 
 
 
 
 
  
Chapter 2 
Results and Discussion 1: 
Synthesis of oligodeoxynucleotides containing the 8-nitroguanine 
modification 
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2 Result and Discussion 1 
2.1 Proposed route for the synthesis of 8-nitroguanine nucleosides 
Prior to the start of this project in 2010, Saito had developed a simple method for the nitration 
of guanosine nucleosides196. This method was subsequently adapted by a postdoctoral worker 
(Dr. I. Bhamra) within our research group to prepare 8-nitro-2’-O-methylguanosine 
phosphoramidite for incorporation into oligodeoxynucleotides194. The initial part of this project 
was to repeat the preparation of this monomer, with the additional aim of trying to optimise the 
critical nitration step which proceeded in low yield. The work in this chapter is based on the 
generation of 8-nitroguanine nucleosides derived from 2’-O-methylribose, but it has also been 
applied to the corresponding ribose derivative (Chapter 3). 
 
Scheme 2.1: Synthetic route to 8-nitro-2’-O-methylguanosine. 
The individual steps for the synthesis of 8-nitro-2’-O-methylguanosine are shown in Scheme 
2.1 and will now be discussed individually. The first step in the scheme is protection of the 
hydroxyl groups of the sugar component. Protection of these groups was necessary to prevent 
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unwanted side reactions from occurring and to ensure selective reaction at the C8 position in 
subsequent steps.  
The acetyl protecting group was considered appropriate for this because it is removed under 
basic conditions. As alluded to in Chapter 1, the nitro group greatly increases the lability of the 
glycosidic bond181. Despite the extra stabilisation provided by the 2’-O-methyl group, under 
acidic conditions the glycosidic bond remains susceptible to hydrolysis. Therefore exposure to 
acidic conditions must be kept to a minimum in order to produce a sufficient quantity of the 
nitrated nucleoside. 
Reaction of 2’-O-methylguanosine with triethylamine and acetic anhydride in the presence of a 
4-dimethylaminopyridine (DMAP) catalyst generated the acetyl protected nucleoside in a 94% 
yield. DMAP acts as a nucleophilic catalyst increasing the rate of the esterification reaction208. 
Analysis of the product by 1H NMR spectroscopy confirmed the addition of the acetyl protecting 
groups due to the presence of two singlets at 2.07 and 2.13 ppm corresponding to the CH3 
groups. 
Following this, an electrophilic bromination reaction was carried out at the C8 position. 
Treatment of the acetylated 2’-O-methylguanosine with saturated bromine water formed the 
desired compound (2) in a yield of 88%. Evidence for the formation of the 8-bromo derivative 
included the disappearance of the peak corresponding to H8 at 7.98 ppm in the 1H NMR. 
Additionally mass spectrometry demonstrated an isotopic pattern corresponding to the 
incorporation of a bromine atom into the molecule. 
The exocyclic amine moiety N2 was then protected using dimethoxytrityl chloride (DMTCl) to 
give the fully protected nucleoside (3) in an 81% yield. Using a DMT protecting group has the 
advantage of greatly improving the solubility of the nucleoside in a range of organic solvents as 
prior to this step the compound was incredibly insoluble. The reaction was particularly sensitive 
to the presence of water, as it can quench the DMT cation formed during the SN1 reaction; 
therefore to ensure complete conversion the reaction was carried out under stringent 
anhydrous conditions. The use of anhydrous pyridine as the solvent not only ensured the 
exclusion of water from the reaction it also acts as an acid scavenger so any HCl generated in 
situ was neutralised. Diagnostic peaks in the 1H NMR spectrum of the N2-DMT nucleoside are 
a peak at 3.71-3.72 corresponding to the six methoxy protons and the appearance of aromatic 
protons at 6.90-7.14 ppm.  
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Largely the synthesis proceeded as reported and isolated yields were typical of those stated 
previously196. However the yields produced during the conversion of the 8-bromo analogue (3) 
to the 8-nitro analogue (4) were not in agreement with those stated by Saito et al. The reaction 
was carried out using a large excess of both 18-crown-6 and potassium nitrite, in DMF and 
was heated at 100°C for 6 hours. The high temperature is necessary to solubilise the 
potassium nitrite.  
Crown ethers are recognised as chelating agents209,210. Ion-dipole interactions form between a 
cation and the oxygen atoms of the polyether ring generating a stable complex. The size of the 
cavity is an important factor in determining which cations are complexed; 18-crown-6 is 
selective for potassium cations (or cations of a similar size)209. Hence, 18-crown-6 is capable 
of chelating the K+ cation from the ionic salt KNO2 thereby improving the nucleophilicity of the 
NO2- anion. 
The reaction was monitored by reverse phase (RP) high performance liquid chromatography 
(HPLC) in order to closely follow the conversion to the nitro compound; this also enabled us to 
limit the production of decomposition products, formed under the harsh conditions, by stopping 
the reaction when these became significant. Analysis of the major decomposition products 
identified the detritylated and the depurinated species. The UV absorption of the 8-nitroguanine 
base provides an efficient method for identifying whether the nitro functionality has been 
incorporated into a molecule. In contrast to the starting material, introduction of the nitro group 
gives the nucleoside a unique UV absorption at ~400nm; therefore it is possible to change the 
detection wavelength on the HPLC so that only molecules containing the 8-nitroguanine base 
are seen. This proved useful not only in identifying the product but also in monitoring the level 
of unwanted depurination which gives 8-nitoguanine as a by-product under the harsh 
conditions. 
Initially, consistently low yields of ~20% were achieved for the nitrated nucleoside and it was 
apparent that optimisation of the reaction was necessary. However, due to uncertainty 
regarding the mechanism by which the reaction proceeds, identifying conditions to improve the 
yield or elucidate the reaction mechanism have proved problematic. Although the reaction in 
vivo with peroxynitrite and its secondary reaction products are thought to proceed via a radical 
based mechanism, it is not clear whether this is the case for the reaction with KNO2. It is 
possible that the reaction could alternatively occur via an addition-elimination type mechanism 
(Figure 2.1). 
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Figure 2.1: Addition-elimination type reaction to form 8-nitroguanine. 
The first attempts to optimise the reaction conditions involved varying the reaction period and 
solvent. In addition to those previously examined by Saito et al., which used DMF and MeCN, 
the high boiling point solvent DMSO was investigated. The use of a polar aprotic solvent was 
required to facilitate solvation of the cation, leaving the anion free to readily react with the 
nucleoside. While acetonitrile generated very low yields of the nitrated nucleosides, DMF and 
DMSO both produced yields comparable to those previously achieved (~20%). Owing to the 
fact that DMSO has a higher boiling point and its removal was more problematic during 
purification, DMF was chosen as the most favourable solvent. 
In an attempt to determine whether the nitration proceeds via a radical or nucleophilic pathway, 
a radical initiator, azobisisobutyronitrile (AIBN), was added to the reaction. It was apparent that 
the radical initiator had no effect on the reaction rate or yield. This suggests that synthetically, 
a radical mechanism is not in operation as if this was the case there would have been a 
significant improvement in the reaction. However additional mechanistic investigation would be 
required to provide unambiguous proof of this. Further failed optimisation attempts have 
included; the use of an alternative source of nitrite (sodium nitrite and tetrabutylammonium 
nitrite), addressing the necessity of anhydrous conditions and an inert atmosphere and varying 
the number of equivalents of each reagent used. 
Efforts to optimise the reaction by varying the concentration illustrated that the reaction shows 
a high concentration dependence. The optimal concentration was found to be 0.01mM of the 
nucleoside achieving an improved yield of 36%. This suggests that there may be competing 
pathways in operation reducing the amount of the desired product generated. 
Speculating upon possible causes for the consistently low yields, it was considered that the 
bromide ion displaced during the reaction could theoretically undergo a further addition-
elimination reaction on the nitro compound to regenerate the starting nucleoside. This would 
account for the absence of by-products formed during the reaction. In order to investigate this, 
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silver (I) salts (AgNO3) were added to small scale reactions. The silver would sequester the 
free bromide ion from the reaction mixture thus eliminate the competing reaction pathway. 
However in the presence of the silver salts the yields were essentially unchanged suggesting 
that displacement of the nitro group by bromide was not a significant reaction. 
Unfortunately no further improvement on the 36% yield for the formation of the nitrated 
nucleoside could be obtained. Despite the yield being low, it was considered acceptable as it 
was possible to recover a significant amount of starting material which could be recycled and 
thereby generate a sufficient quantity of the desired product. 
The absence of protons close to the site of nitration resulted in a 1H NMR spectra similar to 
that of the 8-bromo nucleoside, with the only significant difference being the downfield shift in 
the H1 proton. This is a consequence of the close proximity of the nitro group in the preferred 
syn conformation of the nucleoside. Confirmation of the incorporation of the nitro group is 
evident in the 13C NMR as the peak corresponding to C8 shifts from 121.60ppm to 151.80ppm 
from the starting material to product respectively194. Furthermore, mass spectrometry indicated 
the presence of one isotope with an accurate mass consistent with that of the nitrated 
nucleoside. 
2.2 Manipulation of the protecting groups 
The fully protected 8-nitroguanine nucleosides are common intermediates which required 
further modification depending on the requirements of the project. One application is the 
incorporation into oligodeoxynucleotides. In order to prepare the nucleoside, manipulation of 
the protecting groups was necessary (Scheme 2.2). 
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Scheme 2.2: Synthetic route for the generation of 5’-O,N2-bis-dimethoxytrityl-8-nitro-2’-O-
methylguanosine. 
Typical for acetyl protecting groups, deprotection was carried out using methanolic ammonia 
which reacts with the ester (4) to form acetamide and the unprotected alcohol (5). Despite the 
reaction taking several days, the method is appropriate as it does not cause decomposition of 
the nucleoside. Removal of the excess base followed by purification by flash column 
chromatography afforded N2-dimethoxytrityl-8-nitro-2’-O-methylguanosine (5) in a nearly 
quantitative yield (95%). Confirmation of the deprotection was seen in the 1H NMR spectra due 
to the disappearance of the peaks at 2.09 and 2.05ppm corresponding to the CH3 group of the 
methyl esters.  
Protection at the 5’-hydroxyl group was then required; firstly, to ensure selective reaction at the 
3’-hydroxyl group in subsequent steps and secondly, they are the desired substrates for solid-
phase synthesis which will be discussed later in the chapter. Selective protection of the primary 
5’-hydroxyl group over the secondary 3’-hydroxyl group of nucleoside was achieved using 
DMTCl in anhydrous pyridine. The reaction proceeds via an SN1 mechanism. The 
predominance of the 5’-isomer is attributed to the steric bulk of the DMT cation and the greater 
nucleophilicity of the primary 5’-hydroxyl group. 
Whilst substitution is favoured at the 5’-position, the formation of small amounts of the di-
substituted nucleoside was observed. This was kept to a minimum by using a reduced number 
of molar equivalents of DMTCl and performing the reaction under moderate dilution. 
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Purification of the crude material by flash column chromatography afforded the 5’-O,N2-bis-
dimethoxytrityl-8-nitro-2’-O-methylguanosine (6) in a 78% yield. Addition of the second DMT 
protecting group was confirmed by a twofold increase in the integration of the peaks resulting 
from the trityl moiety. 
2.3 Synthesis of the 8-nitroguanine phosphoramidite 
 
Scheme 2.3: Formation of the 8-nitro-2’-O-methylguanosine phosphoramidite. 
Since the 5’-hydroxyl group is a more effective nucleophile than the secondary 3’-hydroxyl 
group, the phosphite group is best placed on the 3’-position to ensure efficient coupling during 
DNA synthesis. Following manipulation of the protecting groups, the suitably protected 
nucleoside underwent functionalization with 2-cyanoethyl-N,N-
diisopropylchlorophosphoramidite in the presence of a non-nucleophilic base N,N-
diisopropylethylamine to afford the phosphoramidite required for incorporation of the 
modification into oligodeoxynucleotides.  
The phosphitylation reaction proved difficult for a number of reasons. Firstly, monitoring the 
phosphitylation reaction was problematic. The retention factor (Rf) for both the starting material 
and the product were identical in various solvents, as a result the only indication that the 
reaction was proceeding was a slight colour change on developing the TLC plate with the p-
anisaldehyde stain. Secondly, the product was extremely sensitive to both oxidation and 
hydrolysis; however, exposure to these conditions was required in order to isolate the 
compound. Purification was carried out quickly and carefully under a nitrogen atmosphere to 
prevent decomposition of the phosphoramidite. Together these factors account for the low 
yield (45%). 
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The phosphorus atom in the phosphoramidite assumes a tetrahedral geometry, on account of 
it having three different substituents and a lone pair. Therefore due to the chiral centre, the 
phosphoramidite is generated as a mixture of two diastereoisomers. Both diastereoisomers 
were suitable for DNA synthesis since upon oxidation of the P(III) compound to the P(V) 
compound and subsequent deprotection of the 2-cyanoethyl group, the presence of two non-
bridging oxygens causes the phosphorus atom to become achiral. Conveniently this meant that 
separation of the two diastereoisomer was not necessary. 
Despite the factors complicating the synthesis and isolation of the phosphoramidite (7), the 
diastereoisomers were recovered in a reasonable yield (45%). Although 1H NMR could only be 
tentatively assigned, the appearance of aliphatic protons corresponding to the isopropyl amine 
and 2-cyanoethyl moieties was evident. Analysis by 31P NMR confirmed formation of the 
phosphoramidites as two distinct peaks at 152.06ppm and 150.57ppm corresponding to each 
diastereoisomer were identified. 
2.4 Introduction to solid-phase synthesis 
The solid-phase synthesis of nucleic acids is an automated method in which monomers are 
sequentially coupled to growing oligonucleotide sequence which is bound to a solid-support. 
The principle of solid-phase chemical synthesis was first developed by Bruce Merrifield in 1963 
which later (1984) earned him a Nobel Prize. The concept involved the tethering of the final 
amino acid in a peptide to a solid-support, followed by the sequential covalent linkage of the 
relevant amino acids to the fixed terminus. This elegant method allowed for reagents to be 
washed away from the resin following each synthetic step and upon completion of the 
sequence, the polypeptide was readily detached from the solid-support211,212. It was apparent 
that this solid-phase technique could be applicable to monomeric units other than amino acids; 
consequently the technique was adapted for the generation of oligonucleotides. 
Although various methodologies have been developed for the preparation of oligonucleotides; 
the phosphoramidite approach (Figure 2.2) is currently the most widely applied213,214. 
Phosphoramidite chemistry was first established by Beaucage and Caruthers in 1981215, based 
upon the phosphite-triester approach originally developed by Lestinger and Ogilvie216,217. The 
subtle exchange of a chloride leaving group for an amine functionality was fundamental in the 
development of the rapid, robust and efficient means by which oligonucleotides are prepared 
today. 
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Figure 2.2: The generic phosphoramidite route to oligodeoxynucleotides. 
Using this methodology, activated phosphoramidites are sequentially coupled to a growing 
oligonucleotide chain that is tethered to an insoluble support. In contrast to enzymatic DNA 
synthesis, chain elongation occurs in 3’- to 5’-direction. Therefore the oligonucleotide is bound 
to the solid-support via the 3’-terminal residue. Reverse oligonucleotide synthesis, that is, in a 
5’- to 3’-direction can also be achieved; however this approach has not been utilised to the 
same extent218,219.  
2.5 Protecting groups 
In 1961 Khorana et al. introduced the concept of a protecting group scheme which allowed for 
the selective removal of a particular group, at a given time, to facilitate sequential 
oligonucleotide synthesis; this concept is still used today220,221. The reactions utilised in DNA 
synthesis must take into consideration the high sensitivity of nucleic acids to a wide range of 
chemical reagents; therefore mild reaction conditions are required. A number of key criteria 
must be met for a protecting group to be compatible with DNA synthesis including; 
compatibility with reagents used during solid-phase synthesis, commercial availability and 
enhancing the solubility of the nucleoside. 
All nucleophilic moieties that are not directly involved in the coupling require suitable 
protection, to ensure that only the desired oligonucleotide product is generated. These include; 
the exocyclic amino groups of the heterocyclic bases, the 5’-hydroxyl group and the phosphoryl 
oxygen of phosphoramidite moiety. Since all standard nucleosides are 2’-deoxyribose sugars 
and the 2’-O-methyl substituent present on the modified nucleoside is permanently protected 
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and the therefore does not require additional protection, it is not necessary for the scope of this 
thesis to discuss protection of the 2’-hydroxyl group. 
2.5.1 Exocyclic amine nucleobase protecting groups 
The nucleobase protecting groups must be retained throughout assembly of the complete 
oligonucleotide as the residues are susceptible to reactions with electrophilic reagents. It is 
therefore appropriate to use base labile protecting groups since cleavage of the full length 
oligonucleotide from the solid-support is performed under basic conditions at the end of the 
synthesis. 
With the exception of thymine, which lacks an exocyclic amine functionality, all the other 
nucleobases require protection. In addition to preventing reactions from occurring at these 
positions, protection can be advantageous in enhancing the solubility of the nucleosides. 
The classically protected DNA nucleoside phosphoramidites utilised in all oligodeoxynucleotide 
syntheses outlined in this thesis are show in Figure 2.3. A benzoyl group is used to protect 
adenine and cytosine while an isobutyryl group is used to protect guanine215. Alternative 
protection schemes involving N4-acetyl-2’-deoxycytidine and N2-dimethylformamidine-2’-
deoxyguanosine phosphoramidites are now widely used when modifications render 
oligodeoxynucleotides unable to withstand strongly basic conditions214. These protecting 
Standard DNA phosphoramidite 
structure 
N6-benzoyl adenine 
N4-benzoyl 
cytosine 
 
  
N2-isobutyryl guanine Thymine 
  
Figure 2.3: General structure of the phosphoramidites utilised during oligodeoxynucleotide synthesis 
(left) and the exocyclic amine protecting group for each nucleobase (right). Note PG = protecting group. 
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groups are removed readily under conditions milder than those employed for the standard 
protecting groups. However for the scope of this thesis the use of these more labile protecting 
groups was not necessary. 
It was established in the first phase of this project conducted by Dr. I. Bhamra that the 
reactivity of the guanine base is significantly reduced by the incorporation of a nitro group at 
the C8 position. Consequently, permanent protection of the exocyclic amine group was 
considered not to be necessary. The DMT group retained at the N2 position was sufficient to 
enhance the solubility of the nucleoside; although it was undoubtedly removed during the 
subsequent detritylation steps of DNA synthesis194. 
2.5.2 5’-Hydroxy protecting group 
During solid-phase synthesis, the removal of the 5’-hydroxyl protecting group is required prior 
to the introduction of the subsequent nucleoside in the sequence. This sequential removal of 
protecting groups is the basis upon which the formation of unwanted by-products is avoided 
during oligodeoxynucleotide synthesis. As the solid-support and nucleobase protecting groups 
must be retained throughout assembly of the complete oligonucleotide, it is essential that the 
temporary protecting group on the 5’-position of the nucleoside is orthogonal to this. 
The classical triphenylmethyl (trityl) protecting group was largely unsuitable for the synthesis of 
oligodeoxynucleotides due to its cleavage conditions being sufficient to cause significant 
hydrolysis of the glycosidic bond of the acid labile purine nucleosides after repeated cycles of 
DNA synthesis. To avoid the use of strong acids for an extended period of time alternative trityl 
protecting groups were investigated. Introduction of a p-methoxy group to the trityl chlorides 
resulted in an increased rate of reaction and improved hydrolysis conditions acceptable for the 
use with DNA. Therefore, Smith et al. proposed the use of the DMT protecting group which 
combines good general stability with easy removal under mild acid conditions221,222. 
The dimethoxytrityl ether cleaves readily under acidic conditions as it forms a highly stabilised 
carbocation. The electron donating p-methoxy substituent increases the acid lability of the 
protecting group by offering higher resonance stabilisation to the carbocation formed during 
cleavage222. In addition to achieving high yields, retention of the DMT group during RP-HPLC 
purification ensures that failure sequences are well separated from the full length product. The 
DMT cation has a distinctive colour, which can be exploited as a diagnostic tool for measuring 
coupling efficiencies. Efficiencies of each cycle of nucleoside addition can be approximated by 
measuring the absorbance of the detritylation eluent and comparing it to that of the previous 
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step. The cation has a high extinction coefficient; consequently accurate measurements 
quantifying low concentrations of the species can be obtained. Nevertheless, these 
spectrophotometric methods can only be used as a guide for assessing coupling efficiencies 
and will be discussed in more detail later in the chapter. Interestingly, the distinctive colours of 
a range of triarylmethyl protecting groups have been exploited by Caruthers et al. in a colour-
coded method to confirm the sequence of synthetic oligonucleotides223. 
2.5.3 Phosphite protecting group 
A protecting group is also required for the anionic site of the oligodeoxynucleotide backbone; a 
variety of protecting groups have been evaluated for this purpose. During the 1980’s a methyl 
ester protecting group was used in solid-phase oligonucleotide syntheses. Evidence that the 
protecting group could cause small amounts of methylation at the N3 position of thymine, in 
addition to its unpleasant deprotection conditions lead to the development of an alternative 
protection scheme224. Tenner first described the 2-cyanoethyl group as a protecting group for 
phosphates in 1961225 and it was used by Letsinger and Ogilvie in early phosphotriester 
coupling reactions226. However, it was not until it was reintroduced by Sinha et al. and used in 
conjunction with the phosphoramidite approach, that this protecting group became the 
preferred choice for oligonucleotide synthesis224. 
The 2-cyanoethyl protecting group is compatible with solid-phase synthesis conditions and is 
conveniently removed under mild alkaline conditions, alongside the other permanent 
nucleobase protecting groups after generation of the full length oligonucleotide. As a 
consequence of the electron withdrawing 2-cyanoethyl protecting group, the phosphorus 
centre of the phosphite triester is rendered highly electrophilic. Therefore, reaction with the 5’-
hydroxyl group of the support bound nucleoside is favourable. 
Although in large scale syntheses, alkylation of the thymine base during ammonolysis has 
been detected227, it is not normally considered to be a significant problem for small scale 
reactions. Therefore cleavage from the support and deprotection can be performed using 
standard deprotection conditions without modification of the thymine residues in DNA. 
2.5.4 Solid-support and Linker 
The use of an appropriate solid-support is a consideration in efficient oligonucleotide synthesis. 
Many solid-supports have been developed; of these, controlled-pore glass (CPG) and 
polystyrene are the most prevalent. The support is held in a small synthesis ‘column’ that acts 
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as the reaction vessel, the dimensions of which can vary considerably dependant on the scale 
of the synthesis.  
The solid-support utilised for the DNA synthesis described in this thesis was a 500Å CPG 
consisting of deep pores and channels where the protected oligonucleotide is attached. The 
CPG provides a unique composition with a uniform pore size, which does not swell in organic 
solvents. Thus excess reagents can be efficiently rinsed from the column to avoid interference 
in subsequent steps of the synthesis. The rigidity of the support allows high flow rates of 
solvent and reagents. 
CPG supports can be defined by the diameter of their pores, which range from 500Å to 3000Å. 
Oligonucleotide assembly is strictly limited by the pore size; therefore, a larger pore size is 
required for the synthesis of a longer length oligonucleotide. The use of a support in which the 
pore diameter is too small, risks blockage and a reduction in the diffusion of the reagents 
through the matrix as the synthesis proceeds. Steric considerations factor in the loading 
density of the CPG. A loading within a narrow range of 30-60µmol g-1 is maintained to avoid 
crowding between chains and to achieve suitable coupling efficiencies2. The typical loading of 
the CPG can differ depending on the batch, consequently yield can vary accordingly. 
For the work described in this thesis, oligodeoxynucleotides greater than two units in length 
were prepared from supports purchased with the 3’-terminal residue pre-attached to the CPG 
support. The preparation of oligonucleotides which contain a modified nucleoside at the 3’-
terminus require the use of an alternative, so called universal support which can accommodate 
this. As this is applicable to the dinucleotides prepared in this thesis, universal supports will be 
discussed in more detail where appropriate. 
 
Figure 2.4: The solid-support consisting of the 3’-nucleoside connected to the CPG via a succinyl linker 
and a long chain spacer. Note PG = protecting group. 
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The linker and spacer between the matrix and the functionalised 3’-terminal nucleoside have 
been extensively researched. Primarily to optimise the spacer length and chemical structure of 
silica based solid-supports. In this case, the CPG support was functionalised with a long chain 
alkyl amine (LCAA) and a succinyl linker as shown in Figure 2.4228. Upon complete assembly 
of the full length oligodeoxynucleotide, it can be readily released from the solid-support and 
eluted from the column. 
2.5.5 Reaction scheme for solid-phase DNA synthesis 
A general reaction scheme for solid-phase synthesis is presented in Figure 2.5. 
 
Figure 2.5: The solid-phase synthesis of oligodeoxynucleotides via the phosphoramidite approach. 
Chapter 2  Results and Discussion 1 
59 
 
Step 1: Detritylation 
Detritylation (also known as deblocking) of the 5’-hydroxyl group of the terminal nucleoside 
bound to the solid-support is carried out under relatively mild conditions due to the lability of 
the activated DMT groups to weak acid. Treatment with 3% trichlororacetic acid (TCA) in 
dichloromethane (DCM) is suitably acidic to afford the free 5’-hydroxyl group. The reaction 
proceeds rapidly which is valuable in minimising depurination of acid labile nucleosides. 
Step 2: Activation and Coupling 
The coupling reaction can effectively be described as the substitution of the amine functionality 
of the phosphoramidite with the 5’-terminal hydroxyl group of the solid-support bound 
nucleoside; however the mechanism for this transformation is more complex. The 
phosphoramidite which corresponds to the second residue in the oligonucleotide sequence 
requires activation prior to its incorporation. 
Efficient activators are required to act as an acid to protonate the diisopropylamino group of the 
phosphoramidite, a good nucleophile to ensure rapid conversion to the activated intermediate 
and finally a good leaving group to enable the formation of the phosphite triester. Furthermore, 
the pKa of the acid is required to be high enough to ensure that it does not prematurely remove 
the DMT group from the phosphoramidite reagent, yet still acidic enough in order to assist in 
the activation of the phosphoramidite. Typically, tetrazole based activators are used for this 
purpose229. 
The originally used 1H-tetrazole has been increasingly replaced by alternative activators which 
exhibit improved coupling efficiencies and generate greater oligodeoxynucleotide yields. One 
of the most commonly used tetrazole based activators is 5-ethylthio-1H-tetrazole (ETT) and it 
has been used exclusively in the solid-phase synthesis outlined in this thesis. 
ETT has lower pKa (4.28) than that of 1H-tetrazole (4.89)230, as a consequence of the electron 
withdrawing group at the C5 position. The higher acidity of the activator renders it a better 
proton donor, thus generation of the active intermediate is more readily achieved leading to an 
increased rate of reaction. The efficiency of activation can additionally be improved with an 
activator solution of a higher concentration. It is therefore important that the activator does not 
have a low solubility in acetonitrile as this can lead to crystallisation in the DNA synthesiser at 
low temperatures, as can occur for 1H-tetrazole. Accordingly the higher solubility of ETT in 
acetonitrile is advantageous in improving the efficiency of the synthesis229. 
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Step 3: Capping 
While the efficiency of the coupling step is very high (99%), it has a finite failure rate. 
Consequently, there will be a small number (typically 0.1 to 1% abundance) of unreacted 5’-
hydroxyl groups of the solid-support bound nucleoside. If these were to remain exposed, they 
would be available to participate in the successive coupling step. The resulting 
oligodeoxynucleotide would lack one nucleoside relative to the full length oligodeoxynucleotide; 
thus corresponding to a deletion mutation. As these deletion mutations would accumulate 
following each coupling reaction, upon completion of the synthesis a complex mixture of 
oligodeoxynucleotides would be obtained. 
To prevent this, unreacted 5’-hydroxyl groups are acetylated using a mixture of acetic 
anhydride and N-methylimidazole in tetrahydrofuran and pyridine. This capping procedure 
serves to permanently block these positions to avoid further reactions in successive coupling 
reactions.  
Step 4: Oxidation 
The last step in the synthetic cycle involves oxidation of the phosphite triester to form a 
pentavalent phosphate triester, a protected precursor to the phosphate linkage between 
neighbouring nucleosides in an oligodeoxynucleotide. The phosphite triester is fairly unstable 
and susceptible to cleavage by acid, therefore it is necessary to stabilise the backbone prior to 
the following TCA detritylation step. This is achieved using a solution of iodine in THF in the 
presence of water acting as an oxygen donor and pyridine acting as a base. The conditions are 
mild to avoid the unwanted oxidation of the nucleobases. 
Following oxidation, the synthetic cycle relating to the addition of one nucleotide to the 
sequence is completed. Steps 1 to 4 are repeated for each nucleotide in the sequence. 
2.6 Synthesis of oligodeoxynucleotides containing 8-nitroguanine 
The detailed protocol for the synthesis of oligodeoxynucleotides containing 8-nitro-2’-O-
methylguanosine is presented in the experimental section. However the essential alterations 
for inclusion of this modification are as follows: 
 The concentration of the 8-nitro-2’-O-methylguanosine phosphoramidite was increased 
from 0.1M to 0.12M. 
 The coupling time was increased from 30 to 70 seconds. 
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 Removal of the final DMT group, following RP-HPLC purification used 20% acetic acid 
in distilled water rather than the typical 80% acetic acid solution.  
All oligodeoxynucleotides were prepared with the final DMT group retained (DMT-on) in order 
to facilitate purification by RP-HPLC. 
2.7 Oligodeoxynucleotides synthesised 
Overall six different oligodeoxynucleotides were successfully prepared; these are shown in 
Table 2.1. The site 1 oligodeoxynucleotide is a 13mer containing a centrally placed 8-
nitroguanine base and also contains all four natural nucleobases. It was originally prepared by 
Bhamra et al. to study the base pairing preferences of 8-nitroguanine194, but was prepared in 
this study to investigate the reactivity of the 8-nitroguanine base in oligodeoxynucleotides. 
Chemical modifications of the site 1 sequences are described in detail in the Chapter 3. The 
site 2 and site 3 oligodeoxynucleotides were prepared primarily as examples of longer 
oligodeoxynucleotides containing the 8-nitroguanine modification. These sequences also 
correspond to parts of the lac operon and were used to study in vivo replication and repair of 
the 8-nitroguanine lesion (see future work). Control sequences containing 2’-O-
methylguanosine were also prepared. 
Table 2.1: Showing the six different oligodeoxynucleotides synthesised. Note that the G** residues 
highlighted in red correspond to the modified 8-nitro-2’-O-methylguanosine and the G* residues 
highlighted in blue correspond to 2’-O-methylguanosine. 
The trityl traces recorded for site 1 and site 3 sequences are shown in Figure 2.6. These 
demonstrate the high overall coupling efficiencies achieved for the synthesis of the 
oligodeoxynucleotides. Despite there being two trityl groups on the modified monomer, the 
peak corresponding to the incorporation of this nucleoside is similar to that of the preceding 
Oligodeoxynucleotide Sequence 
Site 1 control d(GCGTACG*CATGCG) 
Site 1 d(GCGTACG**CATGCG) 
Site 2 control 5’-d(GCGCAACGCAATTAATGTG*AGTTAGCTCACTCATTAG)-3’ 
Site 2 5’-d(GCGCAACGCAATTAATGTG**AGTTAGCTCACTCATTAG)-3’ 
Site 3 control 5’-d(GTGACTGGG*AAAACCCTGGCGTTACCC)-3’ 
Site 3 5’-d(GTGACTGGG**AAAACCCTGGCGTTACCC)-3’ 
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coupling. This is likely due to the slow release of the DMT group from the N2 position over 
subsequent detritylation steps of DNA synthesis. 
 
Figure 2.6: Trityl traces obtained during spectrophotometric analysis of the detritylation solutions of a 
13mer (site 1) containing one 8-nitroguanine modification at position 7 (top) and a 27mer (site 3) 
containing one 8-nitroguanine modification at position 9 (bottom). Note that the 5’-terminal trityl group is 
not removed so no absorbance is recorded for the final residue. For sequences see Table 2.1. 
2.7.1 Standard post synthetic deprotection and purification 
Upon completion of the synthesis, the full length oligodeoxynucleotide remained attached to 
the CPG solid-support by the 3’-terminal nucleoside and the 5’-hydroxyl group was protected 
with a DMT group. Furthermore, the exocyclic amine base protecting groups and phosphate 
protecting groups were retained. Complete deprotection is necessary to isolate the pure 
oligodeoxynucleotide. This is carried out using a stepwise approach. 
The first step involved treatment with ammonium hydroxide at 55°C. This resulted in cleavage 
of the succinyl linker thus detaching the oligodeoxynucleotide from the solid-support. Under 
these conditions all base labile protecting groups were also removed. The aqueous solution 
was then evaporated and the oligonucleotide was subsequently purified by RP-HPLC using a 
C18 column. This technique separates molecules according to their hydrophobicity and 
polarity. The oligodeoxynucleotides were bound to the hydrophobic matrix in an aqueous 
triethylammonium bicarbonate (TEAB) buffer and eluted from the column using an increasing 
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gradient of acetonitrile. The retained 5’-terminal DMT group serves as a lipophilic ‘handle’ for 
purification. The hydrophobicity of the 5'-DMT group, only present on the desired 
oligodeoxynucleotides, allowed for convenient isolation and separation from the capped failure 
sequences which have much shorter retention times by comparison (Figure 2.7). 
  
Figure 2.7: Analytical RP-HPLC trace obtained for crude site 1 sequence which contains one 8-
nitroguanine modification. Peaks at ~11 minutes correspond to failure sequences and the peak at 21.69 
minutes corresponds to the full length DMT protected site 1 sequence (Control method 0-100, page 139). 
 
Figure 2.8: The analytical RP-HPLC trace recorded for the crude site 1 sequence at 350 nm where only 8-
nitroguanine derivatives have a significant absorbance. Arrow marks the position where 8-nitroguanine 
would elute (Control method 0-100, page 139). 
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As mentioned previously, the distinctive UV absorption of the 8-nitroguanine base at 
approximately 400nm provided us with a unique method for identifying whether it has been 
incorporated into any molecule. This unique method of identification was utilised to determine 
whether the 8-nitroguanine modification had been successfully incorporated into the 
oligonucleotide (Figure 2.8). Moreover, this proved valuable as a means to establish whether 
depurination had occurred releasing the 8-nitroguanine base. Figure 2.8 shows the RP-HPLC 
trace of the crude site 1 sequence recorded at 350nm. It shows only a single peak 
corresponding to the product and there is no peak at 8.40 minutes corresponding to the elution 
position of the 8-nitroguanine base. 
Treatment of the purified ‘DMT-on’ sequence with aqueous 20% acetic acid afforded the 
detritylated oligodeoxynucleotides. This deprotection step was deliberately kept short (20 
minutes) to minimise the possibility of depurination. To avoid prolonged exposure to acidic 
conditions the solution was neutralised with triethylamine. Therefore, in contrast to 
oligodeoxynucleotides which are comparatively stable in acid and can be purified at this stage 
by extraction with ethyl acetate, those containing an 8-nitroguanine modification required 
further RP-HPLC purification as a desalting step. 
Following the final RP-HPLC purification, the TEAB buffer salts were removed by repeated 
evaporation of the eluted oligodeoxynucleotides with water. The resulting 
oligodeoxynucleotides were analysed by RP-HPLC to ensure that they were recovered in 
satisfactory purity (<90%) and were thus suitable for the use in subsequent applications 
(Figures 2.9 and 2.10). 
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Figure 2.9: Analytical RP-HPLC trace obtained for the purified site 1 oligodeoxynucleotide containing one 
8-nitroguanine modification (Control method 0-100, page 139). 
 
Figure 2.10: The analytical RP-HPLC trace recorded for the purified site 1 at 350nm showing the 
absorbance corresponding to the 8-nitroguanine residue within the oligodeoxynucleotide (Control 
method 0-100, page 139). 
2.7.2 Yields and characterisation of oligodeoxynucleotides 
Since the typical loading of the CPG solid-support is in the range of 30-60µmol g-1 the exact 
quantity of oligodeoxynucleotide being produced for a given batch of columns can vary. 
Therefore the yields calculated for oligodeoxynucleotide synthesis is an approximation rather 
than accurate calculation. For this approximation, it was assumed that each reactor column 
had 1µmol of the 3’-terminal nucleoside. Providing each coupling reaction was quantitative, 
theoretically the full length oligodeoxynucleotide would be produced in a 1µmol scale. 
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   Average masses 
Oligodeoxynucleotide OD260 units Yield (%) Theoretical Experimental 
Site 1 control 31.65 26 3975.7066 3975.6844a 
Site 1 39.02 32 4050.7025 4050.6133a 
Site 2 control 25.72 7 nd nd 
Site 2 66.60 18 nd nd 
Site 3 control 51.04 20 8311.42 8314.74b 
Site 3 29.21 11 8460.31c 8460.64b 
Table 2.2: Showing the OD260 units, approximate yields (%) and average theoretical and experimental 
masses for the oligodeoxynucleotides synthesised. Note, nd = not determined, a determined by 
electrospray ionisation, b determined by MALDI and c corresponds to (M-4H)+3Na+K. For sequences see 
table 2.1. 
As the length of the oligodeoxynucleotide sequences increased, the yield of the full length 
product was generally lower. This can be attributed in part to the limitations of the chemistry. 
Even with a 99% coupling efficiency for each addition, the cumulative effect of a 1% failure rate 
can be significant, particularly for long oligodeoxynucleotides. Consequently, the relative 
proportion of failure sequences increases according to the length of the oligodeoxynucleotide. 
Regardless of the quantity of the crude material produced in the synthesis, the yield was 
dramatically reduced during deprotection and purification. Additionally, the increased 
processing required in the purification of oligodeoxynucleotides containing the 8-nitroguanine 
modification was detrimental to the yields, however this was unavoidable. The yields were 
calculated based on extinction coefficients for the oligodeoxynucleotides (see experimental 
section). The yields obtained for synthesis of the modified oligonucleotides is comparable to 
those that are unmodified, thus it was concluded that the synthetic mimic did not significantly 
affect the overall synthesis. 
The principle technique for the characterisation of oligodeoxynucleotides was negative mode 
electrospray mass spectrometry (ESMS). This method has limitations since a molecular weight 
of the parent free acid oligodeoxynucleotide, in which all of all the phosphate groups are 
protonated, cannot be directly obtained. Multiple phosphoryl protons are removed during 
ionisation and as a result a series of multi-charged ions were observed for the mass to charge 
ratio (m/z). It was possible to determine experimental m/z values for multi-charged ions fitting 
the formula [M-nH]n-, where M represents the free acid of the oligodeoxynucleotide and n is the 
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number of charges. Using these values it was possible to determine an average experimental 
m/z value of the parent free acid. 
The molecular weights of the 27mer site 3 oligodeoxynucleotides were determined by MALDI 
and gave masses consistent with the products. The presence of the 8-nitroguanine base in 
both the site 2 and site 3 oligodeoxynucleotides was also confirmed by the absorption at 
350nm in their HPLC traces. 
2.8 Synthesis of dinucleotides 
Oligonucleotide syntheses are generally carried out utilising CPG solid-supports to which the 
3’-nucleoside has been pre-attached. This is appropriate for oligonucleotides containing a 
standard nucleobase at the 3’-terminus. However the preparation of oligonucleotides which 
comprise a modified nucleoside at the 3’-terminus require the use of an alternative support. 
The synthesis of the first universal support for the construction of oligodeoxynucleotides was 
published by Gough et al in 1983. This approach was based upon utilising a terminal uridine 
residue which was removed during treatment with Pb2+ once the synthesis had been 
completed231. Since their discovery many alternative universal supports have been described 
in the literature232–234; a number of these are commercially available. The supports can either 
be nucleoside derived or non-nucleosidic; the majority of which incorporate a 5 membered ring 
similar to the ribose moiety of nucleosides as in Figure 2.11. 
 
Figure 2.11: The universal solid-support attached to the CPG via a hydroquinone-O,O'-diacetic acid linker 
and a long chain alkyl amine (LCAA) spacer. 
In this approach the 3’-nucleoside is added during the first coupling reaction; however this 
generates an undesired phosphate linkage between this nucleoside and the universal support. 
This undesired phosphate group is conveniently removed alongside the other protecting 
groups following generation of the full length oligonucleotide during post synthetic processing. 
For use in studies investigating detection of the 8-nitroguanine lesion using SERS (Chapter 4), 
the synthesis of a dinucleotide (dimer) containing two 8-nitro-2’-O-methylguanosine 
modifications and the corresponding unmodified 2’-O-methylguanosine dimer were required 
Chapter 2  Results and Discussion 1 
68 
 
(structures shown in Figure 2.12). The universal support utilised for this synthesis was that 
developed by Pon et al. (Figure 2.11). It is readily available, and compatible with the 
established phosphoramidite chemistry235. A DMT group is incorporated at the site of 
elongation to enable real-time coupling efficiency measurements.  
 
Figure 2.12: The dinucleotide species required for SERS detection studies. 
The synthesis was largely carried out as described previously (Chapter 2, Section 6) when 
using the 3’-functionalised support. Only minor adjustments of the conditions were required in 
order to adapt the procedure for the universal support. Since the support was non-nucleosidic, 
an initial extended detritylation step was performed in order to ensure that complete 
detritylation of the support was achieved prior to the first synthetic cycle. Upon completion of 
the synthesis, the dimer remained connected to the universal solid-support and the 5’-hydroxyl 
group was protected with a DMT group. Post synthetic deprotection was achieved using a 
solution of concentrated aqueous ammonia and methylamine heated to 55°C for 17 hours 
which 
In the case of the unmodified dimer (8) purification with the 5’-DMT group still attached to the 
dimer proceeded as expected affording the desired product in an excellent yield of 68% based 
on the loading of the resin. The dimer was analysed using RP-HPLC establishing the purity of 
the recovered sample to be 97%. Characterisation by negative mode ESMS provided 
conformation of the generation of the dimer; a mass of 655.1617 was observed compared to 
the calculated mass of 655.1626 (Table 2.3). 
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   Average masses 
Dimer OD260 units Yield (%) Theoretical Experimental 
8 14.65 68 655.1626 655.1617 
9 0.97 4 745.1327 745.1313 
Table 2.3: Showing the OD260 units, approximate yields (%) and average theoretical and experimental 
masses for the dimers synthesised. 
Isolation of the 8-nitro-2’-O-methylguanosine dimer (9) however was somewhat problematic. 
The crude 5’-DMT protected dimer was analysed by RP-HPLC following post synthetic 
deprotection; however there was no peak in the chromatograph representative of what we 
thought at this stage was the bis-DMT protected dimer. This was unexpected as the coupling 
efficiencies measured using the online spectrophotometer present in the DNA synthesiser, 
suggested that the coupling reactions has proceeded in a good yield. 
Thus aside from the nitro group, which is hydrolytically stable under basic conditions, the only 
variation between the two systems is the additional DMT protecting groups on the N2 position 
of the modified bases (Figure 2.13). 
 
Figure 2.13: Showing the structures of the bis- and tris-DMT dimers prior to purification. 
It was anticipated that the DMT group on the 3’-nucleoside would be removed during the 
subsequent detritylation step, leaving a bis-DMT protected species which would elute in the 
HPLC conditions utilised. However subsequent review of the literature revealed that removal of 
trityl groups from primary amines requires stronger acidic conditions or extended reaction 
times236. Therefore it was most likely that the crude product was the tris-DMT dimer and the 
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inability to purify the modified dimer using RP-HPLC was attributed to the extreme lipophilicity 
of the molecule. It was envisaged that had the DNA sequence been longer, the DMT groups on 
the 8-nitroguanine base would have been removed during successive detritylation steps, as 
was apparent for the longer oligodeoxynucleotides previously synthesised. 
In order to obtain a sample suitable for purification, following cleavage from the universal 
support, the crude DMT protected dimer was exposed to conditions analogous to those which 
the longer oligodeoxynucleotides underwent during the DNA synthesis. The modified dimer 
was treated three times with a 3% TCA solution prior to purification in order to generate the 
fully detritylated dimer (9) which was sufficiently polar to be eluted by RP-HPLC. Unfortunately, 
due to the extra steps necessary to purify the 8-nitro-2’-O-methylguanosine dimer, the yield for 
the reaction was lower than expected (4%). Nevertheless, characterisation using negative 
mode ESMS confirmed generation of the desired product; an accurate mass of 745.1313 was 
obtained compared to the calculated mass of 745.1327 (Table 2.3). 
2.9 Conclusion 
A fully protected 8-nitro-2’-O-methyguanosine derivative was successfully prepared in solution 
via a four step procedure. Although the hydrolytically stable analogue was generated using this 
methodology, there is obvious scope for improvement. The nitration reaction remains relatively 
low yielding despite numerous optimisation attempts and perhaps a thorough investigation of 
palladium catalysed coupling reactions would give rise to a more efficient method of 
nitration237. Nevertheless, the devised route provided sufficient quantities and purities of the 
compound for the purposes of this thesis. This synthetic pathway was also reproduced starting 
from the readily available ribose sugar derivative. At this point, the synthesis diverges into two 
distinct pathways dependant on whether the monomer or oligodeoxynucleotide is appropriate 
for the prospective application. 
Following manipulation of the protecting groups, a phosphoramidite was prepared that was 
suitable for the incorporation into DNA. Oligodeoxynucleotides 13, 27 and 37 residues in length 
were generated by the application of a solid-phase synthesis protocol previously developed for 
the 2’-O-methyl analogues. In total, three unmodified and three modified oligodeoxynucleotide 
strands were prepared using a 3’-functionalised solid-support. Additionally a dinucleotide 
containing two 8-nitro-2’-O-methylguanosine modifications and the corresponding unmodified 
2’-O-methylguanosine dimer were prepared. These sequences are suitable for the use in the 
chemical and biological applications described in the following chapters.  
 
 
 
 
 
  
Chapter 3 
Results and Discussion 2: 
Reactions of 8-nitroguanine nucleosides and oligodeoxynucleotides 
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3 Results and Discussion 2 
3.1 Substrates for studying the reactions of 8-nitroguanine 
This chapter describes studies on the reactions of the 8-nitroguanine base in both nucleoside 
and oligodeoxynucleotide substrates. Whilst the synthesis of 8-nitro-2’-O-methylguanosine 
derivatives were described in the previous chapter, because of the relative expense of the 
methylated starting material, it was decided that 8-nitroguanosine would be used for these 
studies. This was considered appropriate as like the 2’-O-methyl derivative, it is also relatively 
stable to depurination due to the additional hydroxyl group destabilising the oxonium ion 
intermediate and making the hydrolysis process less favourable.  
The synthesis of 8-nitroguanosine and some of its partially protected derivatives is shown in 
Scheme 3.1. This route is analogous to that previously described in Chapter 2 Section 1 for the 
2’-O-methyl derivative. The reaction conditions and product yields were comparable to those in 
the 8-nitro-2’-O-methylguanosine synthesis. Thus a fully protected derivative of 8-
nitroguanosine (13) was prepared in an overall yield of 22% from guanosine (Scheme 3.1). For 
the studies described in this chapter it was also necessary to prepare the triacetylated 
derivative of 8-nitroguanosine (14) and the fully deprotected 8-nitroguanosine (15). These were 
obtained using standard deprotection conditions and the yields and reaction conditions are 
shown in Scheme 3.1. 
Additionally, a sample of the 8-nitroguanine base (16) was required for the use as a standard 
to monitor depurination; this was most readily prepared via treatment of 13 with 1M HCl at 
60ºC. Upon complete depurination, the solution was neutralised using 1M NaOH; care was 
taken to maintain a pH greater than 7 to avoid the formation of salts. Filtration of the resulting 
precipitate afforded the 8-nitroguanine base as an orange solid in a 79% yield. The success of 
the depurination reaction was confirmed by the absence of peaks corresponding to the carbon 
atoms in the ribose sugar in the 13C NMR. 
Chapter 3  Results and Discussion 2 
73 
 
 
Scheme 3.1: Synthetic route to 8-nitroguanosine analogues. 
3.2 Alkylation of 8-nitroguanine 
Before discussing the alkylation reactions performed on 8-nitroguanine nucleosides it is 
necessary to briefly review this area. The most nucleophilic sites of the DNA bases have 
previously been identified238,239. Given that the nitrated nucleoside demonstrates a significantly 
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reduced reactivity towards electrophiles due to the electron withdrawing nature of the nitro 
group, it is reasonable to assume that these would not be in agreement with 8-nitroguanine.  
 
Figure 3.1: Failed attempts to derivatise the nucleobase after nitration. * These reactions were attempted 
by Dr I. Bhamra. 
To illustrate this point, a series of reactions are shown in Figure 3.1 which can be carried out 
successfully using guanine nucleosides, however prove to be unsuccessful when performed on 
8-nitroguanosine. Attempts to introduce any of the customary protecting groups, namely acetyl, 
methyl, silyl and formamidine groups and notably efforts to reinstate the trityl group after 
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nitration were ineffective. This failure to derivatise the base demonstrates the extent to which 
the reactivity is reduced by the nitro group. The intrinsic reactivity of the 8-nitroguanine 
nucleoside is of interest in order to gain a comprehensive understanding of the molecular basis 
by which the lesion reacts synthetically and in vivo.  
Alkylating agents are a class of strongly electrophilic species that can react with the 
nucleophilic sites of nucleic acids. A wide range of compounds have been used and studied as 
DNA alkylating agents since the use of cytotoxic ‘mustard gas’ during World War I and World 
War II. It was the delayed biological effects of exposure to low doses of these agents, in 
particular, the inhibition of cell division, that led nitrogen mustards to be evaluated as antitumor 
agents240. This demonstrates the multifaceted role that alkylating agents can play in 
mutagenesis; while they are known to induce cancer, they can also be utilised as a treatment. 
Alkylating agents react with the nucleobases to generate a variety of covalent adducts that 
vary in complexity and regiochemistry. Comprehensive structural characterisation of these 
adducts provides vital information on the types of DNA lesions that can be formed by alkylating 
agents241. 
In order to explore the behaviour of the 8-nitroguanine base, it is first appropriate to discuss 
some general principles of chemical reactivity. The terms ‘hard’ and ‘soft’ are often used to 
describe the varying reactivities of a molecule. Oxygen is considered a ‘hard’ nucleophile and 
its reactions are governed by charges and electrostatic effects. Nitrogen atoms are considered 
to be ‘softer’ nucleophiles than oxygen and are dominated by orbital overlap between the 
HOMO of the nucleophile and the LUMO of the electrophile. Electrophiles can also be defined 
in terms of their ‘hard’ or ‘soft’ nature. ‘Hard’ electrophiles are generally charged species or 
those which contain dipoles while soft electrophiles are dominated by orbital interactions. 
Typically hard nucleophiles prefer to react with hard electrophiles and likewise soft 
nucleophiles with soft electrophiles17. Therefore it is reasonable that the reactivities of the 
various nucleophilic sites of the nucleobases differ accordingly. 
These concepts are consistent with results determined previously for the alkylation of 
nucleosides. For example, hard electrophiles such as those generated by N-alkyl-N-
nitrosourea react via SN1 like processes forming adducts at the electronegative oxygen atoms. 
Whereas soft electrophiles such as dimethyl sulfate and methyl iodide react via SN2 like 
processes to modify the nitrogen nucleophiles239,242–244. 
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Quinone methides are a class of DNA alkylating agents, structurally related to quinones, which 
appear often in both chemistry and biology. Of the three possible isomers, para (1,4) and ortho 
(1,2) quinone methides are the most commonly utilised. Essentially a quinone methide is a 
formally neutral benzylic carbocation, whereby electron donation from the oxygen substituent 
in the para or ortho position contributes towards resonance stabilisation (Figure 3.2). This 
results in molecules that are highly reactive and formally undergo reactions as a Michael 
acceptor. Meta (1,3) substituted ortho quinone methides are comparatively unstable as there is 
no orbital interaction between the meta oxygen and the substituents on the aromatic ring245,246.  
 
Figure 3.2: Resonance stabilisation of para (left) and ortho (right) quinone methide. 
The extensive conjugation of quinone methides generates a benzylic carbon which is highly 
electron deficient making it extremely susceptible to nucleophilic attack; hence it is an 
attractive compound for investigating the properties of the seemingly inert 8-nitroguanine base. 
The reactions between guanine and various quinone methides have been extensively studied 
previously244, it is therefore of interest to be able to compare these results to those obtained 
with the modified nucleoside. 
In order to characterise the nucleophilicity of 8-nitroguanine and evaluate the broader 
implications of these results, the reactions of two quinone methides were examined. 
3.3 Synthesis of a para quinone methide adduct of 8-nitroguanine 
The applications of quinone methides are largely limited to reactions in which the activated 
species is generated in situ from a precursor247. The intrinsic reactivity of a quinone methide, 
that is its propensity to rapidly undergo exocyclic nucleophilic attack, prevents the synthesis 
and isolation of the unstable species prior to reaction. Quinone methides can be stabilised to 
varying degrees by the attachment of bulky groups at the positions ortho to the quinone 
oxygen; thus producing a diverse range of molecules with broad reactivities. The presence of 
large, hydrophobic alkyl substituents, such as tert butyl groups at the 2- and 6-positions, 
effectively prevents solvent interactions with the carbonyl oxygen. Consequently the oxidised 
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quinone methide exists predominantly in the uncharged form and whilst it can still undergo the 
addition of nucleophiles, it is significantly more stable244,247,248. 
Initial efforts were targeted towards the generation and characterisation of an adduct from the 
reaction between 8-nitro-2’,3’,5’-tri-O-acetylguanosine (14) and a para quinone methide 
derivative. All of the hydroxyl groups on the sugar remained protected throughout the alkylation 
studies in order to prevent competing reactions at these positions and aid in purification. 
Scheme 3.2 shows the oxidation of the 2,6-disubstituted phenol, butylated hydroxytoluene 
(BHT), with a large excess of silver oxide (Ag2O) to produce the corresponding quinone 
methide244. Following filtration, the para quinone methide derivative was reacted directly with 
the partially protected 8-nitroguanosine (14) in DMF at 37°C (Scheme 3.2). The reaction was 
monitored closely by TLC and RP-HPLC; after 1 hour all the starting material had been 
consumed. Purification by flash column chromatography generated a single product (17) in a 
68% yield.  
 
Scheme 3.2: Para quinone methide adduct formation. Note, the numbering system of the nitrogen atoms 
in the guanine base is shown in blue. 
The nucleophilic addition of the nucleoside to the electron deficient benzylic carbon of the para 
quinone methide is formally a Michael addition. However, the reaction is significantly different 
to a typical Michael addition as the reaction restores the aromatic stability of the 
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cyclohexadiene ring. Re-establishing the aromaticity of the phenol is thermodynamically 
favourable and therefore drives the reaction245. 
Structural assignments for the alkylated species have not been trivial and have relied 
principally on the interpretation of NMR chemical shifts and their comparison with those values 
previously determined. The literature example whereby deoxyguanosine is alkylated by a para 
quinone methide results in the formation predominantly of the N2 adduct (Scheme 3.3). Minor 
products as a result of alkylation of the N1 and N7 positions were additionally observed; 
though the N7 adduct was unstable and subsequently depurinated to form the guanine 
derivative244. 
 
Scheme 3.3: Showing the literature example of the alkylation of deoxyguanosine with para quinone 
methide244. 
Interestingly, upon evaluation of reaction with the nitrated guanosine derivative (14) there was 
considerably evidence to suggest that the N1 product is exclusively formed. The HPLC data 
and mass spectrometry both confirmed the conversion to a single mono-alkylated product, 
although using these techniques it was not possible to determine which of the competing 
nucleophilic sites of 8-nitroguanine had been modified. 
Structural characterisation was achieved using 1D and 2D NMR studies. The resonance of the 
protons and carbon at the benzylic position are highly sensitive to the site by which they are 
attached to the nucleoside244. Therefore it was necessary initially to ascertain which signals 
were associated with the CH2 group at the benzylic position. This was determined using 
distortionless enhancement by polarization transfer (DEPT), correlation spectroscopy (COSY) 
and heteronuclear single quantum coherence (HSQC) experiments.  
Two CH2 peaks were identified in the 1H NMR spectrum corresponding to the C5’ and the 
benzylic carbon resonance. By utilising HSQC and COSY experiments it was then possible to 
identify the associated protons. HSQC correlates protons with the heteronuclei through which 
they are directly attached to; therefore this experiment determined which proton signals were 
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related to both of the CH2 groups in the molecule. This was followed by analysis of the 
acquired COSY spectra. The cross peaks indicate couplings between neighbouring protons, 
therefore the isolated benzylic protons at 5.11ppm are easily identified. These key 
assignments enabled complete characterisation of the 8-nitroguanosine adduct. 
The benzylic resonance in the 13C NMR at 45.64ppm is characteristic of a carbon-nitrogen 
bond; this is supported since a chemical shift of approximately 70ppm would be expected 
should the benzylic carbon have been attached to an oxygen atom. From the 1H NMR it was 
possible to determine which nitrogen atom was alkylated. Acquisition of the spectra in a non-
protic solvent indicated the absence of the signal corresponding to the N1 proton resonance 
which was present in the starting material at 11.34ppm. Additionally, the broad peak at 
6.06ppm corresponding to the N2 signal integrated to 2 protons. These observations confirm 
that alkylation occurred at the N1 position. This assignment was strengthened as when 
compared to the N2 alkylated product from the literature reported reaction between 
deoxyguanosine and para quinone methide these observations were reversed; the peak at 
10.35ppm associated to the N1 proton was present and the signal associated with the N2 
protons integrated to 1244.  
The pKa values for deprotonation of the N1 position of 8-nitroguanosine and guanosine have 
previously been calculated to be 8.4 and 9.5 respectively194. This increased acidity reflects the 
electron withdrawing capacity of the nitro group. Therefore alkylation occurring exclusively at 
the N1 position could be attributed to the influence the nitro substituent has on the reactivity of 
the modified base. 
3.4 Synthesis of an ortho quinone methide adduct of 8-nitroguanine 
Following these interesting results, we focused upon characterisation of the products 
generated from the reaction of the partially protected 8-nitroguanosine (14) with ortho quinone 
methide. The simplest and most efficient route to form the alkylating agent was using the 
procedure devised by Rokita et al. for an ortho quinone methide precursor (o-QMP)243,249. The 
o-QMP was based on an ortho cresol derivative in which the hydroxyl group is protected as a 
silyl ether and functionalised with a bromine leaving group at the benzylic position. 
The silyl group is frequently used for the protection of alcohol moieties due to the ease of 
which it is removed by nucleophilic attack of a fluoride anion. The best nucleophiles with 
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regards to silicon are charged and highly electronegative, therefore efficient and selective 
removal can be achieved due to the strong affinity of silicon for fluorine17. 
The synthetic pathway followed to obtain the o-QMP is shown in Scheme 3.4. The silyl ether 
was prepared by treatment of ortho cresol with tert-butyldimethylsilyl chloride (TBDMSCl) in the 
presence of a weak base and nucleophilic catalyst, imidazole. The product (18) was isolated in 
a 97% yield by partitioning the reaction mixture between DCM and sodium hydrogen carbonate 
(NaHCO3) to remove excess reagents. Successful silylation was confirmed by 1H NMR 
spectroscopy through the appearance of characteristic peaks corresponding to the 6 methyl 
protons and 9 tert-butyl protons at 0.20ppm and 1.00ppm respectively. 
 
Scheme 3.4: Synthetic pathway towards o-QMP. 
The next step in the synthesis was functionalisation of the benzylic position with a bromine 
leaving group. A radical halogenation reaction was carried out using N-bromosuccinimide 
(NBS) in the presence of AIBN a radical initiator250. The resulting resonance stabilised benzylic 
radical then reacts in a radical chain mechanism ultimately generating the bromo methyl 
derivative. Purification by flash column chromatography afforded the desired product as a 
colourless oil in a 91% yield. Mass spectrometry clearly demonstrated the presence of a 
bromine atom as the peak representing the molecular ion consists of two molecular ions 
differing by 2 amu. 
The reaction with the 8-nitroguanine nucleoside was initiated by the in situ activation of the o-
QMP using potassium fluoride239. Nucleophilic attack of the fluoride anion at silicon atom leads 
to a pentacoordinate intermediate; this is permitted as the orbitals of silicon do not have to 
conform to same geometric constraints as carbon centres17. Subsequent elimination of the 
bromide ion generates the activated ortho quinone methide (Scheme 3.5).  
 
Scheme 3.5: Mechanism for the generation of the activated ortho quinone methide. 
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Initially, a small scale reaction between the nucleoside and ortho quinone methide was 
performed and monitored closely by TLC and RP-HPLC. There was significant evidence to 
suggest that two nucleoside derived products were formed. As previously discussed, the 
introduction of a nitro group at the C8 position of guanine nucleosides shifts the UV spectrum 
towards longer wavelengths. Therefore these distinctive UV properties can be exploited to 
monitor the production of alkylated 8-nitroguanine derivatives. The polarities of the two new 
species varied as was evident from their different retention times on RP-HPLC of 16.55 and 
17.58 minutes, suggesting that more than one alkylation reaction may have occurred. Taking 
into account both the lipophilic and hydrophilic functionalities of the molecule it is reasonable to 
assume that a higher order alkylated species would be significantly less polar than the mono-
alkylated species and have a longer retention time on RP-HPLC.  
In order to isolate a suitable quantity of the two products and clarify the effect of varying the 
number of equivalents of o-QMP, optimisation of the reaction conditions was necessary. 
Consequently, a number of small-scale test reactions were carried out. The time dependent 
profiles produced for the adducts formed upon varying the number of equivalents of ortho 
qunione methide in the reaction are shown in Figure 3.3. 
 
Figure 3.3: Showing the time dependent profile of 8-nitroguanine alkylation with variation of the number 
of equivalents of o-QMP. Note, starting material (retention time = 6.47 minutes) is represented by a blue 
line, the more polar species (retention time = 16.55 minutes) with a red line and the less polar (retention 
time = 17.58 minutes) with a green line (Control method 65/35B, page 141).  
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Whilst the greatest yield of the most polar product was obtained using 2 equivalents of o-QMP, 
these conditions only generated 4% of the less polar species. Therefore in order to maximise 
production of both species the reaction was carried out using 4 equivalents of o-QMP as this 
generated an even distribution of both products. Purification of the crude material by flash 
column chromatography isolated the less polar (21) and more polar species (20) in yields of 
27% and 40%, respectively. The generation of a higher order alkylated nucleoside (21) was 
confirmed as both mass spectrometry and various NMR experiments identified that the two 
products generated were the mono- and di-substituted species. 
 
Scheme 3.6: Formation of ortho quinone methide adducts. Note, the numbering system of the oxygen and 
nitrogen atoms in the guanine base is shown in blue. 
For the mono-alkylated product (20), nucleophilic attack of the ortho quinone methide occurred 
exclusively at the N1 position. Structural characterisation for this compound was achieved 
using 1D and 2D NMR; the results were consistent with those determined for the N1-(para 
quinone methide)-8-nitroguanosine derivative. 
In contrast to the mono-alkylated species, DEPT experiments detected three CH2 resonances 
for the di-alkylated species (21). Previous analysis enabled us to unambiguously assign the 
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C5’-nuclei; therefore the resultant signal at 63.59ppm was discounted. The remaining two 
signals had chemical shifts of 67.25ppm and 39.89ppm in the 13C NMR spectrum; these 
resonances are characteristic of a benzylic carbon-oxygen bond and a benzylic carbon-
nitrogen bond and therefore indicates that O6 is one of the alkylation sites242,251. Since oxygen 
is more electronegative than nitrogen, the carbon-oxygen bond is more polarised, that is the 
oxygen atoms draws the electrons in the bond away from the benzylic carbon more effectively 
than nitrogen. The change in the distribution of electrons causes the benzylic carbon to be less 
shielded from the applied external magnetic field and therefore resonates at higher frequencies 
than the corresponding carbon-nitrogen bond17. 
With regard to the second alkylation site on nitrogen, alkylation at the N1 position seemed 
unlikely as this would generate unfavourable steric interactions with the substituent present in 
the O6 position. Moreover, substitutions at the N3 and N7 positions can be disregarded as they 
would result in unstable nucleosides that depurinate readily at room temperature242. 
Convincing evidence was obtained to support these conclusions. 1H NMR spectra recorded in 
a non-protic solvent revealed the presence of a single NH signal which integrated to one 
proton. This is consistent with the structure of the O6,N2 di-alkylated species as the product 
exists as the enol tautomer and therefore there is no proton present at the N1 position.  
The assumption that the N1 alkylated species would not be able to undergo further alkylation 
reactions due to steric factors was confirmed by subjecting the mono-alkylated species to a 
second reaction with ortho quinone methide. The reaction was monitored closely by RP-HPLC; 
while a less polar nucleoside derived polar was briefly observed it rapidly decomposed back to 
the mono-alkylated species. This suggested that the species was unstable and therefore its 
formation unfavourable. Taking this evidence into account the di-alkylated species was 
assigned as O6,N2-bis-alkylated product (21).  
3.5 Conclusion 
This represents the first example of the generation of an O6,N2 di-alkylated guanosine 
derivative using ortho quinone methide The literature example whereby deoxyguanosine is 
alkylated by ortho quinone methide results in the formation of the both the N2 and N1 
substituted adducts239,242. Though there is computational evidence to suggest that alkylation at 
the O6 position of 9-methylguanine (as a model for deoxyguanosine and guanosine) is as a 
result of kinetic control and modification of the N2 position is generated by thermodynamic 
equilibrations, there is not synthetic evidence to support this252. These results demonstrated 
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the dramatic effect nitration has on the intrinsic reactivity of the nucleoside. It was proposed 
that di-alkylation was not observed when using the para quinone methide species as due to the 
size of the alkylating agent, steric interactions resulting from additional alkylation would cause 
this process to be unfavourable thus preventing the formation of higher order alkylated 
species. 
  
Chapter 3  Results and Discussion 2 
85 
 
3.6 Identification of the 8-nitroguanine lesion using a sulfur nucleophiles 
8-Nitroguanine serves as a biomarker for exposure to inflammation and nitrative stress; it may 
also have the potential to identify associated carcinogenesis. At present there is no method 
that is capable of detecting the levels of 8-nitroguanine in DNA. This is a consequence of the 
susceptibility of the glycosidic bond to hydrolysis following nitration which results in release of 
the 8-nitroguanine base, and the formation of an abasic site in the DNA. Abasic sites arise 
under a variety of circumstances, so it is not possible to distinguish those caused by nitrative 
DNA damage. 
Currently, the most efficient method to quantify production of the lesion entails determination of 
the levels of free 8-nitroguanine in biological fluids151,155. Unfortunately using these analytical 
methods it is not possible to identify whether the 8-nitroguanine detected is formed in the 
nucleotide pool, in RNA or in DNA. Therefore our aim was to generate a method to stabilise 
the lesion within DNA in order to minimise depurination and enable its detection via a sensitive 
technique such as fluorescence. Such a technique would potentially provide a method to 
quantify the steady state levels of this lesion in DNA. 
Fluorescence is one of the many different luminescence processes by which molecules emit 
light. When a molecule is predisposed to absorb electromagnetic energy it is known as a 
fluorophore. Fluorescence can be defined as the light emitted during the rapid relaxation of a 
fluorophore following excitation by light of a specific wavelength253,254.  
Fluorescent nucleosides that have been reported to date are as a result of various 
modifications that range from covalently attaching a fluorescent moiety to the molecule,  to 
directly altering the structure of the nucleobase itself to generate a fluorescent analogue; this 
typically results in minimal perturbation of the natural structure255. As the 8-nitroguanine lesion 
is non-fluorescent, labelling the nucleoside with an extrinsic fluorophore would introduce the 
desired characteristics. 
It is essential that the fluorescent analogue demonstrates the specificity to covalently bind to 
and hence detect the 8-nitroguanine modification, differentiating it from the naturally occurring 
nucleosides. For this purpose, a thiol nucleophile was investigated. Evidence suggests that the 
nitro group is reactive towards sulfur nucleophiles. Saito et al. have previously described the 
reaction of an endogenous 8-nitroguanine derivative with proteinous thiols, thus providing the 
basis for this approach196. Research very recently published by Fuchi et al. demonstrated the 
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covalent capture of 8-nitroguanosine, facilitated by the formation of multiple hydrogen bonds, 
using thiol containing recognition molecules256. The electron donating nature of the thioether 
substituent is favourable as it stabilises the lesion by increasing the electron density of the 
nucleoside through an inductive donating effect.  
The chemical nature and the length of the linker between the fluorescent molecule and the 
nucleoside are of high importance as they can dramatically influence the accessibility and the 
binding of the fluorophore. Due to the simplicity and versatility of the approach, amide bonds 
were chosen to connect the fluorophore to the nucleophilic thiol. 
3.7 Glutathione displacement reactions 
In order to obtain proof of principle, prior to the development of a fluorescent analogue, the 
potential of the concept was verified using glutathione. Glutathione is tripeptide, comprising of 
glutamic acid, cysteine, and glycine residues257 (Scheme 3.7). 
As the reaction will inevitably be carried out under physiological conditions when analysing 
DNA, it is advantageous to develop a protocol compatible with these conditions from the offset. 
However, at this early stage in development, stabilising the labile glycosidic bond in aqueous 
solution prior to its displacement takes precedence over an entirely accurate representation of 
physiological conditions. Consequently the use of a basic 0.1M TRIS HCl (pH 9) buffer was 
considered appropriate.  
The thiol displacement reaction was performed by treating 8-nitroguanosine (15) with a five-
fold excess of glutathione at 37ºC. RP-HPLC was used as a tool to monitor the reaction. Due 
to uncertainty as to which peak in the HPLC trace corresponded to the desired product, our 
aim was to measure the disappearance of 8-nitroguanosine. Additionally this approach was 
valuable in determining the extent of depurination as the 8-nitroguanine base appears as an 
additional peak (retention time = 9.62 minutes) when the chromatograph is recorded at 350nm. 
Upon a 97% conversion of the starting material (retention time = 12.9 minutes), the aqueous 
solution was then evaporated and the product was isolated by RP-HPLC. The new product had 
a shorter retention time (10.34 minutes) than the starting material which was consistent with 
the greater polarity of the glutathione substituent. The purified product was isolated in a 61% 
yield as an off white solid. 
Incorporation of glutathione and displacement of the nitro group was confirmed by mass 
spectrometry, though this did not establish through which atom the adduct was covalently 
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attached. Complete characterisation of the product was critical as glutathione has a number of 
nucleophilic sites with the potential to displace the nitro group, or preferentially functionalise an 
alternative position of the unprotected nucleoside. Therefore, in order to unambiguously 
determine the structure, 1D and 2D NMR experiments were required. 
As the C8 carbon is not directly connected to a proton, the structure of the adduct could not be 
confirmed using short-range heteronuclear correlation. Therefore a heteronuclear multiple 
bond correlation (HMBC) experiment was performed. This technique is used to study 2J and 3J 
connectivity between carbon (or other heteroatom) and hydrogen atoms; direct 1J correlations 
are supressed. 
Analysis of the 1H-13C HMBC contour map showed that there was a correlation between the 
C8 of guanosine and the CH2 group adjacent to the sulfur atom. This established that it is the 
sulfur atom of glutathione acting as a nucleophile to displace the nitro group via an addition-
elimination type mechanism, thus confirming the reactivity of the nitrated nucleoside to thiols 
(Scheme 3.7). 
 
Scheme 3.7: Formation of the C8 glutathione adduct of guanosine. 
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The next aim was to investigate this reaction using the site 1 oligodeoxynucleotide which 
contains the 8-nitroguanine base. This would give a better indication as to how applicable this 
reaction would be to detect this lesion in DNA samples. In preparation, it was decided to 
prepare the glutathione adduct of 8-nitro-2’-O-methylguanosine (24) as this would be a useful 
standard if it proved necessary to characterise the product oligodeoxynucleotides by enzymatic 
digestion. Given the relative expense of 2’-O-methylguanosine and the poor yields of the 
nitration step, it was decided to prepare the glutathione adduct (24) from 8-bromo-2’-O-
methylguanosine (Scheme 3.8). 
The glutathione adduct was prepared by treating 8-bromo-2’-O-methylguanosine (23) with 5 
equivalents of glutathione in a 0.1M TEAB buffer (pH 7.5) at 37°C (Scheme 3.8). The use of 
TEAB was appropriate as this is a more volatile buffer which can easily be removed and 8-
bromoguanosine is not susceptible to depurination therefore more basic conditions were not 
necessary. The reaction was monitored and the product purified using RP-HPLC. The 
increased reaction time required and modest yield of 21% demonstrated the greatly reduced 
susceptibility of the bromo derivative to undergo nucleophilic displacement with a sulfur 
nucleophile when compared to 8-nitroguanosine. 
 
Scheme 3.8: Formation of the glutathione adduct of 2’-O-methylguanosine. 
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Complete structural characterisation was achieved using the same techniques and reasoning 
as employed for the ribose derivative. Confirmation of the displacement was seen from the 1H 
NMR spectrum by the appearance of a peak at 4.51-4.56ppm corresponding to the proton 
directly attached to the glutathione chiral centre in the molecule. Once again the position by 
which glutathione was covalently bonded to the C8 position was verified using a HMBC 
experiment. The long range 1H-13C correlation between C8 and the diastereotopic protons 
adjacent to the sulfur atom was apparent and confirmed that the sulfur atom was acting as the 
nucleophile. 
Following these positive results, the reaction was attempted utilising the site 1 
oligodeoxynucleotide consisting of 13 nucleotides with a single modification located in the 
central position. The reaction was carried out by treating the site 1 oligodeoxynucleotide 
(~26µM) with a large excess of glutathione at pH 9 and 37°C.  
 
Scheme 3.9: Formation of the site 1, adduct 1 oligodeoxynucleotide. Note GOMe = 2’-O-methylguanosine. 
The course of the reaction was monitored by RP-HPLC for 18 hours after which no further 
changes were detectible. Interestingly, the strong yellow colour which is typical of all 8-
nitroguanine containing derivatives was discharged as the reaction proceeded. With regards to 
the RP-HPLC analysis, a new peak (11.46 minutes) was detected which was marginally more 
polar than the starting material (12.32 minutes) and was not visible at 350nm where only nitro 
derivatives are detected. The similar mobilities of the two oligodeoxynucleotides on RP-HPLC 
was unsurprising as taking into consideration the size and composition of sequences it is 
reasonable that the addition of a glutathione substituent would not dramatically affect the 
polarity. This complicated the RP-HPLC purification to a certain extent however the desired 
product (site 1, adduct 1) was isolated.  
The main technique for characterisation of the purified site 1, adduct 1 oligodeoxynucleotide 
was negative mode ESMS which has been discussed previously (Chapter 2 Section 6.4). The 
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identity of the product was confirmed by ESMS which showed a mass of 4310.7052 for the 
glutathione adduct. 
These results successfully demonstrated that sulfur nucleophiles produced the desired effect 
of displacing the nitro group in oligodeoxynucleotides, thus verifying the feasibility of the 
concept. Following this proof of principle, the development of a fluorescent thiol analogue was 
investigated. 
3.8 Development of fluorescent thiol analogue 
Polycyclic aromatic compounds are an extensively used class of fluorescent dyes. The first 
fluorescent dye fluorescein, derived from xanthene, was synthesised by Baeyer in 1871258,259. 
Despite its long history, fluorescein remains one of the most extensively utilised fluorophores in 
modern biochemical research260.  
For the purpose of this research 5(6)-carboxyfluorescein was considered an appropriate 
fluorophore as the carboxylic acid provided a versatile means to derivatise it with the required 
thiol nucleophile through amide bond formation. The formation of amide bonds is an important 
reaction in organic chemistry and many different strategies have been devised for this 
objective261. The synthesis of an amide bond is formally the condensation of a carboxylic acid 
and an amine; however this reaction does not occur spontaneously. Consequently it is first 
necessary to activate the carboxylic acid towards nucleophilic substitution261. This can be 
achieved by converting the OH of the carboxylic acid group into a good leaving group, for 
example an acyl chloride or an ester17. The most commonly used coupling reagents for amide 
bond formation include; carbodiimide, phosphonium and uronium derived reagents261.  
The strategy developed in this case was to functionalise both amine groups of cystamine with 
two equivalents of the fluorophore and subsequently cleave the disulfide bond to generate the 
required thiol nucleophile (Scheme 3.10). Upon reviewing the literature it was apparent that 
only one other example of formation of the fluorescent disulfide had been attempted and 
unfortunately there was no characterisation data available262. Nevertheless, this provided the 
basis upon which the synthesis was developed. 
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Scheme 3.10: Synthetic route to the fluorescent thiol. 
The procedure as originally published utilised a combination of benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and 1-hydroxybenzotriazole 
(HOBt) as the coupling reagents262. However as the coupling agent N,N,N′,N′-tetramethyl-O-
(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) was readily available and is often 
considered more stable than phosphonium reagents, this reagent was judged to be a suitable 
substitute for PyBOP.  
The reaction was carried out by activating 2 equivalents of 5(6)-carboxyfluorescein (this is a 
mixture of regioisomers with the carboxylic acid at either the 5 or 6 position) in DMF by 
treatment with a combination of HBTU, HOBt and DIPEA followed by the addition of cystamine 
dihydrochloride. Purification of the crude material by flash column chromatography afforded the 
desired compound (25) as a mixture of isomers. The complexity of the product, a result of the 
starting material being a mixture of isomers, permitted only a tentative assignment of 1H NMR 
and 13C NMR spectrum. Consequently characterisation primarily replied upon mass 
spectrometry. A good high resolution mass spectrum was obtained finding a mass of 891.1291 
compared to the calculated mass of 891.1289.  
The next stage in the synthesis was cleavage of the disulfide bond of the cystamine moiety. 
Initially we envisaged the use of sodium borohydride for this purpose263; however following 
several failed small scale attempts at the reaction, an alternative reducing agent was sought. 
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Dithiothreitol, also known as Cleland’s reagent, is the most popular reagent utilised for the 
reduction of disulphide bonds in biological molecules264–266. This suggested an alternative 
route for generation of the nucleophilic thiol molecule. Therefore reduction of the disulphide 
was performed using dithiothreitol (Scheme 3.10). Initially the reaction was extremely slow and 
low yielding, but increasing the temperature to 37°C generated the fluorescent thiol (26) in a 
vastly improved yield of 77%. Characterisation of the compound was again complicated due to 
the product being a mixture of isomers; however the 13C NMR chemical shift corresponding to 
the α carbon indicates the presence of a thiol as opposed to a disulfide. An upfield shift in the 
resonance signal, from 38.27ppm to 22.89ppm, is observed upon conversion to the thiol. This 
is consistent with results observed in the literature when distinguishing between disulfides and 
thiols, although the magnitude of the shift difference was somewhat larger than expected267. 
The fluorescent thiol adduct was then prepared by treating 8-nitro-2’-O-methylguanosine (27) 
with 1.5 equivalents of the fluorescent thiol (26) at 37°C in TEAB buffer (0.1M) (Scheme 3.11). 
Whilst monitoring the reaction using RP-HPLC, it was established that oxidation of the thiol 
starting material to the disulfide was competing with the displacement reaction. Therefore a 
further 1.5 equivalents of the fluorescent thiol (26) were added to the reaction to ensure that 
enough of the nucleophile was present for the displacement reaction to occur. Although 
consumption of the starting material was completed in 2 hours, there were multiple peaks in 
the HPLC trace which were not attributable to the desired product. The luminescent yellow 
colour of the product simplified purification and flash column chromatography afforded the 
desired product (28) as a mixture of isomers in a 45% yield. The complexity of the isomers 
means that only a tentative assignment of 1H NMR spectrum could be carried out and other 
methods were used for the characterisation of these compounds. Therefore in order to 
characterise these compounds, HPLC analysis and mass spectrometry were utilised. HPLC 
analysis was recorded at both 260nm and 350nm. Despite the compound being a mixture of 
isomers, only one peak was observed for the product at 260nm. As there was no observable 
peak corresponding to the product at 350nm, which specifically reveals 8-nitroguanine 
derivatives, it could be concluded that the nitro group was displaced during the reaction. 
Characterisation by mass spectrometry provided additional confirmation of the generation of 
the C8 substituted fluorescent nucleoside, as a mass of 729.1636 was observed compared to 
the calculated mass of 729.1615. 
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Scheme 3.11: Formation of the fluorescent adduct of 2’-O-methylguanosine. 
The reaction was then adapted for the displacement of the nitro group within an oligonucleotide 
(Scheme 3.12). The reaction was carried out by treating a solution of the site 1 
oligodeoxynucleotide (~26µM) in TRIS HCl buffer (pH 9, 0.1M) with a large excess of the 
fluorescent thiol nucleophile (26) at 37°C. The use of a pH 9 buffer was anticipated to facilitate 
the reaction by increasing the concentration of the reactive thiolate and by reducing 
depurination. The reaction was monitored by RP-HPLC over a 24 hour period. During this time 
the peak corresponding to the starting oligodeoxynucleotide decreased in intensity and a 
number of new peaks developed which did not have absorbances at 350nm. The complicated 
nature of the chromatograph recorded for this reaction made determining which peak 
corresponded to the desired product challenging. However, based upon retention times and 
co-injections of known compounds, for example the thiol nucleophile and the disulfide, it was 
established that there were four peaks present which could represent the product. Therefore 
isolation of these peaks by RP-HPLC yielded four compounds which were subsequently 
analysed by mass spectrometry in order to ascertain which peak corresponded to the 
fluorescent oligodeoxynucleotide. It was established that the desired fluorescent yellow product 
eluted at 18.63 minutes compared to the starting material which had a retention time of 11.55 
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minutes. The isolated product (site 1, adduct 2) was obtained in 1% yield, this is less than 
expected however as identification and isolation proved problematic, this was acceptable. 
Characterisation by ESMS verified that the displacement reaction had been successful as a 
mass of 4438.7090 was recorded compared to the calculated mass of 4438.7810 
 
Scheme 3.12: Formation of the site 1, adduct 2 oligodeoxynucleotide. Note GOMe = 2’-O-methylguanosine. 
3.9 Displacement reactions using a fully protected cysteine derivative 
Whilst it has been shown that both glutathione and the fluorescent thiol can replace the nitro 
group in nucleosides and oligodeoxynucleotides, neither are ideal reagents for studying and 
optimising this reaction. The glutathione product (site 1, adduct 1) has a retention time on 
HPLC that is very close to the nitrated site 1 oligodeoxynucleotide starting material and 
analysis of reactions with the fluorescent thiol are complicated by the mixture of isomers. As an 
alternative, a simple partially protected cysteine derivative was chosen, which due to the 
lipophilicity of the protecting groups was expected to increase the HPLC retention time of the 
product oligodeoxynucleotide. Conveniently cysteine also has a low extinction coefficient and 
therefore HPLC analysis will not be complicated by absorbances resulting from the 
nucleophile. 
With the aforementioned in mind, a route to a partially protected cysteine nucleophile was 
developed starting from the readily available N,N’-bis(tert-butoxycarbonyl)cysteine (Scheme 
3.13). Protection of the carboxylic acid group was performed according to a protocol previously 
described in the literature268. The reactive carboxylic acid groups were simultaneously 
protected by the sequential addition of ethanol, DMAP and N,N’-dicyclohexylcarbodiimide. The 
fully protected diethyl ester (29) was isolated in an 80% yield following purification by flash 
column chromatography. The emergence of signals in the 1H NMR corresponding to the CH3 
and CH2 groups of the ester at 1.28-1.32 and 4.20-4.26 respectively confirmed the recovery of 
the desired product. 
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Reduction of the disulphide bond was performed using dithiothreitol as previously described. 
The reaction was heated at 37°C for 18 hours to obtain the crude fully protected cysteine thiol. 
Purification by flash column chromatography afforded the pure product as a white solid in a 
73% yield. Although NMR experiments produced spectra which were largely consistent with 
that of the starting material, the presence of a single set of peaks and characteristic chemical 
shifts in the 13C NMR conclusively proved the structure of the product. An upfield shift, from 
41.46ppm to 27.49ppm, in the signal corresponding to the carbon α to the thiol group again 
confirmed that the disulfide bond was reduced267.  
 
Scheme 3.13: Synthetic route to the protected cysteine nucleophile. 
Displacement reactions were then carried out on both 8-nitroguanosine and 2’-O-methyl-8-
nitroguanosine utilising the cysteine derivative 30 (Scheme 3.14). The reaction progress was 
monitored by TLC and in both cases conversion to a single nucleoside product was achieved 
in 2 to 4 hours. Following purification by flash column chromatography, the substituted 
guanosine (31) and 2’-O-methylguanosine (32) analogues were isolated in a 69% and 72% 
yield respectively. 
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Scheme 3.14: Displacement of the nitro group with the fully protected cysteine derivative. 
Complete structural characterisation was accomplished using the same techniques and 
reasoning as employed previously. The position by which the cysteine nucleophile was 
covalently attached to the nucleoside was verified using a HMBC experiment. Analysis of 1H-
13C HMBC contour map revealed a long range 1H-13C correlation between the C8 resonance 
and the protons adjacent to the sulfur atom, thus confirming that the sulfur atom had displaced 
the nitro group in addition-elimination type reaction. The 2’-O-methyl analogue generated was 
a suitable standard for comparison purposes following enzymatic digestion of the DNA. 
Since the displacement reactions were successful when utilising the 8-nitroguanine 
nucleosides, the reaction was applied to oligodeoxynucleotides containing the lesion. Thus the 
site 1 oligodeoxynucleotide (~26µM) in TRIS HCl buffer (pH 9, 0.1M) was treated with a large 
excess of protected cysteine thiol at 37°C (Scheme 3.15). 
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Scheme 3.15: Formation of the site 1, adduct 3 oligodeoxynucleotide. Note GOMe = 2’-O-methylguanosine 
and Pro-Cys = Boc-Cys-OEt. 
The progress of the reaction was closely monitored by RP-HPLC. It was evident the reaction 
proceeded more rapidly than those previously investigated. HPLC analysis indicated that there 
was approximately a 58% conversion of the starting material to a single product after 2.5 hours 
and the reaction appeared to go to completion within 6 hours (Figure 3.4). The HPLC analysis 
was also monitored at 350nm and upon complete conversion, the chromatograph showed no 
observable peak corresponding to 8-nitroguanine derivatives which absorb at this wavelength. 
The HPLC trace was considerably cleaner than those obtained previously; it appeared that a 
single product was exclusively formed. The product (site 1, adduct 3), which had a retention 
time of 14.78 minutes in comparison to the starting material which eluted at 12.55 minutes, 
was isolated using RP-HPLC. The site 1, adduct 3 oligodeoxynucleotide was obtained in 85% 
yield, which represents an excellent conversion from the starting material. 
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Figure 3.4: Chromatographs documenting the conversion from the site 1 oligodeoxynucleotide (retention 
time = 12.55 minutes) to the site 1, adduct 3 oligodeoxynucleotide (retention time = 14.78 minutes). Top = 
0 hours, middle = 2.5 hours, bottom = 6 hours (Control method 0-65, page 140).  
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Characterisation of the oligodeoxynucleotide was carried out using negative mode ESMS. 
Replacement of the nitro group on the modified 2-O-methylguanosine in the site 1 
oligodeoxynucleotide with the protected cysteine derivative (30) caused an increase in 
molecular weight of 200.0717, thus obtaining an accurate mass of 4250.6850 for the product 
compared to the calculated mass of 4250.7996. 
Given the simplicity of the reaction with the protected cysteine derivative and the exclusive 
formation of the desired product, displacement of the nitro group within longer 
oligodeoxynucleotides was investigated. Typically, longer length oligodeoxynucleotide 
sequences are more representative of naturally occurring DNA as they often feature some 
degree of secondary structure formation. Therefore utilising longer sequences synthesised 
previously for biological applications would support the principle of detecting 8-nitroguanine 
within DNA. 
The displacement reactions of both the site 2 (37mer) and site 3 (27mer) 
oligodeoxynucleotides with the cysteine nucleophile were carried out using the same 
conditions as discussed previously for the preparation of site 1, adduct 3. Although the 
reactions were considerably slower when compared with that of site 1, they were completed in 
11 hours. The site 2 and site 3 oligodeoxynucleotides were both predominantly converted to a 
single product with retention times of 13.74 and 14.13 minutes respectively compared to the 
starting materials which eluted at 12.52 and 12.82 minutes. 
Unfortunately the high molecular weight of these oligonucleotides meant that analysis of the 
product using ESMS was not feasible. It was considered that the oligodeoxynucleotides would 
be better suited to analysis by the matrix-assisted laser desorption/ionization (MALDI) 
technique, unfortunately this service was not available within the department. Thus inquiries 
have been made about the possibility of submitting these samples to external analytical service 
departments. 
Consequently, to date characterisation of the longer oligodeoxynucleotide sequences has 
primarily relied upon HPLC analysis. The increased retention time is indicative of incorporation 
of the cysteine nucleophile into the oligodeoxynucleotides. The possible generation of an 
oligodeoxynucleotide containing an abasic site could be disregarded as it had been 
established within the group that the depurinated species has a shorter retention than that of 
the staring material194. Confirmation of the displacement of the nitro group is also apparent due 
to the disappearance of the absorbance in the HPLC chromatograph at 350nm corresponding 
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to the 8-nitroguanine nucleoside. This analysis provided convincing evidence that the 
generation of the desired oligodeoxynucleotides was successful, but more conclusive evidence 
was sort. 
3.10 Characterisation of oligodeoxynucleotide adducts by enzymatic digestion 
Given the problems associated with characterising the site 2, adduct 3 and site 3, adduct 3 
oligodeoxynucleotides, the presence of the cysteine adduct could be established by enzymatic 
hydrolysis to the constituent nucleosides and subsequent analysis by HPLC. 
Phosphodiesterases are responsible for catalysing the hydrolysis of phosphodiesters to 
monophosphate esters. Intracellular phosphodiesterases play a role in signal transduction 
while extracellular phosphodiesterases are present in venoms and their mechanism of action is 
through the stepwise removal of nucleoside 5’-monophosphates from the 3’-end of 
oligodeoxynucleotides269,270. Alkaline phosphatase is then responsible for catalysing the 
hydrolysis of nucleoside 5’-monophosphates to produce inorganic phosphate and the 
nucleoside271. These enzymatic processes generate a hydrolysate which can be analysed by 
HPLC to determine the base composition of DNA. This is achieved by comparing the 
constituent nucleoside retention times to those of natural and synthetically prepared standards.  
Enzymatic digestion of the site 1, adduct 3 sequence was performed using phosphodiesterase 
I from Crotalus Atrox and alkaline phosphatase from bovine intestinal mucosa. The reaction 
was heated at 37ºC for 2 hours to ensure complete hydrolysis of the oligodeoxynucleotide. The 
proteins were precipitated with ice cold ethanol and the heterogeneous mixture was separated 
using centrifugation.  
The relative amounts of deoxyadenosine, deoxycytidine, deoxyguanosine, thymidine and the 
modified 2’-O-methylguanosine in the hydrolysate were analysed using RP-HPLC. The 
nucleoside composition analysis for the enzymatic digestion is shown in Figure 3.5. The 
chromatograph was recorded at 280nm as both the standard and modified nucleosides have 
acceptable extinction coefficients and hence absorbances at this wavelength. By comparing 
the retention times of the remaining unidentified peaks to various reagents and the standards 
which have previously been synthesised, assignments for the key peaks were achieved.  
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Figure 3.5: Chromatograph showing the RP-HPLC nucleoside composition analysis of the site 1, adduct 3 
oligodeoxynucleotide at 280nm. Peaks 1, 2, 3, and 5 correspond to deoxycytidine, deoxyguanosine, 
thymidine and deoxyadenosine respectively. The UV properties of peak 4 indicated that this was also 
nucleoside derived. Peaks 6 and 7 were as a result of residual phophodiesterase and alkaline 
phosphatase enzymes (Control method 0-100B, page 139).  
Displacement of the nitro group with the cysteine nucleophile resulted in nucleoside (32) which 
was considerably less polar than those which are naturally occurring. Accordingly, the retention 
time of adduct 32 was increased to 21.69 minutes on RP-HPLC and it was identified as 
corresponding to peak 9. The integration of the peaks can be used to determine the relative 
amount of each constituent nucleoside in an oligonucleotide and hence establish its 
composition. However, the integration for peak 9 was lower than expected. Interestingly peak 8 
at 19.07 minutes corresponded to the retention time of the cysteine nucleophile (30). This was 
not evident in the chromatograph of the oligodeoxynucleotide prior to enzymatic hydrolysis. 
Therefore the possibility of the thiol substituent being displaced during the reaction was 
investigated. 
To examine this, initially the cysteine substituted nucleoside (32) was treated with 
phosphodiesterase and alkaline phosphatase to determine if the enzymes were not compatible 
with this substrate; however no significant changes were identified. In order to test the 
remaining variable of the enzymatic hydrolysis, the cysteine substituted nucleoside was 
dissolved in TRIS HCl buffer and heated overnight. It was apparent upon analysis that 
decomposition of the nucleoside generated a species which eluted with a retention time 
comparable to peak 4. 
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It was considered that the C8 cysteine substituted nucleoside was possibly being hydrolysed in 
the aqueous buffer to generate 8-oxo-2’-O-methylguanosine and the cysteine derivative (30). 
Consequently, synthesis of an 8-oxo-2’-O-methylguanosine standard (33) was carried out in 
order to confirm this hypothesis. The 8-oxoguanine derivative was generated according to a 
protocol previously described in the literature (Scheme 3.16)272. Briefly, 8-bromo-2’-O-
methylguanosine (23) was heated with sodium benzyloxide in DMSO to produce the 8-
benzyloxy-2’-O-methylguanosine. Following isolation by flash column chromatography, direct 
treatment of the intermediate with 1M HCl in methanol generated the crude 8-oxo-2’-O-
methylguanosine (33). Careful trituration of the residue afforded the desired product as a pale 
yellow sold in a 42% yield. The proton environments of the starting material and product are 
essentially identical in MeOD; therefore characterisation relied principally on 13C NMR and 
mass spectrometry. A downfield shift from 117.44ppm to 152.30ppm was observed for the 
signal corresponding to C8, which is consistent with the literature value and therefore 
confirming the structure of the 8-oxo-2’-O-methylguanosine (33). 
 
Scheme 3.16: Synthetic route for the synthesis of 8-oxo-2’-O-methylguanosine. 
RP-HPLC comparison of 8-oxo-2’-O-methylguanosine and peak 4 (Figure 3.5) revealed them 
to co-elute thereby suggesting that the unidentified peak in the chromatograph was as a result 
of decomposition of the cysteine adduct. Although the presence of the C8 cysteine derivative 
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was established using enzymatic hydrolysis and subsequent HPLC analysis of the hydrolysate, 
quantitative analysis was not feasible. 
3.11 Conclusion 
The concept of displacing the nitro group from an 8-nitroguanine derivative within an 
oligodeoxynucleotide using nucleophilic thiols has been demonstrated. The covalent 
attachment of an extrinsic fluorophore, with the specificity to covalently modify the lesion would 
provide a method to directly detect the levels of 8-nitroguanine in DNA. Additionally, 
displacement of the nitro group using this method would prevent depurination, thereby 
stabilising the adduct for further analysis; although further investigation would be required in 
order to study the hydrolytic stability of the thiol adduct. Thus these derivatives could become 
useful chemical probes for monitoring levels of 8-nitroguanine derivatives in vivo and act as a 
biomarker for inflammation related cancers. Future work will need to investigate the stability of 
the 8-thioguanine adducts to hydrolysis. 
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Results and Discussion 3: 
Detection of the 8-nitroguanine lesion using surface enhanced Raman 
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4 Results and Discussion 3 
4.1 A brief overview of SERS 
The research presented in this chapter was carried out by Susan Dick, supervised by 
Professor Steven Bell at Queen’s University, Belfast. In order to discuss the sensitive detection 
techniques utilised in this application, it is first appropriate to give a brief overview of the 
principles regarding Raman scattering. 
Raman spectroscopy is a technique which can provide insight into the structure of a molecule 
by analysing its vibrational transitions; in this respect it is related to infra-red spectroscopy273. 
An important distinction between these two techniques is while the intensity of an IR 
absorbance is determined by changes in the dipole moment during vibration, Raman signals 
are dependent on a change in polarisability, that is how easily the electrons are distorted in 
response to an external field274. 
The principle of Raman scattering is based upon the premise that upon the interaction of light 
with a substrate, in addition to being transmitted or reflected, a small proportion of the photons 
are scattered. The majority of photons emerge having the same frequency as the incident 
radiation, this is known as elastic or Raleigh scattering. A small quantity of the light scattered 
following a collision with the molecule has a different frequency than that of the incident 
radiation. When energy is transferred from the incident photon to a molecule, excitation of the 
vibrational bonds within the molecule occurs274,275. Essentially, the molecule is promoted to a 
virtual excited state, the molecule then emits a photon of a lower energy (longer wavelength) 
than that which was absorbed. The loss of the photon causes the molecule to decay to a lower 
vibrational state, but as some of the incident photons energy has been transferred to the 
molecule, the energy level is above the initial ground state276. This is defined as stokes 
scattering.  
The alternative is also possible, thus if the molecule is initially in a higher vibrational state, the 
photon may gain energy from the vibration. This causes the molecule to decay to the ground 
state and the scattered light to be of a higher energy (shorter wavelength) than the incident 
radiation. This is defined as anti-stokes scattering; this situation is less frequent and is often 
associated with an increase in temperature of the system274–276. 
The applications of Raman spectroscopy are limited due to it being an inherently weak 
process. For this reason, surface-enhanced Raman scattering (SERS) and surface-enhanced 
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resonance Raman scattering (SERRS) are more frequently utilised as these processes amplify 
the Raman signals. 
SERS is a process that occurs following adsorption of a substrate onto a metal surface. The 
surface electrons of the metal absorb energy from the incident laser. This interaction induces 
collective oscillations of the surface electrons known as plasmons273,277. Smooth surfaces are 
not effective for this enhancement as the plasmon energy is bound to the surface. Utilising a 
roughened metal surface or aggregated metal nanoparticles gives rise to the scattering 
process, as the irregular morphology generates plasmons which are not restricted to 
movement parallel to the surface278. This creates an enhanced localised field at the surface of 
the metal, thus electromagnetic radiation of the same frequency as the laser interacts with the 
substrate adsorbed to the surface. The energy transferred to the molecule gives rise to the 
Raman process. The energy is then returned to the surface plasmon and the scattering 
process ensues. The difference in energy between the incident and scattered radiation is 
consistent with the vibrational transitions within the molecule277,279. The magnitude of the 
enhancement of the Raman signal can vary considerably; values are typically amplified by 
several orders of magnitude using the SERS technique273. 
The weak signal of a Raman emission can also be enhanced using resonance Raman 
spectroscopy. This occurs when the energy of the incident radiation is close to the energy of 
an electronic transition within the molecule. Resonance Raman spectroscopy is often exploited 
when the molecule has a visible chromophore; by utilising a laser wavelength which is 
resonant with this absorption band, considerable enhancement in the intensity of the relevant 
signals may occur. Since only the chromophore is accountable for the scattering observed at 
this wavelength this technique proves particularly useful for identifying unique components 
within a species. This effect produces an enhancement of the Raman signals associated with 
the absorbing chromophore by a factor of 103 to 104, thus presenting a method for introducing 
electronic selectivity273,280,281. 
The SERRS technique combines SERS and resonance Raman spectroscopy in order to obtain 
synergistic enhancements resulting from both metal surface plasmons and a resonant 
chromophore277,282. The laser wavelength must be tuned to the resonance frequency of the 
surface plasmons of the metal, therefore the application of SERRS is limited to molecules 
which have chromophoric components absorbing within these regions281. Although maximum 
enhancements are to be expected when these wavelengths are equivalent, SERRS can be 
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effective even with approximately a 250nm separation between the resonance 
frequencies277,283. 
4.2 Background relevant to the detection of DNA using SERS 
Our collaborators in Belfast have previously shown that surface enhanced Raman 
spectroscopy (SERS) can detect single nucleotide exchanges in DNA. This was achieved by 
absorption of oligodeoxynucleotides on to a suitably enhancing metal surface and subsequent 
acquisition of SERS spectra using appropriate experimental conditions. The SERS spectra 
obtained, display identifiable bands which are characteristic of the constituent bases present in 
an oligodeoxynucleotide, therefore variation of these distinctive bands can be exploited to 
detect polymorphisms in short strands of DNA284.  
Interestingly, studies indicate that specificity as well as enhanced sensitivity can be obtained 
when the SERS technique is applied to the detection of nitro aromatic compounds280,285,286. 
Consequently, this technology is currently being utilised in the development of a real time 
method for trace level detection of nitro based explosives. 
Given this sensitivity, it is an interesting prospect to explore whether SERS is a valid method 
for detection of this naturally occurring biomarker. In view of the unique UV absorption profile 
of the 8-nitroguanine derivatives, it was envisaged that SERRS experiments could selectively 
detect signals corresponding to the chromophore, providing a method to detect the prevalence 
of the lesion in DNA. This approach eliminates the additional processes required to label and 
prepare the sample of DNA which are necessary when using alternative methods for 
detection287. It would allow for the levels of a lesion with a unique chromophore to be 
monitored within a biological system in real time. 
4.3 SE(R)RS experiments on 8-nitroguanine substrates 
For the SE(R)RS experiments the following compounds were prepared: 8-nitroguanine (16), a 
dimer containing only the 8-nitroguanine base (9, for structure see page 68) and site 1 and site 
3 oligodeoxynucleotides (for sequences see page 61) which both contain a single 8-
nitroguanine modification together with the four standard DNA bases. In all cases the 8-
nitroguanine base was associated with the 2’-O-methyl ribose sugar to increase the stability of 
the glycosidic bond. The corresponding control compounds were also prepared in which 
guanine replaced 8-nitroguanine. This gave a series of compounds which presented the 8-
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nitroguanine base in an increasingly complex set of oligonucleotide sequences which aided 
assignment of resonance bands. 
Initial proof of principle was achieved by comparing the experimental data obtained for 8-
nitroguanine to guanine. As the free base is the simplest model of the lesion, this provided a 
suitable foundation on which to develop the approach, where complications arising due to the 
presence of the 2’-O-methyl sugar would not factor in its viability. 
Figure 4.1 shows representative data for the 8-nitroguanine and guanine bases. When using a 
laser wavelength of 785nm, the relative band intensities of the signals in both spectra are quite 
similar. Although 8-nitroguanine shares some bands with those present in the guanine sample, 
there are additional peaks which are exclusive to the modified base. In order to investigate 
whether resonance enhancement of the signals associated with the absorbing chromophore 
could be achieved, the laser wavelength was lowered to 532nm; this was significantly closer to 
the absorption of 8-nitroguanine at approximately 400nm. As is evident in Figure 4.1, the 
signals corresponding to 8-nitroguanine are considerably greater in intensity than those of 
guanine. Furthermore, the signals resulting exclusively from the nitrated base, for example the 
band at approximately 1280cm-1, are more prominent at this wavelength. 
The positions of the peaks observed in the experiments are consistent with density functional 
theory (DFT) calculations also performed by our collaborators in Belfast. These calculations 
enabled the assignment of the identified bands to specific vibrations within the molecules. For 
example, the DFT calculations predict a band at 1282cm-1 representing the symmetrical 
stretching vibration of the nitro group which is evident in the experimental data. Encouraged by 
these preliminary results, the complexity of the system being examined was increased.  
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Figure 4.1: SERS spectra of 5 x 10-6M solutions showing comparison of guanine and 8-nitroguanine at 
785nm and 532nm on the same absolute scale. Green line = guanine (785nm), black line = 8-nitroguanine 
(785nm), red line = 8-nitroguanine (532nm), blue line = guanine (532nm).  
In a previous study evaluating single nucleotide exchanges in oligodeoxynucleotides, the 
SERS spectrum of dGMP was recorded for use as a reference spectrum in order to aid the 
analysis of the DNA spectra284. As the corresponding 8-nitro-2’-O-methylguanosine 
monophosphate was not accessible, a dinucleotide containing two modified residues (9) was 
envisaged as a suitable alternative.  
The spectra of the 8-nitroguanine dimer, site 3 oligodeoxynucleotide and site 3 control 
oligodeoxynucleotide are somewhat different as shown in Figure 4.2. This can be attributed to 
differences in the relative band intensities of identifiable spectral features and the presence of 
additional bands. These inconsistencies were to be expected as the acquired spectra for the 
oligodeoxynucleotide is comprised of bands representative of all the nucleobases present, 
each of which produce varying degrees of Raman scattering287. Notably, the intense broad 
peak at approximately 1238cm-1 is present in the compounds containing the 8-nitroguanine 
base but not in the control samples. 
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Figure 4.2: SERS spectra of 10-5M solutions showing comparison of the 8-nitroguanine dimer (top), site 3 
oligodeoxynucleotide (middle) and site 3 control oligodeoxynucleotide (bottom) at 785nm. 
Despite the varying intensities, it is evident that the characteristic band pattern recorded for the 
8-nitroguanine dimer is distinguishable when analysing the representative data of the mixed 
sequence site 3 oligodeoxynucleotide. The absence of analogous signals in the spectra 
obtained for the site 3 control oligodeoxynucleotide, confirmed that these bands could be 
assigned exclusively to the 8-nitroguanine residue. 
The same series of spectra were then obtained using the 532nm laser, substantial 
enhancement of the signals associated with the 8-nitroguanine modification were apparent 
(Figure 4.3). The difference in the absolute intensities of the sequences containing the 8-
nitroguanine modification and the control sequence is the key aspect of the spectra. The band 
patterns observed for the site 3 oligodeoxynucleotide were consistent with those obtained for 
the 8-nitroguanine dimer and previously for the 8-nitroguanine base. This suggests that the 
Raman scattering observed at this wavelength is predominantly due to contributions resulting 
from the 8-nitroguanine modification.  
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Figure 4.3: SERS spectra of 5 x 10-6M solutions showing comparison of the 8-nitroguanine dimer (top), 
site 3 oligodeoxynucleotide (middle) and site 3 control oligodeoxynucleotide (bottom) at 532nm. Note the 
peak at ~1170cm-1 in the bottom trace is considered to be an experimental artefact. 
While the spectra presented to date show that the 8-nitroguanine base has a unique scattering 
pattern that distinguish it from the four natural DNA bases, it was of interest to analyse 
samples in which the 8-nitroguanine lesion was only a very minor constituent of the DNA 
sample. This would be a closer analogy to the analysis of biological DNA samples containing 
the 8-nitroguanine lesion. As a means to accomplish this, samples were analysed in which the 
site 3 oligodeoxynucleotide was diluted with its control sequence. 
In order to increase the selectivity and specificity for the signal associated with the unique 
absorbing chromophore of 8-nitroguanine, in these diluted samples the excitation wavelength 
was lowered again to 488nm shifting it closer to the λmax for this base at ~400nm. It is evident 
from the representative data shown in Figure 4.4 that doping a site 3 control sample with as 
little as 2% of the site 3 oligodeoxynucleotide containing a single 8-nitroguanine modification 
generated bands diagnostic of the lesion. Unsurprisingly, as the quantity of the site 3 
oligodeoxynucleotide in the experiment was increased, the intensity of the signal at 1248cm-1 
resulting from the 8-nitroguanine residue was enhanced accordingly; this scattering was not 
seen in the control sequence.  
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Figure 4.4: SERS spectra showing doping experiments whereby a small amount of the site 3 
oligodeoxynucleotide was introduced to a bulk sample of the site 3 control oligodeoxynucleotide at 
488nm. Red = site 3 control (scale enhanced for comparison purposes), blue = 2% site 3, purple = 5% site 
3, green = 10% site 3, yellow = 100% site 3. All samples measured at 10-5M. 
Finally, experiments were conducted in order to definitively establish that the bands that are 
observed in the spectra are representative of the 8-nitroguanine modification within an 
oligonucleotide as opposed to the free base resulting from depurination (Figure 4.5). Notably 
the peak at ~830cm-1 which is characteristic of the 8-nitroguanine base but not the modified 
oligodeoxynucleotides, was absent from the site 3 spectra. An equimolar mixture of the site 3 
oligonucleotide and 8-nitroguanine was examined to ascertain whether this signal was 
distinguishable from the background in the presence of the signals representing the natural 
nucleobases. The band at ~830cm-1 was easily observed in the mixed spectra, therefore it was 
determined that the results demonstrated were not due to depurination of the labile 8-
nitroguanine base.  
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Figure 4.5: SERS spectra of 5 x 10-6M solutions showing comparison of site 3 (top), equimolar mixture of 
site 3 control and 8-nitroguanine base (middle) and 8-nitroguanine base (bottom). 
4.4 Conclusion 
This work demonstrates a simple method for detecting the prevalence of the 8-nitroguanine 
lesion within DNA using the SE(R)RS technique. The unique scattering profile of the 8-
nitroguanine derivatives provides a valuable method by which electronic selectivity can be 
achieved. The SERS signals observed for the modification in the free base, dimer and 
oligodeoxynucleotide were enhanced considerably upon lowering the excitation wavelength 
from 785nm to 532nm and 488nm. Thus SE(R)RS is a viable method for the real-time 
detection of this naturally occurring biomarker. The technique is highly sensitive and selective 
for the lesion enabling identification of trace amounts within a bulk sample of DNA. 
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5 Results and Discussion 4 
5.1 Nucleoside triphosphates 
Nucleoside triphosphates are of fundamental importance within biological systems. They act as 
substrates for polymerase-mediated DNA and RNA replication, regulators of signal 
transduction, cofactors of metabolic pathways and adenosine triphosphate (ATP) acts as the 
‘molecular currency’ for intracellular energy transfer288. The hydrolysis of the high energy 
phosphate groups in ATP and other nucleoside triphosphates, results in the release of a large 
amount of free energy. Therefore nucleoside triphosphates play a central role in many 
energetically unfavourable processes within biological systems289. 
With regard to DNA replication, DNA polymerases have evolved to be highly accurate, with 
polymerases α, δ, ε and γ generating less than 1 error for every 10,000 correct 
incorporations290,291. While oxidative DNA damage can be as a result of direct reactions 
between reactive oxygen and nitrogen species and DNA, oxidation products generated within 
the nucleoside pool can act as substrates for DNA polymerases and be incorporated into the 
nascent strand. Accordingly there are enzymes functioning to reduce the mutagenic potential 
of the oxidised nucleotide triphosphates within the nucleotide pool. 
As previously discussed, valuable information regarding the repair mechanisms against the 
mutagenesis caused by 8-oxoguanine has been gathered by studying the fidelity of replication 
in the presence of the modified nucleoside triphosphates165. Of particular interest with regards 
to sanitising the nucleotide pool of oxidised nucleoside triphosphates is the enzyme MutT 
(MTH1). The enzyme is a triphosphatase that is responsible for hydrolysing 8-oxo-dGTP in the 
nucleotide pool to the corresponding monophosphate and pyrophosphate, thus eliminating it as 
a potential substrate for replication by DNA polymerases166. MutT efficiently hydrolyses a 
number of oxidised triphosphates including 8-oxo-dGTP and 2-OH-dATP and the 
corresponding ribonucleotides in nucleotide pools292,293. 
The aim of this part of the project was to synthesise 8-nitroguanosine triphosphate in order to 
investigate its behaviour both as a template for polymerase mediated replication and as a 
substrate for the triphosphatase MutT. Since MutT catalyses the hydrolysis of both ribo- and 
deoxyribo-triphosphates we opted to synthesise the ribonucleotide analogue 8-nitroguanosine 
triphosphate. In addition to the starting material being cheap and readily available, the labile 
glycosidic bond is sufficiently stabilised by the 2’-hydroxyl group and as the sugar functionality 
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is identical to that of the natural triphosphate any results would be as consequence of the nitro 
group alone. 
5.2 Synthetic approaches to nucleoside triphosphates  
The biological significance of nucleoside triphosphates and their involvement in a host of 
biochemical processes has led to the development of a number of methods for their synthesis. 
Early synthetic procedures were based upon the use of natural nucleoside 5’-monophosphates 
as precursors294,295. In 1964 Moffat reported that the conversion of a monophosphate to its 
morpholidate followed by displacement by pyrophosphate afforded the corresponding 
triphosphate in a 76% yield (Scheme 5.1)294. 
 
Scheme 5.1: Triphosphate synthesis using an activated monophosphate. 
In order to generate synthetic triphosphates containing modified sugars or bases there became 
an increasing demand for procedures suitable for the 5’-phosphorylation of modified 
nucleosides. 
A lack of regioselectivity of reagents for the 5’-position made synthesis of monophosphates 
problematic; primarily due to the production of a mixture of 2’-, 3’- and 5’-phosphorylated 
compounds and the difficulty in their identification and isolation296. The approach developed by 
Yoshikawa et al. in 1967 which lead, not only to accelerated reactions rates but also to 
selectivity at the 5’-position, was a noteworthy development and still remains the basis of one 
of the most popular methods for synthesising nucleoside triphosphates today297. The use of a 
trialkylphosphate as a solvent was the defining feature of this method. In addition to forming a 
homogeneous solution with the nucleoside, trialkylphosphates are believed to form an 
activated intermediate with the phosphorylating reagent giving rise to an increased rate of 
reaction298. 
Some of the early studies were carried out on 2′,3′-O-isopropylidene nucleosides to prevent 
side reactions at these positions. However it was soon established that protection of the 2’- 
and 3’-hydroxyl groups was not necessary to phosphorylate selectively at the 5’-hydroxyl group 
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in good yields297. Ludwig then adapted this procedure in 1981 to generate nucleoside 
triphosphates in a ‘one pot, three step procedure’. The initial methodology developed by 
Yoshikawa was retained to generate nucleoside 5’-dichlorophosphates which were then 
transformed into triphosphates by a short, in situ treatment with tri-n-butylammonium 
pyrophosphate followed by neutral hydrolysis (Scheme 5.2)299. 
 
Scheme 5.2: One pot, three step formation of nucleoside triphosphates. 
In 1986 the use of salicyl chlorophosphite was reported as a method to introduce a 3’-5’-
phosphodiester linkage between nucleosides300. Ludwig and Eckstein utilised the 
multifunctionality of the cyclic phosphite intermediate in the synthesis of 5’-nucleoside 
triphosphates. The reaction initially gave rise to an activated phosphite that was reacted, in a 
double displacement process, with pyrophosphate to form the cyclic intermediate that was 
oxidized to give the corresponding triphosphate (Scheme 5.3)298,301.  
 
Scheme 5.3: The Ludwig and Eckstein approach to nucleoside triphosphate synthesis. Note R1 = 
protecting group and R2 = H or protected OH. 
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The procedure is carried out in one pot; hence the intermediates shown in Scheme 5.3 were 
not isolated. There is however evidence for their formation, as Ludwig and Eckstein followed 
the course of the reaction using 31P NMR298. While protection of the exocylic amino groups of 
the nucleobases was not necessary, protection of the 2’- and 3’-hydroxyl groups is required. 
Consequently, this route to the synthesis of nucleoside triphosphates is lengthier due to the 
additional steps in preparing the nucleoside for the reaction, but is certainly valuable due to the 
reduced quantity of undesired by-products which can be generated in alternative routes. 
Other strategies include; a solid-phase approach involving phosphorylation of the suitably 
protected nucleoside derivative anchored to a resin, direct nucleophilic substitution of leaving 
groups at the 5’-hydroxyl position by a triphosphate analogues and biocatalytic methods298. Of 
these additional strategies, biocatalysis is arguably the most successful approach to date. 
Whilst enzymatic method can be ideal for the synthesis of standard nucleoside triphosphates, 
modified nucleoside triphosphates present a more complex challenge. The potential for a lack 
of base specificity with regard to the modified nucleoside substrate renders this method less 
attractive than the chemical based approaches. 
There is no method that is universally applicable for the synthesis of triphosphates; while some 
approaches will produce excellent yields with certain substrates, others are not tolerated288,298. 
Ideally to produce the 8-nitroguanosine triphosphate, the approach adopted would not require 
the lengthy protection and deprotection of multiple functional groups and would produce a high 
yield of the desired product. With this in mind, we initially focused our efforts on the 
phosphorylation procedure developed by Yoshikawa and modified by Ludwig.  
5.3 Initial route towards the synthesis of 8-nitroguanosine triphosphate 
The Yoshikawa approach modified by Ludwig was attractive as it does not require selective 
protection of the 2’- and 3’-hydroxyl groups, thus reducing the length of the overall synthesis 
considerably. With the aim of enhancing solubility, which would in turn make the compounds 
easier to handle, we intended carrying out the monophosphorylation on the N2-DMT protected 
nucleoside, even though it would undoubtedly be removed on addition of the phosphorus 
oxychloride (POCl3). In order to confirm that this was the case, trial reactions were carried out 
using both guanosine and N2-DMT protected guanosine (Scheme 5.4). 
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Scheme 5.4: Synthetic route to guanosine triphosphate. Note R = H or DMT. 
The Yoshikawa phosphorylation was conducted utilising a published protocol302. After 
meticulous drying of the reagents, solvents and equipment, a 0.2mmol solution of the 
nucleoside in trimethylphosphate (PO(OMe)3) was treated with 1.2 equivalents of POCl3 to 
generate a highly reactive phosphorodichloridate intermediate. Upon sufficient conversion to 
the corresponding monophosphate (as monitored by HPLC, see below), the intermediate was 
reacted with tri-n-butylammonium pyrophosphate and subsequent hydrolysis with aqueous 
TEAB afforded the nucleoside triphosphate302. 
Both stages of the phosphorylation reaction were monitored directly by HPLC using a Dionex 
ion exchange (IE) column. To aid the interpretation of the chromatograms, standards of 
guanosine, guanosine monophosphate and guanosine triphosphate were analysed by IE- 
HPLC and gave retention times of 1.15, 4.46 and 10.79 minutes respectively. 
Interpretation of the HPLC chromatographs from the reactions of guanosine indicated that the 
deprotected mono- and tri-phosphates were formed. The monophosphate (34) eluted at 4.71 
minutes with an optimal conversion of 68% within 1.5 hours. The triphosphate (35) which had a 
retention time of 10.88 minutes was subsequently generated in a 40% yield. Very similar 
results were obtained when the reaction was repeated using N2-DMT-protected guanosine 
with conversions of 59% and 38% for the mono- and tri-phosphates, respectively. As 
anticipated these results confirmed that the addition of POCl3 removed the DMT protecting 
group but notably also suggests that the presence of a DMT group does not affect the 
phosphorylation reaction. Isolation was not carried out at this point, though this is necessary to 
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unambiguously assign these compounds as 5’-phosphates. The purification of nucleoside 
triphosphates remains to be intricate and extensive288; therefore, it was reasoned that 
attempted purification and its optimisation would be delayed until we had the desired 8-
nitroguanosine triphosphate in hand. 
Following this positive result, phosphorylation of N2-dimethoxytrityl-8-nitroguanosine (36) was 
attempted using the same conditions. However in this case, the reaction proved unsuccessful 
as following addition of POCl3 and stirring for 3 hours, no monophosphate could be seen in the 
HPLC trace (Scheme 5.5).  
 
Scheme 5.5: Unsuccessful Yoshikawa approach to N2-dimethoxytrityl-8-nitroguanosine monophosphate. 
Taking into account the considerable difference between the two nucleosides, particularly in 
terms of their conformation, it was considered that the DMT group may not affect the reaction 
whilst using unhindered guanosine, but have a deleterious effect when using the 8-nitro 
derivative as a substrate. Therefore detritylation of the compound was carried out. Treatment 
of N2-dimethoxytrityl-8-nitroguanosine with 0.25 equivalents of p-toluenesulfonic acid dissolved 
in methanol, in order to remove the N2-DMT protecting group, proceeded smoothly and after 
optimisation of the purification conditions afforded the detritylated nucleoside in a good yield. 
The formation of 8-nitroguanosine (15) was confirmed by 1H NMR through the loss of 13 
aromatic proton signals. The complete deprotection of the modified nucleoside dramatically 
reduced its solubility in the majority of organic solvents, complicating its handling considerably. 
The conformational bias imposed on the nucleoside by the 8-nitro substituent is also largely 
present in 8-bromoguanosine. Therefore to address the effect of steric bulk at the C8 position 
on the phosphorylation, the reaction was now performed using 8-bromoguanosine (37) as a 
substrate. Introduction of the bromine group at the C8 position was achieved by the reaction of 
guanosine with bromine water. Confirmation of the addition was seen in the 1H NMR, with the 
disappearance of the signal at 7.94ppm corresponding to H8. 
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Optimisation of the triphosphate synthesis was then carried out using 8-bromoguanosine. 
HPLC analysis indicated a 43% conversion to the monophosphate (38), which eluted at 5.37 
minutes, after a reaction time of 1 hour. It was established that contrary to the 10 minutes 
suggested for pyrophosphate coupling, the optimal time for this step was in fact 40 minutes, 
with a 23% conversion to the triphosphate (39) (retention time = 11.15 minutes). The 
procedure was then repeated using the modified nucleoside 8-nitroguanosine. 
The monophosphorylation reaction initially appeared to be successful as an intermediate 
containing the 8-nitroguanine analogue was detected in the HPLC trace eluting at 4.17 minutes 
and with a 50% conversion. The species containing the nitro modification was easily 
identifiable due to its distinctive UV profile. However on addition of the pyrophosphate, despite 
the formation of several compounds with longer retention times visible in the HPLC trace, no 
peaks characteristic of the triphosphate were observed. There seems to be two possible 
reasons for the failure of this reaction: 
 The required phosphorodichloridate intermediate was not formed and the peak at 4.17 
minutes was due to a decomposition product rather than the monophosphate. 
 The phosphorodichloridate did not subsequently react with the pyrophosphate. 
The guanosine-TMP complex303 (Figure 5.1) is suggested to be an active intermediate formed 
between the nucleoside and the trimethylphosphate solvent in this reaction. This may go some 
way in explaining why the reaction with 8-nitroguanosine does not proceed. The complex 
forces the nucleoside into a high-anti conformation to allow N7 to interact with the phosphorus 
atom, and the sp2 oxygen forms a hydrogen bond with the 5’-hydroxyl group. This activates the 
5’-hydroxy group to preferentially react with the phosphorus oxychloride303. If this complex is in 
fact the reactive intermediate, the conformation adopted by 8-nitroguanosine may affect the 
reaction.  
 
Figure 5.1: Guanosine-TMP complex, adapted from reference 303303. 
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NMR shifts are diagnostic of a change in the conformation of a nucleoside from anti to syn. A 
comparison of 8-nitroguanosine and guanosine showed that not all of the chemical shifts 
indicative of the syn conformation were observed. The signals corresponding to H1’, H2’, and 
C1’ experienced downfield shifts as would be expected for the syn nucleoside, likewise the 
peak corresponding to C2’ showed the anticipated upfield shift. However the peaks 
corresponding to C3’ and C4’ did not behave as expected. For these signals, the direction of 
the shift in the chemical signals changes from an upfield shift which would be expected in a 
syn nucleoside to a downfield shift, as shown in Table 5.1. This is in contrast to that which was 
observed for the 8-nitro-2’-O-methyl derivative, which suggests the conformation of the two 
species differs194,200. 
Nucleoside H1’ H2’ C1’ C2’ C3’ C4’ 
Guanosine 5.73 4.45 87.34 74.72 71.40 86.23 
8-Nitroguanosine 6.27 4.92 90.46 71.08 70.10 85.67 
2’-O-Methylguanosine 5.82 4.28 85.85 82.73 68.66 84.32 
8-Nitro-2’-O-methylguanosine 6.32 4.68 89.12 80.88 69.55 86.20 
Table 5.1: 1H and 13C NMR shifts of the sugar protons and carbons of guanosine, 8-nitroguanosine, 2’-O-
methylguanosine and 8-nitro-2’-O-methylguanosine194 measured in D6-DMSO. 
Computational modelling of guanosine and 8-nitroguanosine was carried out in order to 
support this conclusion. Molecular modelling calculations were performed using Spartan ’10 
version 1.1.0. The molecular mechanics model was considered suitable for a conformation 
distribution calculation to determine the lowest energy conformer of each nucleoside. The 
lowest energy conformations generated for guanosine and 8-nitroguanosine show 
considerable differences (Figure 5.2). Whilst guanosine exists in the syn conformation due to 
internal hydrogen bonds within the free nucleoside, 8-nitroguanosine adopts the anti 
conformation. Furthermore, 8-nitroguanosine can form two intramolecular hydrogen bonds in 
comparison to guanosine which forms only one. The contrasting orientation of the two lowest 
energy conformers may account for the different reactivities of the two species. It is possible 
that formation of the guanosine-TMP complex does not occur in this conformation, thus 
preventing the phosphorylation reaction. However this suggestion is speculative and further 
investigation would be required to determine if this was in fact the case. 
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Figure 5.2: Lowest energy conformation of guanosine (left) and 8-nitroguanosine (right) calculated using 
Spartan. Note hydrogen bonds are represented by green dashed lines. 
Based on previous studies of the 8-nitro-2’-O-methylguanosine194 the observation that 8-
nitroguanosine adopted the anti conformation was somewhat unexpected, hence the validity of 
the computational methods were questioned. In order to determine the accuracy of the model, 
computational modelling of 8-nitro-2’-O-methylguanosine was carried out. As shown in Figure 
5.3, 8-nitro-2’-O-methylguanosine assumes a syn orientation and is consistent with results 
previously established. Therefore the model was considered to be valid.  
 
Figure 5.3: Lowest energy conformation of 8-nitro-2’-O-methylguanosine (left) and 8-nitroguanosine 
(right) calculated using Spartan. Note hydrogen bonds are represented by green dashed lines. 
We concluded that the Yoshikawa procedure was not suitable for the phosphorylation of 8-
nitroguanosine. It was evident that a more reliable method where complications arising from 
unprotected hydroxyl groups need not be considered would be advantageous. Therefore our 
efforts were focused on a synthetic pathway where the 2’- and 3’-hydroxyl groups are 
protected and a more reactive P(III) reagent is used to effect phosphorylation. In this approach 
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the trialklyphosphate solvent is not needed to give selectivity for the 5’-hydroxyl group and the 
guanosine-TMP complex will not form. 
5.4 Ludwig and Eckstein phosphorylation: selective deprotection 
With the aforementioned in mind, an efficient route was sought for the preparation of a 2’-, 3’-
selectively protected 8-nitroguanosine analogue. It had been observed during previous 
syntheses, that deprotection of the acetyl protecting groups of fully protected 8-nitroguanine 
nucleosides proceeded in a stepwise manner. In general reaction at the primary 5’-position 
occurs more readily when compared to that of the secondary 2’- and 3’-positions, this suggests 
that the relative reactivity is a consequence of steric control. Therefore it is reasonable to 
assume that upon treatment with ammonia, deacetylation of the 5’-hydroxyl group would occur 
first. Based upon this reasoning, the generation of a regioselectively protected derivative via 
selective deprotection of the primary hydroxyl group was envisioned. 
 
Scheme 5.6: Attempted regioselective deacetylation reaction. 
Unfortunately despite numerous attempts transformation of the fully protected nucleoside to 
the corresponding 5’-hydroxyl derivative was unsuccessful. A balance was required between 
adequate formation of the 5’-hydroxyl derivative; that is disappearance of the starting material 
and limiting the generation of the 2’- and 3’-deprotected nucleosides. Although during the 
deacetylation, a slower running compound was initially formed on TLC that was presumed to 
be the 5’-deacetylated nucleoside, isolation of a sufficient quantity of material prior to further 
reaction was unfeasible. Thus it was evident that this route was not viable and exploration of 
alternative routes to prepare the suitably protected 8-nitroguanosine was necessary. 
5.5 Ludwig and Eckstein phosphorylation: orthogonal protection (route A) 
Scheme 5.7 demonstrates the alternative procedure proposed to generate the appropriately 
protected 8-nitroguanosine derivative. This route features some steps common to syntheses 
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outlined previously in this thesis and despite the additional steps, suggests a seemingly 
reliable approach. 
 
Scheme 5.7: Proposed synthetic route to N2- dimethoxytrityl-8-nitro-2’-3’-di-O-acetylguanosine. Note R = 
DMT or TBDMS. 
The first step involved standard acetyl deprotection, carried out using methanolic ammonia to 
afford unprotected hydroxyl groups at the 2’-, 3’- and 5’-positions. It is essential that the 
temporary protecting group on the 5’-position of the nucleoside is orthogonal to that of the 2’- 
and 3’-protecting groups as these must be preserved during the phosphorylation reaction. For 
this purpose it was anticipated that selective protection of the 5’-hydroxyl group with the acid 
labile DMT or tert-butyldimethylsilyl (TBDMS) protecting groups would be suitable. The greater 
nucleophilicity of the primary 5’-hydroxyl group and the steric bulk of these protecting groups 
favour formation of the desired compound. 
Unexpectedly, attempts to introduce both the DMT and TBDMS groups using standard reaction 
conditions were unsuccessful. This is in contrast to the 2’-O-methyl derivative whereby 
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functionalisation of the 5’-hydroxyl group occurs readily. It is feasible that the altered electronic 
and stereochemical properties of the 8-nitroguanosine derivative may result in difference in the 
reactivity of the 5’-hydroxyl group towards electrophiles. Taking these results into 
consideration, it seemed appropriate to selectively protect the nucleoside prior to the nitration 
reaction. Moreover, this would prove advantageous as it would avoid unnecessary waste of the 
valuable nitrated nucleoside. Alternative methods for the dimethoxytritylation such as those 
based on tetrafluoroborate salts were not investigated304. 
5.6 Ludwig and Eckstein phosphorylation: orthogonal protection (route B) 
A second strategy for the synthesis of a suitably protected 8-nitroguanosine derivative for use 
as a substrate in the Ludwig and Eckstein phosphorylation procedure was developed, route B 
(Scheme 5.8). This involved manipulation of the protecting groups prior to functionalisation of 
the C8 position with a nitro group. 
 
Scheme 5.8: Synthetic route B. 
The first step in the route B approach was to introduce a silyl protecting group at the 5’-
hydroxyl position. The use of TBDMS is favourable, as silyl protecting groups can be 
selectively removed using a source of fluoride ions; hence the protecting group can be 
removed without treating the compound with either acid or base. Consequently it is possible to 
retain both an acid labile DMT group on the base, to improve solubility of the nucleoside, and 
the base labile acetyl protecting groups on the 2’- and 3’-hydroxyls, to prevent phosphorylation 
at this position in subsequent steps. Introduction of the 5’-O-TBDMS group was achieved by 
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the addition of a small excess of TBDMSCl to a solution of guanosine and imidazole in 
anhydrous DMF. The protection proceeded smoothly in a 71% yield; some 2’- and 3’-protection 
was also observed which accounted for the loss of yield in this reaction. This is in marked 
contrast to the previous attempt to silylate the 8-nitroguanosine derivative. The appearance of 
characteristic singlets in the 1H NMR at 0.04ppm and 0.87ppm indicated the presence of the 
silyl protecting group in the product; these peaks correspond to the 6 protons of the methyl and 
9 protons of the t-butyl group respectively. 
Protection of the 2’- and 3’-hydroxyl groups with acetyl groups was completed using a similar 
method to that used previously. However a slight modification of the purification procedure was 
required, as due to the enhanced solubility of the TBDMS-protected nucleoside 
recrystallization from propan-2-ol was not feasible. Consequently the desired product (42) was 
obtained in a 94% yield by partitioning the residue obtained between DCM and water. 
Diagnostic peaks in the 1H NMR spectrum at 2.00ppm and 2.11ppm corresponding to the 
methyl ester protons indicated the presence of the acetyl protecting groups. 
Following this, electrophilic bromination at the C8 position was attempted; unfortunately the 
reaction conditions lead to untimely desilylation of the 5’-hydroxyl group. Regrettably, the 
generation of hydrogen bromide during the reaction was not given due consideration whilst 
developing the route to the suitably protected nucleoside. However it was apparent that the 
quantity of hydrogen bromide produced was sufficient to remove the TBDMS protecting group. 
This was confirmed by the disappearance of the peaks at 0.07ppm and 0.88ppm in 1H NMR 
indicative of the silyl group. Upon re-evaluation of the approach, it was evident that 
electrophilic bromination must be performed prior to introduction of the silyl protecting group. 
5.7 Ludwig and Eckstein phosphorylation: orthogonal protection (route C) 
In order to circumvent the complications which arose during the electrophilic bromination step 
in the initial strategy, the steps in the synthetic pathway were reordered to present an 
alternative approach, route C (Scheme 5.9). Incorporating the bromine functionality at the 
outset removes the incompatibility of the TBDMS group with the bromination conditions. 
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Scheme 5.9: Synthetic route C. 
Although route B was ultimately unsuccessful, the initial steps are common to this route, thus 
the section below describes only the reactions that were attempted exclusively in route C. With 
the nucleobase brominated and the sugar suitably protected, the exocyclic amine moiety was 
then protected using DMTCl to give the fully protected nucleoside (45) in an 84% yield. The 
identity of the product was confirmed by the presence of diagnostic peaks in the 1H NMR at 
3.71ppm corresponding to the six methoxy protons and the appearance of aromatic protons at 
7.12-7.36ppm. 
The nitration reaction was carried out on the fully protected 8-bromoguanosine using the 
optimised conditions established for the 2’-O-methyl derivative which used a concentration of 
0.01mM. The reaction was monitored closely by RP-HPLC and TLC in order to follow the 
conversion to the nitro compound; however no reaction was observed. The absence of peaks 
in the HPLC absorbing at 350nm where only 8-nitroguanine derivatives have a significant 
absorbance was testament to this. Analysis of the major decomposition products identified the 
detritylated, desilylated and the depurinated species. Taking into consideration the sensitivity 
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of the reaction and that the use of alternative protection schemes has previously led to failure 
to convert these compounds through to the nitro derivatives, it was concluded that the 
presence of the silyl protecting group is detrimental to the reaction194. Steric hindrance 
resulting from the relatively bulky TBDMS group may additionally factor in the lack of success 
of the reaction. 
Theoretically, removal of the silyl protecting group ahead of nitration would prevent these 
complications. As previously mentioned, the affinity of silicon for fluoride ions makes the 
protecting group particularly susceptible to treatment with tetra-n-butylammonium fluoride 
(TBAF) (Scheme 5.10). In order to supress the undesirable side reactions which can occur due 
the basicity of the fluoride ion, the reaction was buffered with acetic acid305. However this 
proved unsuccessful and concurrent removal of the acetyl protecting groups was also 
observed.  
 
Scheme 5.10: Failed attempt at desilylation reaction. 
5.8 Molecular modelling 
In order to gain a better insight into the differences in reactivity and behaviour of the N2-
dimethoxytrityl-8-nitroguanosine and N2-dimethoxytrityl-8-nitro-2’-O-methylguanosine we 
focused upon the application of molecular modelling. It was envisioned that by using 
computational methods it would be possible to identify factors that may have resulted in the 
unsuccessful reactions encountered in this route and how this differs from the 2’-O-methyl 
analogue. As the molecular mechanics model had been successfully used previously to 
produce a global energy minima conformer, it was again considered a suitable model. 
Conformer distribution calculations were utilised to find the energetically preferred 
conformations of the molecules; shown in Figure 5.4. 
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Figure 5.4: Lowest energy conformation of N2-dimethoxytrityl-8-nitro-2’-O-methylguanosine (left) and N2-
dimethoxytrityl-8-nitroguanosine (right) calculated using Spartan. Note hydrogen bonds are represented 
by green dashed lines. 
The lowest energy conformations of N2-dimethoxytrityl-8-nitroguanosine and N2-
dimethoxytrityl-8-nitro-2’-O-methyguanosine vary considerably with respect to the orientation of 
the functionalised base with respect to the sugar moiety. Furthermore the number and nature 
of hydrogen bonds within the molecules also differs. In order to explain how these differences 
may affect the reactivity of the molecules, it is first necessary to consider the properties of 
hydrogen bonds. 
A good hydrogen bond acceptor is characterised as having a larger electronegativity relative to 
hydrogen and a lone pair of electrons. A good hydrogen bond donor has a hydrogen atom 
covalently bonded to a small highly electronegative atom. The electronegative atom draws 
electron density away from the hydrogen atom, resulting in a partial positive charge. Therefore 
an electrostatic interaction between the partially positive hydrogen atom and the 
electronegative acceptor atom leads to the formation of a hydrogen bond17. The electron 
density between the hydrogen donor and hydrogen acceptor is rearranged upon formation of a 
hydrogen bond. The electron density flows from the lone pair of the proton acceptor to the 
proton donor which in turn induces a negative charge on the hydrogen atom and a more 
positive charge on the electronegative atom306. Moreover, as the difference in electronegativity 
between oxygen and hydrogen (1.24) is greater than that of nitrogen and hydrogen (0.84), it 
stands to reason that the hydrogen bond that is formed in the ribose derivative is stronger than 
that formed in the 2’-O-methyl derivative (Figure 5.5)17. Taking these factors into consideration 
Hydrogen bond between 
2’-OH and N3 of guanine 
 
Hydrogen bond 
between 5’-OH 
and oxygen of 
the nitro group 
Hydrogen bond between 
5’-OH and N3 of guaninee 
Chapter 5  Results and Discussion 4 
131 
 
it is possible that reactivity of the 5’-hydroxyl group towards electrophiles is reduced in the 
ribonucleoside as compared to the 2’-O-methyl derivative. 
 
Figure 5.5: Enlarged image of the hydrogen bonding regions of N2-dimethoxytrityl-8-nitro-2’-O-
methylguanosine (left) and N2-dimethoxytrityl-8-nitroguanosine (right) predicted using Spartan. Note 
hydrogen bonds are represented by green dashed lines. 
5.9 Conclusion 
Although the initial aim of synthesising 8-nitroguanosine triphosphate has not been successful, 
the principles for the phosphorylation of a nucleoside have been shown. It should be noted that 
computational studies suggest that the preferred conformation of the ribose derivative is 
dissimilar to that of the 2’-O-methyl derivative and this may account for the different reactivities 
of the two species. On account of functionalization of the 5’-hydroxyl group having being 
demonstrated using the 2’-O-methyl derivative following nitration, it is possible that this may 
prove to be a better substrate for the phosphorylation reaction. In general, the synthesis of 8-
nitroguanosine triphosphate derivative remains a work in progress and further studies should 
include the use of 2’-O-methylguanosine as the starting material and the investigation of 
alternative protecting group schemes. 
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6 Future work 
Two collaborations are currently in progress that start to address whether there are processes 
that can repair the 8-nitroguanine lesion. 
In collaboration with Professor Andy Bates (University of Liverpool, Biological Sciences) 
investigations into the miscoding potential of the 8-nitroguanine lesion incorporated into 
bacterial plasmid DNA are currently being undertaken. 
The basic principle of this experiment is that an oligodeoxynucleotide containing the stabilised 
lesion is annealed to its analogous sequence in a 300 nucleotide single-stranded gap within a 
plasmid. The site 2 and site 3 sequences, synthesised for this purpose correspond to specific 
sequences within the lacZ gene of the lac operon. The lacZ gene encodes the cytoplasmic 
enzyme β-galactosidase, which catalyses the hydrolysis of lactose into glucose and galactose 
in Escherichia coli307. Following introduction of the modified plasmid to the bacterial cells, 
constituent enzymes carry out gap filling DNA synthesis. The double-stranded plasmid can 
then be completely replicated in a series of reactions catalysed by innate bacterial enzymes 
and subsequently colonies of the bacteria grown. 
The indicator of lacZ activity which will be utilised in these studies is the chromogenic substrate 
bromochloroindolygalactoside (Xgal). This compound is colourless but upon hydrolysis by lacZ, 
dimerization of the resulting compound forms the insoluble dye indigo307. Therefore if the lesion 
is faithfully copied in replication, that is, it is recognised as a guanine base paired with cytosine, 
the lacZ enzyme will be active and a blue colony will be formed. However any 
misincorporations opposite the lesions will result in inactivation of the gene and the colonies 
generated will be white. 
Hence screening colonies which do not produce a blue colour and subsequent sequence 
analysis enables identification of the specific substitutions involved. Performing these 
replication experiments in bacteria either containing or deficient in specific DNA repair 
enzymes that are of particular interest with regards to oxidative DNA lesions, should enable us 
to establish whether these enzymes are involved in a repair system directed against 8-
nitroguanine in DNA. 
A second collaboration with Professor Aidan Doherty (University of Sussex, Genome Damage 
and Stability Centre) is aimed at studying a protein with the potential to remove the 8-
nitroguanine lesion by direct reduction back to guanine. The enzyme is a deazaflavin (F420) 
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dependent nitroreductase (Ddn). Reduction of nitroimidazole using Ddn has been 
demonstrated and the suggested mechanism proceeds via hydride transfer from the enzyme 
complex to the imidazole ring followed by protonation of the C2 position and elimination of the 
nitrous acid (Scheme 6.1)308.  
 
Scheme 6.1: Suggested mechanism for the reduction of nitroimidazole with Ddn308. 
Based on this research it was proposed that a related enzyme that binds to DNA could be 
responsible for replacement of the nitro group in 8-nitroguanine with hydride, effectively 
regenerating guanine. Thus, evaluation of the site 1, site 2 and site 3 sequences as substrates 
for this putative repair enzyme are currently being carried out, however this remains a work in 
progress. In preliminary chemical model studies that are not described in this thesis, sodium 
borohydride was shown to reduce 8-nitroguanine back to guanine, suggesting that a hydride 
type reducing agent could carry out the repair. 
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7 Experimental 
7.1 General techniques, protocols, solvents and reagents 
7.1.1 General techniques 
Analytical thin layer chromatography (TLC) 
TLC was performed on UV254 sensitive, silica gel coated, aluminium TLC plates purchased 
from Merck. The developed chromatographs were visualised using a UV lamp (254nm). Most 
TLC plates were stained with p-anisaldehyde with spots turning blue upon heating with the 
exception of those compounds containing a DMT group which produced an orange colour on 
contact becoming darker upon heating. Ellman’s reagent was used to identify compounds 
containing a thiol or disulfide group, this turned the respective compounds bright yellow upon 
heating. Compounds containing the ribose or 2’-O-methylribose moiety could be distinguished 
by treatment with the sugar stain which upon heating, the spots were observed at black spots. 
Flash column chromatography 
The required quantity of silica gel (particle size 40-63µM supplied by Sigma Aldrich) was made 
into a homogeneous slurry with the column eluent and applied to the column over a base layer 
of sand. The material to be purified was then introduced to the column in a minimum volume of 
eluent or as a powder by pre-absorption onto silica. All eluted fractions were collected and 
analysed by TLC. 
Nuclear magnetic resonance (NMR) spectroscopy 
All NMR spectra were recorded on either a Bruker AMX-400 MHz or 500 MHz spectrometer. 
Chemical shifts are reported in ppm and coupling constants (J) in hertz. 13C NMR and 31P 
NMR spectra were all proton decoupled. For all samples ran in deuterated chloroform (CDCl3) 
and deuterated dimethyl sulfoxide (D6-DMSO) 1H NMR and 13C NMR spectra are relative to an 
internal standard of tetramethylsilane (TMS).  
Mass spectrometry 
All electrospray and chemical ionisation mass spectra were recorded by Ms Moya McCarron at 
the University of Liverpool using a Micromass LCT mass spectrometer. All samples were 
recorded using the ionisation mode specified and were injected using a direct infusion syringe 
pump. All purified and fully deprotected oligodeoxynucleotides were diluted with distilled water 
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and analysed using negative mode electrospray ionisation. Mass spectra of the site 3 
oligodeoxynucleotides were obtained using a Bruker UltrafleXtreme MALDI-TOF/TOF mass 
spectrometer (Bruker Daltonics, UK) using 3-hydroxypicolinic acid as a matrix and recorded by 
Dr. Phillip Brownridge (University of Liverpool, Biological Sciences). 
pH Measurements 
pH Measurements were carried out using a Metrohm 691 pH meter. This was calibrated prior 
to use with buffers purchased from Thermo Russell (pH 4.00, 7.00 and 10.00 ± 0.01 at 25°C).  
Solid-phase oligodeoxynucleotide synthesis 
All oligodeoxynucleotides and dinucleotides were synthesised on a Mermade® 4 column DNA 
synthesiser purchased from BioAutomationTM, equipped with Mermade 12© v2.3.2 software. 
All 1μM, 500Å controlled pore glass (CPG) columns, standard phosphoramidite monomers and 
synthesis reagents were purchased from Link Technologies. Sensitive reagents were stored 
over DNA Moisture Traps supplied by ChemGenes. Modified phosphoramidites were 
synthesised as outlined in Chapter 2 Section 3 and stored under nitrogen at -22°C.  
UV spectrophotometry 
The UV absorbance of the oligodeoxynucleotides, dinucleotides and nucleosides were 
measured at 260nm, unless otherwise stated, on a PerkinElmer LAMBDA Bio+ 
spectrophotometer. A Hellma® TraycellTM was used as an alternative to making the serial 
dilutions of oligodeoxynucleotide stock solutions required when using standard quartz cuvettes 
of 1cm pathlength. UV absorbance measurements were made on 5µl of the stock 
oligodeoxynucleotide solution using either a TrayCell-0.2 mm (Factor 50) Cap or an TrayCell- 
0.1 mm (Factor 100) Cap. The pathlength compensation factor was then applied to the 
absorbance obtained in order to adjust the values to that of a 1cm cuvette.  
High performance liquid chromatography (HPLC) 
HPLC was performed on an automated Gilson HPLC system equipped with a 234 Autoinjector, 
a 170 Photodiode Array Detector and a 231 Dual Hydraulic Pump. Chromatographic data was 
handled using UniPoint Version 3.0. 
Reverse Phase (RP) HPLC was performed on a Gemini® 5 µm C18 110Å, LC Column 250 x 
4.6 mm which was supplied from phenomenex®. A two buffer system, with differing eluent 
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compositions and control methods, were used depending on the relative polarity of the 
compounds being analysed. A flow rate of 1ml/min was used in all protocols. The RP-HPLC 
column was stored in HPLC grade MeCN. 
Ion Exchange (IE) HPLC was performed on a DNA Pac® PA-100, Analytical Column 4 x 
250mm which was supplied by Dionex using a two buffer system. A flow rate of 1ml/min was 
used in all protocols. The IE-HPLC column was stored in distilled H2O. 
7.1.2 HPLC solvents 
Acetonitrile HPLC gradient grade was purchased from Fisher Scientific 
1M Aqueous triethylammonium bicarbonate (TEAB) was prepared by bubbling CO2 gas 
through a solution of triethylamine and distilled water until a pH between 7.50 and 7.70 was 
obtained. This was then diluted to give a final concentration of 1M which was then further 
diluted as necessary. 
RP-HPLC Buffer A (0.1M aqueous TEAB solution, 1L) was prepared by diluting 100ml of the 
1M TEAB solution with 900ml distilled water. 
RP-HPLC Buffer B (0.1M aqueous TEAB containing 40% MeCN, 1L) was prepared by diluting 
100ml of the 1M aqueous TEAB solution with 500ml distilled water and 400ml MeCN. 
1M Aqueous triethylammonium acetate (TEAA) was prepared by the addition of triethylamine 
to a solution of acetic acid and distilled water until a pH of 4 was obtained. This was then 
diluted to give a final concentration of 1M. 
RP-HPLC Buffer C (23mM TEAA) was prepared by diluting 23ml of the 1M aqueous 
triethylammonium acetate solution with 977ml distilled water. 
1M Aqueous potassium phosphate pH 6.6 was prepared by dissolving 87.78g potassium 
phosphate monobasic and 61.84g potassium phosphate dibasic in distilled water to give a final 
volume of 1L.  
IE-HPLC Buffer 1 (10mM aqueous potassium phosphate) was prepared by diluting 10ml of the 
1M aqueous potassium phosphate solution with 990ml distilled water. 
IE-HPLC Buffer 2 (500mM aqueous potassium phosphate) was prepared by diluting 500ml of 
the 1M aqueous potassium phosphate solution with 500ml distilled water. 
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7.1.3 HPLC protocols 
Control method 0-100 
The eluent was gradually changed from 100% buffer A to 100% buffer B over 25 minutes and 
held at 100% buffer B for 5 minutes before being gradually changed back to 100% buffer A 
over 5 minutes. 
 
Figure 7.1: Control method 0-100. 
Control method 0-100B 
The eluent was gradually changed from 100% buffer A to 100% buffer B over 24 minutes and 
held at 100% buffer B for 3 minutes before being gradually changed back to 100% buffer A 
over 5 minutes. 
 
Figure 7.2: Control method 0-100B. 
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Control method 0-65 
The eluent was gradually changed from 100% buffer A (0% buffer B) to 35% buffer A (65% 
buffer B) over 19 minutes, and then to 100% buffer B in the following 1 minute. After holding 
buffer B for 2 minutes the eluent was changed back to 100% buffer A over 2 minutes. 
 
Figure 7.3: Control method 0-65. 
Control method 0-50 
The eluent was gradually changed from 0% MeCN (100% buffer B) to 50% MeCN (50% buffer 
B) over 20 minutes, and then to 100% MeCN in the following 2 minutes. After holding MeCN 
for 5 minutes the eluent was changed back to 100% buffer B over 2 minutes. 
 
Figure 7.4: Control method 0-50. 
Control method 0-22 
The eluent was gradually changed from 0% MeCN (100% buffer B) to 22% MeCN (78% buffer 
B) over 20 minutes and then to 100% MeCN in the following 2 minutes. The eluent was held at 
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100% buffer B for 5 minutes before being gradually changed back to 100% buffer A over 2 
minutes. 
 
Figure 7.5: Control Method 0-22. 
Control method 65/35  
The composition of the mobile phase was kept constant with isocratic elution of 65% buffer B 
and 35% MeCN for 12 minutes. The eluent was then changed to 100% MeCN over the 
following 3 minutes. After holding the buffer at 100% MeCN for 1 minute the eluent was 
gradually changed back to its original composition over 3 minutes.  
 
Figure 7.6: Control method 65/35. 
Control method 65/35B 
The composition of the mobile phase was kept constant with isocratic elution of 65% buffer C 
and 35% MeCN for 12 minutes. The eluent was then changed to 100% MeCN over the 
following 3 minutes. After holding the buffer at 100% MeCN for 11 minutes the eluent was 
gradually changed back to its original composition over 3 minutes.  
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Figure 7.7: Control method 65/35B. 
Control method IE 0-100 
The eluent was gradually changed from 100% buffer 1 to 100% buffer 2 over 20 minutes and 
held at 100% buffer 2 for 5 minutes before being gradually changed back to buffer 1 over 5 
minutes. 
 
Figure 7.8: Control method IE 0-100. 
7.1.4 Solvents 
Unless otherwise stated, solvents were purchased from Fisher Scientific. Anhydrous solvents 
were obtained at follows: 
Acetonitrile: Pre-dried DNA synthesis grade purchased from Link Technologies. 
Dichloromethane: distilled from calcium hydride. 
N,N-Dimethylformamide: Sure-SealTM anhydrous solvent purchased from Sigma Aldrich or 
fractionally distilled from calcium hydride. 
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Dimethyl sulfoxide: Sure-SealTM anhydrous solvent purchased from Sigma Aldrich or 
fractionally distilled from calcium hydride. 
Pyridine: Sure-SealTM anhydrous solvent purchased from Sigma Aldrich. 
7.1.5 General Reagents 
Unless otherwise stated general reagents were purchased from Sigma Aldrich, Acros Organics 
or Chemgenes. 
1M TRIS.HCl: Tris(hydroxymethyl)aminoethane (Tris) was dissolved in distilled water and 
concentrated hydrochloric acid was added until the desired pH was achieved. The volume was 
adjusted to achieve a final concentration of 1M. 
p-Anisaldehyde Stain: p-Anisaldehyde (3ml) was mixed with sulfuric acid (4ml), acetic acid 
(1.2ml) and ethanol (114ml). 
Ellman’s Reagent (0.1% w/v): 5,5’-dithiobis(2-nitrobenzoic acid) (0.15g) was dissolved in 
ethanol (75ml) and 0.45M TRIS.HCl (75ml). 
Sugar Stain: Phenol (3g) was dissolved in a solution of ethanol (95ml) and sulfuric acid (5ml).  
N2-Dimethoxytritylguanosine was previously prepared by Dr. I. Bhamra. 
Tri-N-butylammonium pyrophosphate was prepared according to a published protocol302. 
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7.2 Experimental procedures for results and discussion 1 
3’,5’-Di-O-acetyl-2’-O-methylguanosine (1)194 
 
To a stirred solution of 2’-O-methylguanosine (5.00g, 16.80mmol) in MeCN (50ml) was added 
Et3N (9.38ml, 67.28mmol) and DMAP (0.14g, 1.11mmol), the solution was cooled to 0°C prior 
to addition of Ac2O (3.17ml, 33.60mmol). The mixture was allowed to warm to room 
temperature and was stirred for a further 2 hours. The reaction was quenched with MeOH 
(6ml) and the solvent removed in vacuo. The white solid formed was recrystallised from boiling 
iPrOH which yielded the title product as a white solid (6.04g, 94%). HRMS (ES+) (m/z): 
404.1196 ([M+Na]+); C15H19N5O7Na requires 404.1182 (+3.4643 ppm). 1H NMR (400 MHz, D6-
DMSO): δ (ppm) 10.77 (1H, bs, NH); 7.98 (1H, s, H8); 6.57 (2H, s, NH2); 5.80-5.82 (1H, d, J 
7.0 Hz, H1’); 5.38-5.39 (1H, d, J 5.2, H3’); 4.60-4.63 (1H, dd, J 6.9 and 5.3, H3’); 4.23-4.31 
(3H, m, H4’, H5’ and H5’’); 3.28 (3H, s, 2’OCH3); 2.13 (3H, s, COCH3); 2.07 (3H, s, COCH3). 
13C NMR (100 MHz, DMSO): δ (ppm) 170.66 (CO), 170.09 (CO), 157.19 (C6), 154.51 (C2), 
151.86 (C4), 135.59 (C8) 117.16 (C5), 84.62 (C1’), 80.26 (C2’) 80.21 (C4’), 71.16 (C3’), 63.84 
(C5’), 58.72 (2’OCH3’), 21.11 (COCH3). 
 
8-Bromo-3’,5’-di-O-acetyl-2’-O-methylguanosine (2)194 
 
To a solution of 3’,5’-di-O-acetyl-2’-O-methylguanosine (1, 6.35g, 13.01mmol) suspended in 
distilled H2O (40ml) was added aliquots of saturated bromine water (ca. 25ml) with vigorous 
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stirring. Once the solution was permanently yellow, the mixture was filtered and washed with 
cold iPrOH, before drying in a vacuum dessicator for 12 hours, to yield the product as a pale 
orange solid (7.07g, 88%). Rf = 0.31 (15% MeOH, 85% DCM). HRMS (ES-) (m/z): 458.0301 
and 460.0304 ([M-Na]-); C15H17N5O7Br requires 458.0311 and 460.0291 (-2.1833 and +2.826 
ppm). 1H NMR (400 MHz, D6-DMSO): δ (ppm) 10.93 (1H, s, NH), 6.61 (2H, s, NH2), 5.77-5.78 
(1H, d, J 5.5, H1’), 5.48-5.51(1H, dd, J 5.5 and 4.7, H3’), 5.01-5.04 (1H, ap t, J 5.7, H2’), 4.37-
4.41 (1H, dd, J 11.0 and 3.3, H5’), 4.20-4.28 (2H, m, H4 and H5’’) 3.28 (3H, s, 2’OCH3), 2.13 
(3H, s, COCH3), 2.02 (3H, s, COCH3). 13C NMR (100 MHz, DMSO): δ (ppm) 170.64 (CO), 
170.09 (CO), 155.92 (C6), 154.18 (C2), 152.56 (C4), 120.62 (C8), 117.74 (C5), 88.26 (C1’), 
80.05 (C2’), 78.61 (C4’), 71.29 (C3’), 63.59 (C5’), 58.76 (2’OCH3), 21.04 (COCH3), 21.02 
(COCH3). 
 
N2-Dimethoxytrityl-8-bromo-3’,5’-di-O-acetyl-2’-O-methylguanosine (3)194 
 
8-Bromo-3’,5’-di-O-acetyl-2’-O-methylguanosine (2, 6.35g, 13.80mmol) was co-evaporated to 
dryness with anhydrous pyridine before re-dissolving in anhydrous pyridine (40ml). The 
resultant solution was stirred under an atmosphere of N2 at 0°C and DMTCl (7.01g, 
20.70mmol) was added in ca. 0.5g portions over 5 minutes. The mixture was allowed to warm 
to room temperature and stirred for a further 16 hours. The pyridine was removed in vacuo and 
the resultant oil partitioned between DCM (50ml) and H2O (50ml), the organic layer was further 
washed with H2O (2 x 50ml) and saturated aqueous NaHCO3 (50ml), dried over Na2SO4, 
filtered and evaporated to give the crude material. Purification by flash column chromatography 
(100% DCM - 5% MeOH, 95% DCM) gave the product as a white solid (8.52g, 81%). Rf = 0.21 
(40% EtOAc, 60% DCM). HRMS (ES+) (m/z): 784.1584 and 786.1576 ([M+Na]+); 
C36H36N5O9BrNa requires 784.1594 and 786.1574 (-1.2753 and +0.2544 ppm). 1H NMR (400 
MHz, D6-DMSO): δ (ppm) 10.97 (1H, s, NH), 7.72 (1H, s, NH), 7.14-7.34 (9H, m, DMT Ar-H), 
6.87-6.90 (4H, m, DMT CHCOCH3), 5.40-5.42 (1H, d, J 6.7, H1’), 4.80-4.82 (1H, dd, J 6.1 and 
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4.0, H3’), 3.98-4.02 (1H, ap t, J 6.7, H2’), 3.88-3.92 (1H, dd, J 11.2 and 6.23, H5’), 3.71-3.72 
(7H, m, Ar-OCH3 and H4’), 3.48-3.52 (1H, dd, J 11.7 and 7.1, H5’’), 2.74 (1H, s, 2’OCH3), 2.07 
(3H, s, COCH3), 2.00 (3H, s, COCH3). 13C NMR (100 MHz, D6-DMSO): δ (ppm) 170.15 (CO), 
169.92 (CO), 158.41 (Ar-C), 158.35 (Ar-C), 155.60 (C6), 151.78 (C4), 151.15 (Ar-C), 130.63 
(Ar-C), 129.97 (Ar-C), 128.63 (Ar-C), 128.33 (Ar-C), 127.27 (Ar-C), 121.60 (C8), 118.69 (C5), 
113.63 (Ar-C), 113.56 (Ar-C), 88.20 (C2’), 79.56 (C1’), 76.10 (C4’), 70.75 (NHC), 69.77 (C3’), 
62.77 (C5’), 57.95 (2’OCH3), 55.42 (Ar-OCH3), 55.39 (Ar-OCH3), 20.96 (COCH3). 
 
N2-Dimethoxytrityl-8-nitro-3’,5’-di-O-acetyl-2’-O-methylguanosine (4)194 
 
To a solution of N2-dimethoxytrityl-8-bromo-3’,5’-di-O-acetyl-2’-O-methylguanosine (3, 1.50g, 
1.97mmol) in anhydrous DMF (150ml) under an inert atmosphere was added 18-crown-6 
(5.20g, 19.67mmol) and KNO2 (1.67g, 19.67mmol). The resultant mixture was heated to 100°C 
and stirred for 6 hours before being cooled to room temperature. The solution was poured into 
saturated NaHCO3 (50ml), extracted with EtOAc (3 x 50ml), dried over Na2SO4, filtered and 
concentrated in vacuo. Flash column chromatography of the crude material (50% EtOAc, 50% 
hexane – 80% EtOAc, 20% hexane) afforded the title product as a yellow amorphous solid 
(0.52g, 36%). Rf = 0.46 (40% EtOAc, 60% DCM). HRMS (ES+) (m/z): 751.2313 ([M+Na]+); 
C36H36N6O11Na requires 751.2340 (-3.7272 ppm). 1H NMR (400 MHz, D4-MeOD): δ (ppm) 
7.23-7.31 (9H, m, DMT Ar-H), 6.86-6.89 (4H, m, DMT CHCOCH3), 5.60-5.61 (1H, d, J 4.5, 
H1’), 5.06-5.09 (1H, ap t, J 6.9, H3’), 4.27-4.30 (1H, dd, J 6.9 and 4.6, H2’), 4.10-4.14 (1H, m, 
H5’), 3.99-4.03 (1H, m, H4’), 3.94-3.98 (1H, dd, J 11.6 and 5.4, H5’’), 3.78 (6H, s, 2 x Ar-
OCH3), 2.84 (3H, s, 2’OCH3), 2.09 (3H, s, COCH3), 2.05 (3H, s, COCH3). 13C NMR (100 MHz, 
MeOD): δ (ppm) 170.87 (CO), 170.15 (CO), 158.72 (CO), 157.41 (C4), 153.14 (C6), 151.48 
(C8), 144.78 (C2), 143.66 (Ar-C), 136.46 (Ar-C), 135.79 (Ar-C), 129.92 (Ar-C), 129.77 (Ar-C), 
128.41 (Ar-C), 127.66 (Ac-C), 126.81 (Ac-C), 115.03 (C5), 112.95 (Ar-C), 89.75 (C1’), 78.71 
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(C2’), 78.66 (C4’), 70.50 (NHC), 70.35 (C3’), 61.81 (C5’), 57.49 (2’OCH3), 54.39 (Ar-OCH3), 
19.24 (COCH3),19.06 (COCH3). 
 
N2-Dimethoxytrityl-8-nitro-2’-O-methylguanosine (5)194 
 
N2-Dimethoxytrityl-8-nitro-3’,5’-di-O-acetyl-2’-O-methylguanosine (4, 1.74g, 2.39mmol) was 
dissolved in NH3 (7M) in MeOH (15ml) and stirred in a sealed vessel for 48 hours. The solvent 
was removed in vacuo and purified by flash column chromatography (50% EtOAc, 50% DCM) 
to yield the deacetylated nucleoside as a yellow amorphous solid (1.47g, 95%). Rf = 0.27 (50% 
EtOAc, 50% DCM). HRMS (ES+) (m/z): 667.2131 ([M+Na]+); C32H32N6O9Na requires 667.2128 
(+0.4496 ppm). 1H NMR (400 MHz, D4-MeOD): δ (ppm) 7.20-7.31 (9H, m, DMT Ar-H), 6.85-
6.88 (4H, m, DMT CHCOCH3), 5.82-5.82 (1H, d, J 3.2, H1’), 3.79-3.81 (1H, dd, J 7.0 and 3.2, 
H2’), 3.73-3.77 (6H ,s, 2x Ar-OCH3), 3.76 (1H, ap t, J 7.1, H3’), 3.58-3.62 (1H, dt, J 7.2 and 
2.9, H4’), 3.52-3.55 (1H, dd, J 12.2 and 2.9, H5’), 3.36-3.41 (1H, dd, J 12.2 and 7.2, H5’’), 3.03 
(3H, s, 2’OCH3). 13C NMR (100 MHz, MeOD): δ (ppm) 160.13 (Ar-C), 160.08 (Ar-C), 158.95 
(C4), 154.42 (C6), 152.65 (C8), 146.10 (C2), 145.24 (Ar-C), 137.90 (Ar-C), 137.31 (Ar-C), 
131.20 (Ar-C), 131.11 (Ar-C), 129.81 (Ar-C), 129.11 (Ar-C), 128.20 (Ar-C), 116.52 (C5), 114.41 
(Ar-C), 114.37 (Ar-C), 91.14 (C1’), 85.44 (C2’), 81.28 (C3), 71.90 (C4), 70.58 (NHC), 63.49 
(C5’), 58.50 (2’OCH3), 55.77 (Ar-C), 54.80 (Ar-C). 
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5’-O,N2-bis-dimethoxytrityl-8-nitro-2’-O-methylguanosine (6)194 
 
N2-Dimethoxytrityl-8-nitro-2’-O-methylguanosine (5, 1.45g, 2.25mmol) was dried by co-
evaporation of anhydrous pyridine before re-dissolving in anhydrous pyridine (15ml) and 
adding DMTCl (1.02g, 3.00mmol) in portions. The solution was stirred for 16 hours at room 
temperature under an inert atmosphere. The pyridine was removed in vacuo and the residue 
was subjected to flash column chromatography (20% EtOAc, 80% Hexane) to afford the title 
compound as a yellow solid (1.66g, 78%). Rf = 0.66 (40% EtOAc, 60% DCM). HRMS (ES+) 
(m/z): 969.3444 ([M+Na]+); C53H50N6O11Na requires 969.3435 (+0.9285 ppm). 1H NMR (400 
MHz, D6-DMSO): δ (ppm) 11.22 (1H, br s, NH), 8.10 (1H, br s, NH), 7.13-7.31(18H, m, DMT 
Ar-H), 6.80-6.87 (8H, m, DMT CHCOCH3), 5.70 (1H, d, J 1.8, H1’), 4.55-4.57 (1H, d, J 8.5, 
H3’), 3.86-3.87 (1H, m, H4’) 3.68-3.73 (13H, 4 x Ar-OCH3 and H2’), 3.03-3.05 (1H, d, J 9.73, 
H5’), 2.93- 2.95 (4H, m, 2’OCH3 and H5’’). 13C NMR (100 MHz, DMSO): δ (ppm) 158.03 (Ar-
C), 157.88 (Ar-C), 157.91 (Ar-C), 157.86 (Ar-C), 156.11 (C4), 153.06 (C6), 150.02 (C8), 144.79 
(Ar-C), 144.28 (Ar-C), 143.21 (C2), 136.89 (Ar-C), 135.82 (Ar-C), 135.82 (Ar-C), 135.50 (Ar-C), 
129.76 (Ar-C), 129.66 (Ar-C), 129.58 (Ar-C), 128.23 (Ar-C), 127.81 (Ar-C), 127.68 (Ar-C), 
127.62 (Ar-C), 115.40 (C5), 113.21 (Ar-C), 113,12 (Ar-C), 113.05 (Ar-C), 113.02 (Ar-C), 89.57 
(C1’), 85.26 (NHC), 81.83 (C2’), 79.63 (C4’), 69.70 (NHC), 69.36 (C3’), 63.57 (C5’), 57.04 
(2’OCH3), 55.05 (Ar-C), 55.02 (Ar-C), 54.99 (Ar-C), 54.97 (Ar-C). 
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5’-O,N2-bis-dimethoxytrityl-8-nitro-2’-O-methylguanosine-3’-O-[(2-cyanoethyl)-(N,N-
diisopropyl)]-phosphoramidite (7)194 
 
5’-O,N2-bis-dimethoxytrityl-8-nitro-2’-O-methylguanosine (6, 1.00g, 1.06mmol) was dissolved 
in anhydrous DCM (10ml), and cooled to 0°C under an inert atmosphere. N,N-
Diisopropylethylamine (2.30ml, 13.20mmol) was added followed by dropwise addition of 2-
cyanoethy-N,N-diisopropyaminochlorophosphoramidite (0.47ml, 2.11mmol). The solution was 
allowed to warm to room temperature and stirred for 3 hours before adding H2O (20ml) and 
DCM (40ml). The phases were separated and the organic solution was dried with Na2SO4, 
filtered and concentrated in vacuo to give a pale brown solid. Purification by flash column 
chromatography (30% EtOAc, 70% DCM) resulted in a yellow amorphous solid containing both 
diastereoisomers (a) and (b) (0.55g, 45%). Rf = 0.81 (75% EtOAc, 25% DCM). HRMS (ES+) 
(m/z): 1169.4540 ([M+Na]+); C62H67N8O12PNa requires 1169.4514 (+2.2233 ppm). 31P NMR 
(160 MHz, CDCl3): δ (ppm) 152.06, 150.57. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.10-7.44 
(36H, m, DMT Ar-H), 6.73-6.80 (16H, m, DMT CHCOCH3), 6.67-6.69 (1H, d, J 8.89, H1’ (a)), 
6.63-6.66 (1H, d, J 8.9, H1’ (b)) 5.66-5.72 (2H, br peak, H4’ (a) and (b)), 4.48-4.54 (2H, br 
peak, H2’(a) and H2’(b)), 4.02-4.04 (2H, br peak, H3’ (a) and (b)), 3.80-3.87 (2H, m, 
CH2CH2CN), 3.71-3.71 (13H, m, Ar-OCH3 (a) and (b), H3’), 3.57-3.65 (12H, br peak, Ar-OCH3 
(a) and (b)), 3.41-3.49 (4H, m, N(CH(CH3)2)2 (a) and (b)), 3.12-3.23 (4H, m, H5’ (a) and (b)), 
3.03-3.08 (2H, br peak, H2’ (a) and (b)), 3.06 (3H, br peak, 2’OCH3 (a) and (b)), 2.61-2.65 (2H, 
t, J 6.5, CH2CH2CN (a)), 2.32-2.36 (2H, t, J 6.4, CH2CH2CN (b)),1.09-1.15 (18H, m, 
N(CH(CH3)2)2 (a) and (b)), 0.88.0.90 (6H, d, J 6.73, N(CH(CH3)2)2 (a) and (b)). 
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7.2.1 General procedure for the solid-phase synthesis of unmodified and modified 
oligodeoxynucleotides 
All oligodeoxynucleotides were synthesised on a 1μmol scale using either SynBaseTM CPG 
Functionalised supports or Universal Q SynBaseTM CPG supports both of which were 1μmol, 
500Å CPG columns. Synthesis was carried out using a MerMade® 4 DNA/RNA synthesiser. 
All commercially supplied 5’-O-(4,4’-dimethoxytrityl)-2’-deoxynucleoside-3’-[(2-cyanoethyl)-
N,N-diisopropyl]-phosphoramidite derivatives were diluted with anhydrous MeCN to the 
recommended concentration of 0.1M and loaded at ports 1-4 on the synthesiser. 5’-O-(4,4’-
dimethoxytrityl)-2’-O-methylguanosine-3’-[(2-cyanoethyl)-N,N-diisopropyl]-phosphoramidite 
was also used at the recommended 0.1M concentration and loaded into port 6 on the 
synthesiser. 
The modified phosphoramidite monomer was dissolved in anhydrous MeCN (0.12M) and 
loaded at position 5 on the synthesiser. In order to prevent the modified phosphoramidite from 
crystallising inside the reagent lines, the solution was loaded into the port immediately prior to 
the start of the X cycle. This required a soft pause of the synthesiser and manual priming of the 
line 5. 
1  START TRITYL 
2  DEBLOCK 
3  DEBLOCK 
4  END TRITYL 
5  MeCN WASH 
6  MeCN WASH 
7 COUPLING 
8 COUPLING 
9  MeCN WASH 
10  CAPPING 
11  MeCN WASH 
12  OXIDATION 
13  MeCN WASH 
14  MeCN WASH 
Table 7.1: Generalised cycle corresponding to the standard Mermade® 4 1µmol protocol. 
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Prior to oligodeoxynucleotide synthesis the reagent lines were primed accordingly. All 
unmodified and modified oligodeoxynucleotides using a functionalised support were 
synthesised according to the standard Mermade ® 4 1μmol protocol (Table 7.1). Dimers 
synthesised on a non nucleosidic universal support were treated with an initial extended 
detritylation pre-cycle (Table 7.2) to ensure complete detritylation of the support. 
A MeCN WASH 
B MeCN WASH 
C MeCN WASH 
D DEBLOCK 
Table 7.2: Pre-cycle employed when using universal supports. 
Standard 3’-5’ synthesis procedures and reagents were used for detritylations, capping and 
oxidations steps (Table 7.3). Coupling settings with extended coupling times for 2’-O-methyl 
phosphoramidites and modified 2’-O-methyl phosphoramidites were employed as shown in 
Table 7.4. Coupling efficiencies were measured using an integrated spectrophometer. In all 
cases the final 5’-DMT group was left on the 5’-terminus of the oligodeoxynucleotide strand at 
the end of the synthesis and the oligodeoxynucleotide was left attached to the solid-support. 
Function Reagent 
Injection  
volume (μl)  
DEBLOCK 3% Trichloroacetic acid in dichloromethane 240 
MeCN WASH Anhydrous acetonitrile 275 
ACTIVATOR ETT (0.25M): 5-thylthio-1H-tetrazole in acetonitrile, anhydrous 50 
CAPPING 
CAP A: Acetic anhydride in THF/pyridine (1:8:1) 110 
CAP B: 10% N-methylimidazole in THF 125 
OXIDISER 0.2M Iodine in THF/pyridine/water (7:2:1) 150 
Table 7.3: General reagents used for standard DNA synthesis and modified DNA synthesis. 
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Phosphoramidite Standard 2'-O-methyl Modified 2'-O-methyl 
CPG support 
Function- 
alised 
Function- 
alised 
Universal 
Function- 
alised 
Universal 
Number of  
amidite primes 
3 3 3 1 1 
Amidite injection 
volume (μl) 
40 40 40 40 40 
Activator injection 
volume (μl) 
50 50 50 50 50 
Wait time (s) 30 70 70 70 80 
Table 7.4: Coupling settings for all phosphoramidites and supports.  
7.2.2 General procedure for the cleavage of oligodeoxynucleotide strands from the 
functionalised CPG support and removal of base labile protecting groups 
After the synthesis was complete the support bound oligodeoxynucleotides were transferred to 
a Wheaton V-Vial®, and H2O (0.50ml) and concentrated aqueous ammonia (1.00ml) were 
added. The vial was sealed and the resulting mixture was heated at 55°C for 8 hours until 
cleavage of the oligodeoxynucleotides from the linker and removal of the base labile protecting 
groups was achieved. The ammonium hydroxide solution was then transferred into eppendorf 
vials (1.5ml). Care was taken to avoid transferring any of the CPG support as it can prove 
problematic during purification. The remaining solid was washed with H2O (0.5ml) and the 
supernatant was transferred into an eppendorf vial. The eppendorfs were then centrifuged for 
10 minutes to ensure that any residual solid was not present.  
7.2.3 General procedure for the cleavage of oligodeoxynucleotides strands from the 
Universal Q CPG support and removal of base labile protecting groups 
After the synthesis was complete the support bound oligodeoxynucleotides were transferred to 
a Wheaton V-Vial®, and H2O (0.25ml), concentrated aqueous ammonia (0.50ml) and 40% 
methylamine (0.75ml) were added. The vial was sealed and the resulting mixture was heated 
at 55°C for 17 hours until cleavage of the oligodeoxynucleotides from the linker and removal of 
the base labile protecting groups was achieved. The supernatant was then transferred into 
eppendorf vials (1.5ml). Care was taken to avoid transferring any of the CPG support as it can 
prove problematic during purification. The remaining solid was washed with H2O (0.5ml) and 
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the solution was transferred into an eppendorf vial. The eppendorfs were then centrifuged for 
10 minutes to ensure that any residual solid was not present.  
7.2.4 Procedure for the removal of the DMT groups on the modified dinucleotide prior 
to purification  
Removal of the 5’-DMT and 2 x N2-DMT was achieved by treatment of the unpurified 
dinucleotide with 3% trichloroacetic acetic acid in dichloromethane (0.5ml, 0.09mmol) and the 
resulting mixture was left to stand at room temperature for 10 minutes. The acidic solution was 
neutralized with triethylamine (0.026ml, 0.18mmol) and then concentrated in vacuo. The yellow 
solid was dissolved in H2O (0.5ml), extracted with EtOAc (3 x 0.5ml) and the aqueous layer 
concentrated in vacuo. The resulting residue was resuspended in distilled water (1ml) and the 
fully deprotected dinucleotide was purified by the general procedure for fully deprotected 
oligodeoxynucleotides described below (section 2.7). 
7.2.5 General procedure for RP-HPLC analysis and purification of the crude 5’-DMT 
oligodeoxynucleotides 
Analytical scale 
Analytical, RP-HPLC was performed with a sample injection of 15µl. The composition of the 
eluent was controlled by the control method 0-100 as shown in Figure 7.1 (page 139). Full 
length oligonucleotides with the 5’-DMT group present have a retention time of greater than 19 
minutes. Eluted compounds were detected by UV absorbance at both 254 and 350nm. 
Preparative scale 
Preparative RP-HPLC was performed with sample injections of up to 400µl using the control 
method 0-100 (Figure 7.1, page 139). The fractions collected containing the desired 5’-DMT 
protected oligonucleotides were combined and concentrated in vacuo. The resulting residue 
was co-evaporated with water (1ml) and concentrated under reduced pressure. The solid that 
remained was resuspended in distilled H2O to afford the pure 5’-DMT protected 
oligodeoxynucleotide. The 5’-DMT group was then removed by treatment with acid as 
described in the following procedure.  
7.2.6 General procedure for the removal of the 5’-DMT group 
Removal of the 5’-DMT was achieved by treatment of the purified 5’-DMT oligodeoxynucleotide 
with 20% aqueous acetic acid solution (1ml) and the resulting solution was left to stand at room 
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temperature for 20 minutes. The aqueous acid was removed in vacuo and the remaining 
residue was washed with distilled water (1ml) and reconcentrated.  
7.2.7 General procedure for the RP-HPLC analysis and purification of the fully 
deprotected oligodeoxynucleotides 
Analytical scale 
Analytical, RP-HPLC was performed with a sample injection of 15µl using the control method 
0-100 described previously (page 139). Fully deprotected oligodeoxynucleotides eluted 
between ~11-14 minutes and were detected by UV absorbance at both 254 and 350nm. 
Preparative scale 
Preparative RP-HPLC was performed on up to 400µl sample injections using the control 
method 0-100 (page 139). The fractions containing the desired oligonucleotides were 
collected, combined and concentrated in vacuo. The resulting residue was co-evaporated with 
water (1ml), concentrated under reduced pressure to afford the pure full length 
oligonucleotides. 
7.2.8 Quantification of oligodeoxynucleotides 
The fully deprotected, dried oligodeoxynucleotide samples were dissolved in 1.0ml of distilled 
water to give the oligodeoxynucleotide stock solution. The concentration and final yield of the 
purified oligodeoxynucleotides were calculated using the values obtained for the UV 
absorbance at 260nm. 
The pathlength compensation factor was applied to the absorbance obtained from 5μl of the 
stock solutions using the TrayCellTM in order to adjust the values to that of a 1cm cuvette 
(Equation 7.1). 
Absorbance(stock) = Absorbance(260) x Pathlength compensation factor 
Equation 7.1: Calculation of the absorbance of the stock solution. 
The Beer-Lambert law was utilized to calculate the concentrations of the 
oligodeoxynucleotides. As there is no molar extinction coefficient (ε) value for the modified 
oligodeoxynucleotides, the ε value for the analogous unmodified sequence was used.  
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Concentration =  
Absorbance(stock) 
 x106 
ε x Pathlength 
Equation 7.2: Beer-Lambert Law. 
Equation 7.3 is used to calculate the optical density (OD) from the absorbance. Since the stock 
solution was generally in 1ml, the optical density and the absorbance of the stock solution were 
often equivalent. 
Optical Density(260) = Absorbance(stock) x Volume (ml) 
Equation 7.3: Calculation of optical density. 
In order to determine the overall yield it was necessary calculate the theoretical optical density 
at 260nm. The calculation is based on a 1μmole scale and assumes that each coupling step is 
quantitative.  
Theoretical optical density(260) = ε x Moles x 1000 
Equation 7.4: Calculation of theoretical optical density. 
The percentage yield of the purified oligodeoxynucleotide was then calculated using Equation 
7.5.  
Percentage yield of oligodeoxynucleotide =  
Optical density(260) 
Theoretical optical density(260) 
Equation 7.5: Calculation of the % yield of the purified oligodeoxynucleotide. 
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7.2.9 HPLC and UV analysis of all oligodeoxynucleotide synthesised 
The HPLC analysis obtained for all oligonucleotide syntheses is shown in Table 7.5 
 HPLC analysis (Control method 0-100) 
 Retention time (minutes) 
Purity (%) 
Oligodeoxynucleotide DMT-on DMT-off 
Site 1 control 21.45 11.35 97 
Site 1 21.69 10.95 95 
Site 2 Control 18.15 11.54 86 
Site 2 19.51 11.46 87 
Site 3 Control 20.28 11.67 95 
Site 3 19.88 11.71 90 
Dimer (8) 19.16 13.80 97 
Dimer (9) - 13.83 74 
Table 7.5: All oligodeoxynucleotides prepared together with their retention times and purity as determined 
by HPLC. For sequences see table 2.1 or abbreviations section. 
As aforementioned the typical loading of the CPG solid-support is in the range of  
30-60µmol g-1. Therefore the yields calculated for oligodeoxynucleotide synthesis are an 
approximation rather than accurate calculation. 
 UV Analysis 
Oligodeoxynucleotide ε (260nm)* OD260 units Yield (%) 
Site 1 control 122100 31.65 26 
Site 1 122100 39.02 32 
Site 2 Control 361200 25.72 7 
Site 2 361200 66.60 18 
Site 3 Control 254400 51.04 20 
Site 3 254400 29.21 11 
Dimer (8) 21600 14.65 68 
Dimer (9) 21600 0.97 4 
Table 7.6: The yields of the purified oligodeoxynucleotides as determined by UV analysis. * ε was 
calculated using the IDT Biophysics website309. 
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7.2.10 Mass spectrometry data for all oligodeoxynucleotides 
Table 7.7 and Table 7.8 show the theoretical and experimental molecular weights of all 
oligodeoxynucleotides synthesised.  
 
Mass spectrometry analysis 
Oligodeoxynucleotide Charge Theoretical mass Experimental mass 
Site 1 Control -3 1324.2277 1324.2203 
Site 1 -4 1011.6678 1011.6455 
Table 7.7: Theoretical and experimental molecular weights for the mass to charge ratio (m/z) for 
electrospray spectra. For sequences see table 2.1 or abbreviations section. 
The [M-nH]n- peaks were then used to give experimental average masses for the parent ions of 
each oligodeoxynucleotide product. 
 Parent ion molecular weight 
Oligodeoxynucleotide Theoretical mass Experimental mass Error (ppm) 
Site 1 Control 3975.7066 3975.6844a -5.6033 
Site 1 4050.7025 4050.6133a -22.1026 
Site 2 Control nd nd Nd 
Site 2 nd nd Nd 
Site 3 Control 8311.42 8314.74b Nd 
Site 3 8460.31c 8460.64b Nd 
Dimer (8) 655.1626 655.1617a -1.3737 
Dimer (9) 745.1327 745.1313a -1.8789 
Table 7.8: Theoretical and experimental average molecular weights of the parent ion for all 
oligodeoxynucleotides synthesised. Note the experimental masses of the dimers were obtained directly 
from the spectra. Note nd = not determined, a determined by electrospray ionisation, b determined by 
MALDI and c corresponds to (M-4H)+3Na+K. For sequences see table 2.1 or abbreviations section. 
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7.3 Experimental procedures for results and discussion 2 
2’,3’,5’-Tri-O-acetylguanosine (10)310  
 
Acetic anhydride (1.00ml, 10.6mmol) was added dropwise to an ice cooled mixture of 
guanosine (1.00g, 3.5mmol), triethylamine (2.95ml, 21.1mmol) and DMAP (0.043g, 0.35mmol) 
in MeCN (10ml). The reaction mixture was then allowed to warm to room temperature. There 
was complete solubilisation when the reaction had gone to completion. The reaction was 
quenched with MeOH. The solvent was removed in vacuo to give a cloudy gel. The product 
was then isolated by recrystallisation from the minimum amount of hot iPrOH. The white solid 
was then co-evaporated with Et2O to remove excess triethylamine. This yielded the product as 
a white solid (1.24g, 86%). HRMS (ES+) (m/z): 432.1115 ([M+Na]+); C16H19N5O8Na requires 
432.1131 (-3.7027 ppm). 1H NMR (400 MHz, D6-DMSO): δ (ppm) 10.83 (1H, br s, NH), 7.94 
(1H, s, C8), 6.59 (2H, br s, NH2), 5.98-6.00 (1H, d, J 6.1, H1’), 5.78-5.81 (1H, ap t, J 6.1, H2’), 
5.48-5.51 (1H, dd J 5.9 and 4.1, H3’), 4.36-4.40 (1H, dd J 11.2 and 3.7, H5’), 4.30-4.34 (1H, m, 
H4’), 4.24-4.27 (1H, dd J 11.2 and 5.7, H5’’), 2.12 (3H, s, COCH3), 2.05 (3H, s, COCH3), 1.90 
(3H, s, COCH3). 13C NMR (100 MHz, DMSO): δ (ppm) 170.47 (CO), 169.82 (CO), 169.65 (CO), 
157.03 (C6), 154.30 (C2), 151.48 (C4), 135.97 (C8), 117.150 (C5), 84.70 (C1’), 79.89 (C2’), 
72.39 (C4’), 70.66 (C3’), 63.44 (C5’), 21.70 (COCH3), 20.75 (COCH3), 20.56 (COCH3). 
 
8-Bromo-2’,3’,5’-tri-O-acetylguanosine (11)311 
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To a stirred solution of 2’,3’,5’-tri-O-acetylguanosine (10, 1.20g, 2.9mmol) suspended in 
distilled H2O (10ml), was added bromine water in aliquots (3ml) with vigorous stirring until the 
solution remained permanently yellow. The mixture was filtered and washed with cold iPrOH 
leaving the product as a pale orange solid (1.36g, 89%). HRMS (ES+) (m/z): 510.0227 and 
512.0200 ([M+Na]+); C16H18N5O8BrNa requires 510.0236 and 512.0216 (-1.7646 and -3.1249 
ppm). 1H NMR (400 MHz, D6-DMSO): δ (ppm) 10.95 (1H, br s, NH), 6.63 (2H, br s, NH2), 5.99-
6.02 (1H, dd, J 6.4 and 4.5, H3’), 5.88-5.89 (1H, d, J 4.4, H1’), 5.54-5.66 (1H, ap t, J 6.3, H2’), 
4.36-4.4 (1H, dd, J 11.8 and 3.7, H5’), 4.31-4.35 (1H, ddd, J 6.2, 6.1 and 3.8, H4’), 4.19-4.23 
(1H, dd, J 11.8 and 6.2, H5’’), 2.12 (3H, s, COCH3), 2.08 (3H, s, COCH3), 2.00 (3H, s, COCH3). 
13C NMR (100 MHz, DMSO): δ (ppm) 170.47 (CO), 169.86 (CO), 169.78 (CO), 155.78 (C6), 
154.16 (C2), 152.27 (C4), 120.50 (C8), 117.53 (C5), 87.99 (C1’), 79.65 (C2’), 71.64 (C3’), 
70.27 (C4’), 63.13 (C5’), 20.84 (COCH3), 20.67 (COCH3), 20.61 (COCH3). 
 
N2-Dimethoxytrityl-8-bromo-2’,3’,5’-tri-O-acetylguanosine (12)194 
 
8-Bromo-2’-3’-5’-tri-O-acetylguanosine (11, 1.10g, 2.3mmol) was co-evaporated with 
anhydrous pyridine (3 x 10ml) and subsequently dissolved in anhydrous pyridine (10ml). 
DMTCl (1.5g, 4.5mmol) was added over 5 minutes to the solution under a nitrogen 
atmopshere. The reaction mixture was stirred overnight and then partitioned between H2O 
(10ml) and CHCl3 (20ml). The aqueous layer was washed with CHCl3 (3 x 20ml) and the 
combined organic extracts were dried over Na2SO4. The solvent was then removed in vacuo to 
give a brown oil. The crude product was purified by column chromatography (100% CHCl3 - 
2% MeOH, 98% CHCl3) to give the desired product as a yellow amorphous solid (1.78g, 90%). 
Rf = 0.50 (10% MeOH, 90% DCM). HRMS (ES+) (m/z): 812.1520 and 814.1494 ([M+Na]+); 
C37H36N5O10BrNa requires 812.1543 and 814.1523 (-2.8320 and -3.5620 ppm). λmax (H2O) 236 
and 274nm. 1H NMR (400 MHz, D4-MeOD): δ (ppm) 7.21-7.30 (9H, m, DMT Ar-H), 6.84-6.87 
(4H, ap d, DMT CHCOCH3), 5.58-5.60 (1H, d, J 6.1, H1’), 5.22-5.25 (2H, ap t, J 6.4, H2’), 4.97-
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5.00 (1H, dd, J 6.4 and 4.7, H3’), 4.00-4.04 (1H, dd, J 11.2 and 6.1, H5’), 3.83-3.92 (2H, m, H4’ 
and H5’’), 3.78 (6H, s, Ar-OCH3), 2.11 (3H, s, COCH3), 2.03 (3H, s, COCH3), 1.96 (3H, s, 
COCH3). 13C NMR (100 MHz, MeOD): δ (ppm) 172.00 (CO), 170.97 (CO), 170.79 (CO), 160.03 
(Ar-C), 159.98 (Ar-C), 158.14 (C6), 153.02 (C2), 152.87 (C4), 146.73 (Ar-C), 137.40 (Ar-C) 
131.14 (Ar-C), 131.02 (Ar-C), 129.72 (Ar-C), 129.08 (Ar-C), 128.11 (Ar-C), 123.23 (C8) 119.18 
(C5), 114.31 (Ar-C), 114.25 (Ar-C), 89.31 (C1’), 80.64 (C2’), 71.89 (C3’), 71.76 (NHC), 71.35 
(C4’), 64.19 (C5’), 55.68 (Ar-OCH3), 20.70 (COCH3), 20.45 (COCH3), 20.16 (COCH3). 
 
N2-Dimethoxytrityl-8-nitro-2’,3’,5’-tri-O-acetylguanosine (13)194 
 
N2-Dimethoxytrityl-8-bromo-2’,3’,5’-tri-O-acetylguanosine (12, 1.50g, 1.90mmol) was dissolved 
in anhydrous DMF (150ml). To this solution was added KNO2 (1.61g, 19.0mmol) and 18-crown-
6 (5.01g, 19.0mmol). The resulting mixture was then heated at 100°C for 6 hours under an 
inert atmosphere before cooling to room temperature and pouring directly into H2O (50ml). The 
aqueous solution was extracted with EtOAc (3 x 50ml), and the combined organic extracts 
were washed with NaHCO3 (50ml), dried with Na2SO4, filtered and concentrated to an oil. The 
crude product was purified by flash column chromatography (50% EtOAc, 50% Hexane – 70% 
EtOAc, 30% Hexane). This gave the product as a yellow amorphous solid (0.46, 32%). Rf = 
0.48 (40% EtOAc, 60% DCM). HRMS (ES+) (m/z): 779.2302 ([M+Na]+); C37H36N6O12Na 
requires 779.2289 (+1.6683 ppm). λmax (H2O) 237, 274 and 398. 1H NMR (400 MHz, D6-
DMSO): δ (ppm) 11.20 (1H, br s, 1H, NH), 8.08 (2H, br s, NH2), 7.12-7.35 (9H, m, DMT Ar-H), 
6.86-6.91 (4H, m, DMT CHCOCH3), 5.58-5.59 (1H, d, J 4.8, H1’), 5.44-5.47 (1H, dd, J 6.7 and 
5.1, H2’) 5.14-5.18 (1H, ap t, J 6.9, H3’), 4.12-4.16 (1H, dd, J 11.9 and 2.8, H5’), 3.97-4.01 
(1H, ddd, J 6.6, 6.2 and 3.3, H4’), 3.83-3.88 (1H, dd, J 12.0 and 6.0, H5’’), 3.73 (6H, s, Ar-
OCH3),2.06 (3H, s, COCH3), 2.00 (3H, s, COCH3), 1.79 (3H, s, COCH3). 13C NMR (100 MHz, 
DMSO): δ (ppm) 169.89 (CO), 169.16 (CO), 168.85 (CO), 157.98 (Ar-C), 157.92 (Ar-C), 
156.05 (C6), 153.33 (C4), 151.29 (C8), 144.68 (C2), 142.92 (Ar-C), 135.98 (Ar-C), 129.70 (Ar-
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C), 129.66 (Ar-C), 128.26 (Ar-C), 127.92 (Ar-C), 126.85 (Ar-C), 115.26 (C5), 113.18 (Ar-C), 
113.11 (Ar-C), 82.27 (C1’), 78.25 (C2’), 70.90 (C3’), 70.00 (NHC), 68.63 (C4’), 61.85 (C5’), 
55.03 (Ar-OCH3), 55.02, 20.41 (COCH3), 20.24 (COCH3), 19.87 (COCH3). 
 
8-Nitro-2’,3’,5’-tri-O-acetylguanosine (14) 
 
N2-Dimethoxytrityl-8-nitro-2’,3’,5’-tri-O-acetylguanosine (13, 0.25g, 0.33mmol) was dissolved in 
CHCl3 (5ml) before adding a solution of pTsOH (0.028g, 0.17mmol) in MeOH (1ml). After 20 
minutes the solvent was removed in vacuo. The orange solid was the triturated with Et2O to 
afford the detritylated nucleoside (0.1259g, 84%). HRMS (ES-) (m/z): 453.1014 ([M-H]-); 
C16H17N6O10 requires 453.1006 (+1.7656 ppm). 1H NMR (400 MHz, D6-DMSO): δ (ppm) 11.34 
(1H, br s, NH), 7.18 (1H, br s, NH2), 6.54 (1H, d, J 3.0, H1’), 5.90-5.93 (1H, d, J 6.3 and 3.2, 
H2’), 5.71-5.74 (1H, t, J 7.0, H3’), 4.41-4.44 (1H, dd, J 11.8 and 2.7, H5’), 4.30-4.33 (1H, ap dt, 
J 2.8 and 6.9, H4’), 4.19-4.23 (1H, dd, J 6.5 and 11.9, H5’’), 2,08 (3H, s, COCH3), 2.05 (3H, s, 
COCH3), 1.98 (3H, s, COCH3). 13C NMR (100 MHz, DMSO): δ (ppm) 170.46 (COCH3), 169.80 
(COCH3), 169.63 (COCH3), 157.20 (C4), 156.26 (C6), 152.67 (C8), 142.98 (C2), 115.33 (C5), 
88.73 (C1’), 79.52 (C2’), 72.78 (C3’), 69.99 (C4’), 63.26 (C5’), 20.81 (COCH3), 20.64 (COCH3), 
20.60 (COCH3). 
 
8-Nitroguanosine (15)194 
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N2-Dimethoxytrityl-8-nitro-2’,3’,5’-tri-O-acetylguanosine (13, 0.12g, 0.2mmol) was dissolved in 
CHCl3 (3ml) before adding a solution of pTsOH (6.8mg, 0.04mmol) in MeOH (0.5ml). After 20 
minutes the solvent was removed in vacuo. The resulting orange solid was triturated with Et2O 
three times to afford the crude base deprotected nucleoside. This was then dissolved in NH3 
(7M) in MeOH (3ml) and stirred in a sealed vessel for 36 hours. The precipitate was isolated by 
drawing off the solution with a syringe followed by trituration of the solid with Et2O three times 
to afford the desired compound as an orange solid (40mg, 77%). HRMS (ES-) (m/z): 327.0700 
([M-H]-); C10H11N6O7 requires 327.0689 (+3.3632 ppm). 1H NMR (400 MHz, D6-DMSO): δ 
(ppm) 9.60 (1H, br s, NH), 7.18 (2H, br s, NH2), 6.26-6.28 (1H, d, J 5.3, H1’), 5.41 (1H, br s, 
OH), 5.07 (1H, br s, OH), 4.91-4.93 (1H, ap t, J 5.5, H2’), 4.19-4.21 (1H, ap t, J 5.3, H3’), 3.83-
3.87 (1H, ap q, J 4.9, H4’), 3.65-3.70 (1H, dd, J 11.8 and 4.4, H5’), 3.50-3.55 (1H, dd, J 11.8 
and 5.9, H5’’). 13C NMR (100 MHz, DMSO): δ (ppm) 157.69 (C4), 156.06 (C6), 152.59 (C8), 
143.40 (C2), 115.24 (C5), 90.46 (C1’), 85.67 (C4’), 71.08 (C2’), 70.10 (C3’), 61.85 (C5’). 
 
8-Nitroguanine (16) 
 
8-Nitroguanosine (15, 0.20g, 0.61mmol) was dissolved in 1M HCl and heated at 60°C for 6 
hours. The solution was then neutralised with 1M NaOH taking care that the pH did not fall 
below 7 to avoid formation of salts. The resulting precipitate was isolated by filtration, washed 
with ice cold H2O and triturated with EtOAc to give the product as an orange solid (94mg, 
79%). λmax (H2O) 254 and 400nm; 1H NMR (400 MHz, D6-DMSO): δ (ppm) 11.28 (1H, br s, 
NH), 6.75 (2H, br s, NH2), 3.62 (1H, br s, NH). 13C NMR (100 MHz, DMSO): δ (ppm) 158.47 
(C4), 156.76 (C6), 153.83 (C2), 153.44 (C8), 119.84 (C5). 
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N1-(3,5-di-tert-butyl-4-hydroxybenzyl)-2’3’5’-tri-O-acetyl-8-nitroguanosine (17) 
 
To a solution of butylated hydroxytoluene (24mg, 0.11mmol) in hexane (10ml) was added 
Ag2O (0.77g, 3.30mmol), the resulting mixture was stirred in the dark for 20 minutes to 
generate 2,6-di-tert-butyl-4-methylidenecyclohexa-2,5-dien-1-one. The mixture was filtered into 
a flask containing DMF (1ml), the hexane was removed in vacuo and the remaining solution 
was heated to 37°C. A solution of 8-nitro-2’,3’,5’-tri-O-acetylguanosine (14, 0.05g 0.11mmol) in 
DMF (1ml) was added and the resulting mixture was stirred at 37°C for 1 hour. Upon complete 
conversion, as indicated by TLC and RP-HPLC (Control method 65/35B, page 141), the 
reaction was diluted with EtOAc (15ml) and washed with H2O (3 x 15ml). The combined 
organic extracts were dried under (MgSO4) and concentrated to an orange residue. Purification 
by flash column chromatography (70% Hexane, 30% EtOAc) isolated the title compound 
(24mg, 68%). HRMS (ES+) (m/z): 695.2678 ([M+Na]+); C31H40N6O11Na requires 695.2653 
(+3.5957 ppm). 1H NMR (400 MHz, D3-CD3CN): δ (ppm) 7.14 (2H, s, Ar-H), 6.60-6.61 (1H, d, J 
3.2, H1’), 6.08-6.10 (1H, dd, J 6.2 and 3.2, H2’), 6.06 (2H, br s, NH2), 5.86-5.90 (1H, dd, J 7.2 
and 6.4, H3’), 5.50 (1H, br s, OH), 5.11 (2H, s, NCH2), 4.47-4.51 (1H, dd, J 12.0 and 3.7, H5’), 
4.33-4.35 (1H, ddd, J 6.8, 6.6 and 3.7, H4’), 4.20-4.24 (1H, dd, J 12.0 and 6.1, H5’’), 2.07 (3H, 
s, COCH3), 2.05 (3H, s, COCH3), 1.90 (3H, s, COCH3), 1.37 (18H, s, C(CH3)3). ). 13C NMR 
(100 MHz, CD3CN): δ (ppm) 171.41 (CO), 170.79 (CO), 158.01 (C4), 156.60 (C2), 154.47 
(C6), 151.18 (C8), 138.70 (Ar-C), 126.87 (Ar-C), 125.07 (Ar-C), 118.31 (C5), 89.93 (C1’), 80.41 
(C2), 73.62 (C3), 71.06 (C4), 63.73 (C5’), 45.64 (NCH2), 35.21 (C(CH3)3), 30.44 (C(CH3)3), 
20.84 (COCH3), 20.69 (COCH3). 
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O-tert-butyldimethylsilyl-2-methylphenol (18)249  
 
ortho-Cresol (3g, 27.74 mmol) was dissolved in DCM (12ml) and cooled to 0°C. To the solution 
was added imidazole (3.78g, 55.48mmol) and tert-butyldimethylsilyl chloride (5.02g, 
33.29mmol) over 10 minutes. The reaction was allowed to warm to room temperature and 
stirred for a further 18 hours. The mixture was then diluted with DCM (100ml) and washed with 
5% NaHCO3 (50ml), before drying with MgSO4, filtering and evaporating to give the product as 
a colourless oil (5.99g, 97%). HRMS (CI+) (m/z): 223.1516 ([M+H]+); C13H22OSi requires 
223.1513 (+1.3444 ppm). 1H NMR (400 MHz, CDCl3): δ (ppm) 7.10-7.11 (1H, d, J 7.4, Ar-H3), 
7.01-7.05 (1H, ap t, J 7.7, Ar-H5), 6.81-6.85 (1H, ap t, J 7.4, Ar-H4), 6.74-6.76 (1H, d, J 8.1, 
Ar-H6), 2.19 (3H, s, CH3), 1.00 (9H, s, SiC(CH3)3), 0.20 (6H, s, Si(CH3)2). 13C NMR (100 MHz, 
CDCl3): δ (ppm) 154.02 (Ar-C1), 131.09 (Ar-C3), 129.07 (Ar-C2), 126.72 (Ar-C5), 121.12 (Ar-
C4), 118.65 (Ar-C6), 25.93 (SiC(CH3)3), 18.41 (SiC(CH3)3), 17.00 (CH3), -4.05 (Si(CH3)2). 
 
2-Bromomethyl-O-tert-butyldimethylsilylphenol (19)249 
 
To a solution of O-tert-butyldimethylsilyl-2-methylphenol (18, 2.00g, 8.99mmol) dissolved in 
CHCl3 (30ml) was added N-bromosuccinimide (1.76g, 9.89mmol) and AIBN (0.15g, 0.89mmol). 
The resulting mixture was heated to reflux for 6 hours before cooling to room temperature and 
removing the solvent in vacuo. Hexane (100ml) was added and the precipitate formed was 
removed by filtration. The solvent was removed under reduced pressure and the crude product 
was purified by flash column chromatography (100% Hexane – 1% EtOAc, 99% Hexane) to 
give the title compound as a colourless oil (2.47g, 91%). HRMS (CI+) (m/z): 301.0622 and 
303.0604 ([M+H]+); C13H22OBrSi requires 301.0618 and 303.0603 (+1.3286 and +0.330 ppm). 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.18-7.20 (1H, dd, J 7.6 and 1.7, Ar-H3), 7.02-7.06 (1H, 
ddd, J 9.1, 7.5 and 1.8, Ar-H5), 6.76-6.80 (1H, ddd, J 8.6, 7.5 and 1.1, Ar-H4), 6.66-6.68 (1H, 
dd, J 8.2 and 0.9, H6), 4.39 (2H, s, CH2Br), 0.92 (9H, s, SiC(CH3)3), 0.15 (6H, s, Si(CH3)2). 13C 
NMR (100 MHz, CDCl3): δ (ppm) 154.04 (Ar-C1), 131.34 (Ar-C3), 130.05 (Ar-C2), 128.56 (Ar-
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C6), 121.41 (Ar-C4), 118.77 (SiC(CH3)3), 29.46 (CH2Br), 25.94 (SiC(CH3)3), 18.43 (SiC(CH3)3), 
-3.97 (Si(CH3)3). 
N1-2-hydroxybenzyl-2’3’5’-tri-O-acetyl-8-nitroguanosine (20) and O6,N2-bis-(2-
hydroxybenzyl)-2’3’5’-tri-O-acetyl-8-nitroguanosine (21) 
A solution of 2-bromomethyl-O-tert-butyldimethylsilylphenol (19, 0.27g, 0.88mmol) dissolved in 
DMF (0.3ml) was added to a stirred solution of 8-nitro-2’,3’,5’-tri-O-acetylguanosine (14, 0.10g, 
0.22mmol) in DMF (1.00ml). The mixture was warmed to 37°C followed by addition of 2.64M 
KF(aq) (0.36ml, 0.92mmol). The red solution which formed turned pale orange over the course 
of 10 minutes when the reaction reached completion as confirmed by RP-HPLC (Control 
method 65/35B, page 141) and TLC analysis. The solution was partitioned between EtOAc 
(30ml) and H2O (30ml), the organic layer was further washed with H2O (2 x 30ml) before drying 
over Na2SO4, filtering and evaporating to give the crude product. Purification by flash column 
chromatography (40% Hexane, 60% EtOAc – 20% Hexane, 80% EtOAc) isolated the di-
alkylated (Rf = 0.69 in 80% EtOAc, 20% Hexane) (0.040g, 27%) and mono-alkylated (Rf = 0.29 
in 80% EtOAc, 20% Hexane) (0.049g, 40%) products. 
N1-2-hydroxybenzyl-2’3’5’-tri-O-acetyl-8-nitroguanosine (20) 
 
HRMS (ES+) (m/z): 583.1398 ([M+Na]+); C23H24N6O11 requires 583.1401 (-0.5144 ppm). 1H 
NMR (400 MHz, CD3CN): δ (ppm) 7.25-7.28 (1H, dd, J 7.7 and 1.4, CH2CCH aromatic), 7.16-
7.21 (1H, ap t, J 7.7, COHCHCH aromatic), 6.92-6.94 (1H, d, J 8.07, COHCH aromatic), 6.85-
6.88 (1H, ap t, J 7.5, CH2CCHCH aromatic), 6.6 (1H, d, J 3.0, H1’), 6.52 (1H, bs, OH), 6.06-
6.08 (1H, dd, J 6.2 and 3.0, H2’), 5.88 and 5.92 (1H, dd, J 7.5 and 6.3, H3’) 5.17 (2H, s, 
NCH2Ph), 4.46- 4.50 (1H, dd, J 12.0 and 3.6, H5’), 4.32-4.36 (1H, ddd, J 7.5 and 6.0 and 3.6, 
H4’), 4.12-4.22 (1H, dd, J 6.0 and 12.0, H5’’), 2.06 (3H, s, COCH3), 2.05 (3H, s, COCH3), 1.90 
(3H, s, COCH3). 13C NMR (100 MHz, CD3CN): δ (ppm) 170.10 (CO), 169.50 (CO), 169.48 
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(CO), 156.93 (C4), 155.19 (C6), 153.39 (C8), 149.89 (COH), 142.98 (C2), 129.32 (NCH2C), 
129.21 (CCH), 121.14 (COHCHCH), 120.63 (CCHCH), 115.05 (C5), 114.70 (COHCH), 88.60 
(C1’), 78.97 (C2’), 72.30 (C3’), 69.64 (C4’), 62.30 (C5’), 39.54 (NCH2), 19.45 (COCH3), 19.36 
(COCH3). 
O6,N2-bis-(2-hydroxybenzyl)-2’3’5’-tri-O-acetyl-8-nitroguanosine (21) 
 
HRMS (ES+) (m/z): 689.1823 ([M+Na]+); C30H30N6O12 requires 689.1819 (+0.5804 ppm). 1H 
NMR (400 MHz, CD3CN): δ (ppm) 7.51 (1H, bs, NH), 7.39-7.41 (1H, dd, J 7.4 and 1.5, Ar-H) 
7.29-7.33 (1H, dt, J 7.8 and 1.64, Ar-H), 7.21-7.25 (2H, m, Ar-H), 7.15-7.17 (1H, d, J 8.4, Ar-
H), 6.89-6.95 (3H, ap dq, 8.4, 7.6 and 7.4, Ar-H), 6.61 (1H, d, J 3.0, H1), 6.36 (2H, bs, OH), 
6.06-6.08 (1H, dd, J 6.2and 3.0, H2’), 5.87-5.91 (1H, dd, J 7.4 and 6.2, H3’), 5.18 (2H, s, 
OCH2), 5.17 (2H, s, NHCH2), 4.47-4.50 (1H, dd, J 12.0 and 3.6, H5’), 4.32-4.36 (1H, ddd, J 7.4, 
5.9 and 3.6, H4’), 4.18-4.22 (1H, dd, J 12.0 and 6.0, H5’’), 2.07 (3H, s, COCH3), 2.05 (3H, s, 
COCH3), 1.88 (3H, s, COCH3). 13C NMR (100 MHz, CD3CN); δ (ppm) 171.43 (COCH3), 170.78 
(COCH3), 170.74 (COCH3), 158.00 (C6), 156.67 (COH), 156.40 (C2), 156.06 (C4), 151.12 
(C8), 131.26 (OCH2CCH), 130.86 (OCH2CCHCHCH), 130.45 (OCH2C), 129.85 
(NHCH2CCHCHCH), 124.19 (OCH2CCHCH), 123.44 (NHCH2C), 122.46 (NHCH2CCHCH), 
121.00 (NHCH2CCH), 116.44 (COHCH), 115.95 (COHCH), 113.39 (C5), 89.95 (C1’), 80.23 
(C2’), 73.58 (C3’), 70.94 (C4’), 67.25 (OCH2), 63.59 (C5’), 39.89 (NHCH2), 20.74 (COCH3), 
20.63 (COCH3). 
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g-Glutamyl-S-(2-amino-6-oxo-9-pentofuranosyl-6,9-dihydro-1H-purin-8-
yl)cysteinylglycine (22) 
 
To a solution of 8-nitroguanosine (15, 10mg, 0.03mmol) in 0.1M (pH 9) TRIS HCl (5ml) heated 
to 37°C was added glutathione (46mg, 0.15mmol). The resulting mixture was allowed to stir for 
1 hour during which time the reactions progress was monitored by RP-HPLC (Control method 
0-50, page 140). Purification was carried out by RP-HPLC with the product eluting at 10.34 
minutes. Removal of the solvent in vacuo gave the title compound as an off white solid (11mg, 
61%). HRMS (ES-) (m/z): 587.1511 ([M-H]-); C20H27N8O11S requires 587.1520 (-1.5328 ppm). 
λmax (H2O) 271nm. 1H NMR (400 MHz, D2O): δ (ppm) 5.86-5.88 (1H, d, J 6.8, H1’), 4.78-4.81 
(1H, dd, J 6.6 and 5.9, H2’), 4.51-4.56 (1H, dd, J 8.8 and 4.3, SCH2CH) 4.27-4.29 (1H, dd, J 
5.6 and 2.9, H3’), 4.06-4.08 (1H, ddd, J 6.4, 3.5 and 3.1, H4’), 3.74-3.78 (1H, dd, J 12.7 and 
2.9, H5’), 3.67-3.71 (1H, dd, J 12.7 and 3.9, H5’’), 3.61-3.62 (1H, d, J 4.9, SCH2CH), 3.57-3.58 
(2H, d, J 4.3 NHCH2), 3.49-3.52 (1H, t, J 6.3, CHCH2CH2) 3.21-3.26 (1H, dd, J 14.4 and 8.8, 
SCH2CH), 2.28-2.32 (2H, t, J 7.6, CHCH2CH2), 1.87-1.93 (2H, dt, J 7.6 and 6.3, CHCH2CH2). 
13C NMR (100 MHz, D2O): δ (ppm) 176.19 (CO), 174.81 (CO), 171.08 (CO), 155.61 (C6), 
153.51 (C2)), 148.12 (C4), 144.52 (C8), 119.92 (C5), 88.83 (C1’), 85.81 (C4’), 71.83 (C2’), 
70.61 (C3’), 61.88 (C5’), 54.19 (SCH2CH), 52.97 (CHNH2), 43.34 (CH2COOH), 34.81 (SCH2), 
31.49 (CH2CH2CH), 26.16 (CH2CH2CH).  
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8-Bromo-2’-O-methylguanosine (23) 
 
To a suspension of 2’-O-methylguanosine (0.50g, 1.68mmol) in H2O (5ml) was added bromine 
water (10ml) with vigorous stirring for 2 hours. The mixture was filtered and washed with cold 
iPrOH before drying in a vacuum dessicator for 12 hours, to yield the product as a pale orange 
solid (0.55g, 84%). HRMS (ES+) (m/z): 398.0073 and 400.0061 ([M+Na]+); C11H14N5O5NaBr 
requires 398.0076 and 400.0056 (-0.7538 and -1.2500 ppm). 1H NMR (400 MHz, D6-DMSO): δ 
(ppm) 10.86 (1H, s, NH), 6.55 (2H, s NH2), 5.77 (1H, d, J 6.3, H1’), 4.76 (1H, ap t, J 5.83, H2’), 
4.35 (1H, dd, J 5.2 and 3.7, H3’), 3.88 (1H, dd, J 8.8 and 5.2, H4’), 3.64-3.68 (1H, dd, J 11.8 
and 5.1, H5’), 3.50-3.55 (1H, dd, J 11.8 and 5.7, H5’’), 3.31 (3H, s, 2’OCH3). 13C NMR (100 
MHz, DMSO): δ (ppm) 155.39 (C6), 153.53 (C2), 152.03 (C4), 120.71 (C5), 117.44 (C8), 87.60 
(C1’), 86.22 (C4’), 79.38 (C2’), 68.85 (C3’), 61.79 (C5’), 57.53 (2’OCH3). 
 
g-Glutamyl-S-[2-amino-9-(2-O-methylpentafuranosyl)-6-oxo-6,9-dihydro-1H-purin-8-
yl]cysteinylglycine (24) 
 
To a solution of 8-bromoguanosine (23, 30mg, 0.08mmol) in 0.1M TEAB (5ml) heated to 37°C 
was added glutathione (0.12g, 0.40mmol). The resulting mixture was allowed to stir for 22 
hours during which time the reactions progress was monitored by RP-HPLC (Control method 
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0-22, page 140). Purification was carried out by RP-HPLC with the product eluting at 17.27 
minutes. Removal of the solvent in vacuo yielded the title compound as a white solid (10mg, 
21%). HRMS (ES-) (m/z): 601.1683 ([M-H]-); C21H29N8O11S requires 601.1677 (+0.9981 ppm). 
1H NMR (400 MHz, D2O): δ (ppm) 5.97-5.99 (1H, d, J 7.1, H1’), 4.44-4.51 (2H, m, H2’ and 
SCH2CH), 4.12-4.13 (1H, dd, J 4.6 and 2.5, H4’), 3.76-3.79 (1H, dd, J 12.9 and 2.3, H5’), 3.67-
3.71 (1H, dd, J 12.9 and 2.8, H5’’), 3.60-3.64 (1H, dd, J 10.8 and 3.8, H3’), 3.53-3.59 (3H, m, 
NHCH2 and SCH2), 3.15-3.23 (4H, m, 2’OCH3 and CH2CH2CH), 3.08-3.14 (1H, ap q, J 7.2, 
SCH2), 2.17-2.21 (2H, t, J 7.8, CH2CH2CH), 1.70-1.76 (2H, m, CH2CH2CH). 13C NMR (100 
MHz, D2O): δ (ppm) 179.25 (CO), 176.19 (CO), 175.61 (CO), 171.28 (CO), 159.01 (C6), 
158.83 (C2), 151.47 (C4), 142.18 (C8), 118.73 (C5), 87.42 (C1’), 86.81 (C4’), 80.85 (C2’), 
69.41 (C3’), 62.13 (C5’), 58.08 (2’OCH3), 55.04 (SCH2CH), 53.32 (CHNH2), 43.37 
(CH2COOH), 35.49 (SCH2), 31.87 (CH2CH2CH), 29.10 (CH2CH2CH). 
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N,N’-(Disulfanediyldiethane-2,1-diyl)bis(3’,6’-dihydroxy-3-oxo-3H-spiro[2-benzofuran-
1,9’-xanthene]-5(6)-carboxamide) (25)262 (Prepared as a mixture of the 3 isomers shown 
below) 
 
To a solution of 5(6)-carboxyfluorescein (0.20g, 0.53mmol), N,N,N′,N′-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (0.34g, 0.88mmol), 1-hydroxybenzotriazole 
hydrate (0.6g, 0.44mmol) and diisopropylethylamine (0.15ml, 0.88mmol) in DMF (5ml) was 
added cystamine dihydrochloride (0.50g, 0.22mmol) and the solution was stirred at room 
temperature for 18 hours. The reaction mixture was concentrated and the crude residue was 
triturated with Et2O and CHCl3. Purification by flash column chromatography (Rf = 0.55 in 90% 
DCM, 8% MeOH, 2% AcOH) isolated the title compound as a mixture of isomers (81mg, 42%). 
HRMS (ES+) (m/z): 891.1291 ([M+Na]+); C46H32N2O12S2Na requires 891.1289 (-0.2244 ppm). 
1H NMR (400 MHz, D6-DMSO) The number of hydrogens corresponding to each peak is not 
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given due to the compound being a mixture of 3 isomers: δ (ppm) 10.19 (br s, OH), 9.02-9.07 
(m, NH), 8.87-8.91 (m, NH), 8.46-8.49 (m, g), 8.22-8.28 (m, f), 8.13-8.20 (m, h), 8.04-8.13 (m, 
d), 7.68-7.75 (m, i), 7.38-7.45 (m, e), 6.70 (m, a), 6.57-6.61 (m, b and c), 3.46-3.66 (m, 
NHCH2), 2.83-3.16 (m, CH2SH). 13C NMR (100 MHz, DMSO): δ (ppm) 168.21 (CO), 168.06 
(CO), 164.76 (CO), 164.63 (CO), 159.64 (Cm), 154.81 (Co), 152.73 (Cq), 151.85 (Cl), 140.43 
(Cs), 136.00 (Cf), 134.72 (Cr), 129.44 (Cp) 129.32 (Cc) 129.24 (Cc), 128.33 (Ch), 126.53 (Cd), 
124.98 (Ce), 124.36 (Cn), 123.29 (Cg), 122.25 (Ci), 112.78 (Cb), 112.71 (Cb), 109.14 (Ck), 
109.07 (Ck), 102.28 (Ca), 83.32 (Cj), 53.61 (NHCH2), 38.27 (CH2S). 
 
3’,6’-Dihydroxy-3-oxo-N-(2-sulfanylethyl)-3H-spiro[2-benzofuran-1,9’-xanthene]-5(6)-
carboxamide (26) (Prepared as a mixture of 2 isomers shown below) 
 
To a solution of N,N’-(disulfanediyldiethane-2,1-diyl)bis(3’,6’-dihydroxy-3-oxo-3H-spiro[2-
benzofuran-1,9’-xanthene]-5(6)-carboxamide) (25, 0.11g, 0.12mmol) in degassed MeOH (5ml) 
was added DL-dithiothreitol (0.11g, 0.73mmol) and the resulting solution was heated at 37°C 
for 24 hours. Flash column chromatography (1% MeOH, 99% DCM, 0.1% AcOH - 6% MeOH, 
94% DCM, 0.1% AcOH) afforded the yellow product as mixture of isomers (0.81g, 77%). 
HRMS (ES+) (m/z): 436.0849 ([M+H]+); C23H18NO6S requires 436.0855 (-1.3759 ppm). 1H NMR 
(400 MHz, D6-DMSO): δ (ppm) 10.32 (4H, br s, 4 x OH), 8.45-8.48 (1H, d, J 11.9, g), 8.78-8.85 
(1H, m, NH), 8.93-8.90 (1H, m, NH), 8.23-8.26 (1H, m, f), 8.14-8.21 (1H, m, h), 8.07-8.09 (1H, 
m, i), 7.67-7.70 (1H, m, d), 7.37-7.39 (1H, d, J 7.6, e), 6.56-6.69 (12H, m, 4 x a, 4 x b and 4 x 
c), 3.68-3.64 (1H, dd, J 12.1 and 6.2, NHCH2), 3.57-3.62 (1H, dd, J 12.5 and 6.4, NHCH2), 
3.51-3.56 (1H, dd, J 12.9 and 6.4, NHCH2), 3.45-3.50 (1H, dd, J 13.6 and 6.6, NHCH2), 3.00-
3.04 (1H, ap t, J 6.8, CH2SH), 2.90-2.96 (1H, dd, J 13.3 and 6.5, CH2SH), 2.83-2.86 (1H, ap t, 
J 6.7, CH2SH), 2.71-2.78 (1H, m, CH2SH) 1.24 (2H, br s, 2 x SH). 13C NMR (100 MHz, DMSO): 
δ (ppm) 168.10 (CO), 164.68 (CO), 164.55 (CO), 161.58 (Cm), 151.96 (Co), 151.92 (Cl), 
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147.39 (Cq), 140.89 (Cs), 140.22 (Cf) 136.03 (Cr), 134.43 (Cp), 129.33 (Ch), 129.31 (Cc), 
129.29 (Ce), 129.23 (Cd), 129.15 (Cn), 129.11 (Cg), 124.34 (Ci), 113.54 (Cb), 112.86 (Cb), 
109.22 (Ck), 109.15 (Ck), 102.26 (Ca), 63.20 (Cj), 58.10 (Cj), 48.56 (CH2CH2SH), 42.87 
(CH2CH2SH), 23.20 (CH2SH), 22.89 (CH2SH). 
 
8-Nitro-2-O-methylguanosine (27)194 
 
5’-O,N2-bis-dimethoxytrityl-8-nitro-2’-O-methylguanosine (6, 0.20g, 0.21mmol) was dissolved 
in CHCl3 (3ml) before adding a solution of pTsOH (18mg, 0.11mmol) in MeOH (0.5ml). After 20 
minutes the solvent was removed in vacuo leaving an orange solid which was triturated with 
Et2O three times and EtOAc three times to afford the nucleoside as an orange solid (0.57mg, 
79%). HRMS (ES-) (m/z): 341.0847 ([M-H]-); C11H13N6O7 requires 341.0846 (+0.2932 ppm). 
λmax (H2O) 233 and 408nm. 1H NMR (400 MHz, D6-DMSO): δ (ppm) 11.27 (1H, br s, NH), 7.02-
7.20 (2H, br s, NH2), 6.30-6.31 (1H, d, J 4.6, H1’), 4.86-5.19 (2H, br s, OH), 4.62-4.64 (1H, ap 
t, J 5.3, H2’), 4.36-4.39 (1H, ap t, J 5.9, H3’), 3.78-3.82 (1H, dd, J 10.1 and 6.1, H4’), 3.63-3.67 
(1H, dd, J 11.9 and 3.9, H5’), 3.46-3.51 (1H, dd, J 11.9 and 6.4, H5’’), 3.36 (3H, s, 2’OCH3). 
13C NMR (100 MHz, DMSO): δ (ppm) 156.58 (C4), 155.55 (C6), 152.55 (C8), 143.28 (C2), 
115.19 (C5), 88.87 (C1’), 85.61 (C4’), 80.57 (C2’), 69.21 (C3’), 61.67 (C5’), 57.97 (2’OCH3).  
 
  
Chapter 7  Experimental 
173 
 
8-[(2-{[(3',6'-dihydroxy-3-oxo-3H-spiro[2-benzofuran-1,9'-purin-6-one-xanthen]-5(6)-
yl)carbonyl]amino}ethyl)sulfanyl]-2’-O-methylguanosine (28) (Prepared as a mixture of 2 
isomers shown below) 
 
To a solution of 8-nitro-2’-O-methylguanosine (27, 12mg, 0.034mmol) in 0.1M TEAB was 
added 3’,6’-dihydroxy-3-oxo-N-(2-sulfanylethyl)-3H-spiro[2-benzofuran-1,9’-xanthene]-5(6)-
carboxamide (26, 22mg, 0.050mmol). The reaction mixture was stirred at 37°C for 2 hours. 
The reaction progress was monitored by RP-HPLC (Control method 0-65, page 140) with the 
product eluting at 14.04 minutes. Purification by flash column chromatography (15% MeOH, 
85% DCM) gave the title compound as a bright yellow solid as a mixture of isomers (11mg, 
45%). HRMS (ES-) (m/z): 729.1636 ([M-H]-); C34H29N6O11S requires 729.1615 (+2.8800 ppm). 
1H NMR (500 MHz, D2O): δ (ppm) 7.96 (1H, d, J 1.9, Hi), 7.95 (1H, d, J 1.7, Hf), 7.93 (1H, s, 
d), 7.91 (1H, s, g), 7.18 (1H, s, c), 7.16 (1H, s, c), 7.11-7.12 (2H, m, e and h), 7.09 (1H, s, c), 
7.07 (1H, s, c), 6.87-6.89 (4H, m, a), 8.61-6.82 (1H, d, J 2.3, b), 6.79-6.80 (1H, d, J 2.3, b), 
6.77-6.78 (1H, d, J 2.1, b), 6.74-6.75 (1H, d, J 2.1, b), 5.84-5.86 (2H, d, J 6.1, H1’), 4.51-4.53 
(2H, ap t, J 4.8, H3’), 4.31-4.34 (2H, ap t, J 5.9, H2’), 4.04-4.07 (2H, dd, J 7.6 and 4.0, H4’), 
3.87-3.92 (2H, m, H5’), 3.77-3.80 (2H, m, H5’’), 3.70-3.72 (4H, m, CH2S), 3.22 (6H, s, 2’OCH3), 
2.96-3.02 (4H, m, CH2CH2S). 
 
Diethyl N,N'-bis(tert-butoxycarbonyl)cystinate (29)268 
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To a solution of N,N’-bis(tert-butoxycarbonyl)cystine (0.50g, 1.13mmol) in DCM (5ml) was 
added DMAP (25mg, 0.23mmol) and EtOH (0.38ml). The solution was allowed to stir for 10 
minutes before addition of N,N’-dicyclohexylcarbodiimide (0.70g, 3.40mmol) over 30 minutes. 
The reaction was monitored by TLC and upon completion the solid precipitate was removed by 
filtration and the solvent removed in vacuo. Purification by flash column chromatography (70% 
Hexane, 30% EtOAc) isolated the title compound as a white solid (0.45g, 80%). Rf = 0.49 (70% 
EtOAc, 30% DCM). HRMS (ES+) (m/z): 519.1807 ([M+Na]+); C20H36N2O8S2Na requires 
519.1811 (-0.7704 ppm). 1H NMR (400 MHz, CDCl3): δ (ppm) 5.39-5.41 (2H, d, J 6.6, NH), 
4.56-4.58 (2H, dd, J 6.7 and 5.9, NHCHCH2), 4.21-4.26 (2H, q, J 7.1, CH2CH3), 4.20-4.25 (2H, 
q, J 7.1, CH2CH3), 3.17-3.18 (4H, d, J 3.1, SCH2), 1.45 (18H, s, 2 x C(CH3)3), 1.28-1.32 (6H, t, 
J 7.1, 2 x CH3). 13C NMR (100 MHz, CDCl3): δ (ppm) 170.64 (CO), 155.06 (CO), 80.19 
(C(CH3)3), 61.84 (OCH2), 53.01 (CHCH2), 41.46 (CH2S), 28.30 (C(CH3)3), 14.11 (CH2CH3). 
 
Ethyl N-(tert-butoxycarbonyl)cysteinate (30) 
 
To a stirred solution of diethyl N,N'-bis(tert-butoxycarbonyl)cystinate (29, 0.18g, 0.36mmol) in 
degassed MeOH (5ml) was added DL-dithiothreitol (82mg, 1.42mmol) and the resulting 
mixture was heated to reflux for 18 hours. The progress of the reaction was monitored by TLC 
(30% EtOAc, 70% Hexane), using KMnO4 in order to visualise the product, and upon 
completion the solvent was removed in vacuo. Purification by flash column chromatography 
(10% EtOAc, 90% Hexane) gave the title compound as a white solid (0.13g, 73%). Rf = 0.74 
(70% EtOAc, 30% Hexane). HRMS (ES+) (m/z): 272.0929 ([M+Na]+); C10H19NO4SNa requires 
272.0932 (-1.1026 ppm). 1H NMR (400 MHz, CDCl3): δ (ppm) 5.43-5.45 (1H, d, J 6.61, NH), 
4.57-4.60 (1H, dt, J 7.6 and 3.8, CHCH2SH), 4.22-4.28 (1H, dq, J 7.2 and 4.6, CH2CH3), 4.22-
4.28 (1H, dq, J 10.8 and 7.2, CH2CH3), 4.21-4.27 (1H, dq, J 10.8 and 7.1, CH2CH3), 2.97-3.01 
(2H, dd, 8.7 and 4.3, CHCH2SH), 1.46 (9H, s, C(CH3)3), 1.37-1.41 (1H, t, J 8.9, SH), 1.29-1.32 
(3H, t, J 7.1, CH2CH3). 13C NMR (100 MHz, CDCl3): δ (ppm) 170.42 (CO), 155.26 (CO), 80.33 
(C(CH3)3), 61.99 (OCH2), 54.93 (CHCH2), 28.41 (C(CH3)3), 27.49 (CH2S), 14.34 (CH2CH3). 
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Ethyl S-(guanosine)-N-(tert-butoxycarbonyl)cysteinate (31) 
 
To a solution of 8-nitroguanosine (15, 30mg, 0.09mmol) in 0.1M TEAB (4ml) was added ethyl 
N-(tert-butoxycarbonyl)cysteinate (30, 34mg, 0.14mmol). The reaction mixture was stirred at 
37°C for 4 hours. The reaction progress was monitored by TLC and upon completion the 
solvent was removed in vacuo. Purification by flash column chromatography (5% MeOH, 95% 
DCM) gave the title compound as a yellow solid (33mg, 69%). HRMS (ES+) (m/z): 553.1711 
([M+Na]+); C20H0N6O9SNa requires 553.1693 (+3.2540 ppm). 1H NMR (500 MHz, D6-DMSO): δ 
(ppm) 13.26 (1H, br s, NH), 8.87-8.89 (1H, d, J 10.3, NHCH), 7.70 (2H, br s, NH2), 6.53-6.55 
(1H, d, J 8.2, H1’), 6.18-6.19 (1H, d, J 7.21, 2’OH), 5.83 (1H, br s, 3’OH), 5.68-5.70 (1H, ap t, J 
6.3, 4’OH), 5.52-5.53 (1H, dd, J 7.5 and 6.8, H2’), 4.74-4.81 (1H, dt, J 10.6 and 6.2, CHCH2S), 
4.54-4.60 (3H, m, H3’ and CH2CH3), 4.20-4.24 (1H, dd, J 10.3 and 5.9, H4’), 3.92-4.00 (2H, m, 
H5’ and CH2S), 3.77-3.84 (1H, dd, J 15.1 and 7.4, H5’’), 3.50-3.54 (1H, m, CH2S), 1.05 (9H, s, 
C(CH3)3), 0.78-0.83 (3H, t, J 9.1, CH2CH3). 13C NMR (125 MHz, DMSO): δ (ppm) 170.84 
(COOCH2CH3), 155.80 (OCONH), 155.49 (C6), 153.42 (C1), 152.76 (C4), 142.57 (C8), 117.36 
(C5), 88.49 (C1’), 85.95 (C4’), 78.76 (C(CH3)3), 70.85 (C3’), 70.78 (C2’), 62.26 (C5’), 61.11 
(CH2CH3), 53.35 (CHCH2S), 33.61 (CH2S), 28.32 (C(CH3)3), 14.25 (CH3).  
 
  
Chapter 7  Experimental 
176 
 
Ethyl S-(2’-O-methylguanosine)-N-(tert-butoxycarbonyl)cysteinate (32) 
 
To a solution of 8-nitro-2’-O-methylguanosine (27, 36mg, 0.11mmol) in 0.1M TEAB (4ml) was 
added ethyl N-(tert-butoxycarbonyl)cysteinate (30, 32mg, 0.13mmol). The reaction mixture was 
stirred at 37°C for 2 hours. The reaction progress was monitored by TLC (8% MeOH, 92% 
DCM) and upon completion the solvent was removed in vacuo. Purification by flash column 
chromatography (6% MeOH, 94% DCM) gave the title compound as a pale yellow solid (41mg, 
72%). HRMS (ES+) (m/z): 567.1848 ([M+Na]+); C21H32N6O9SNa requires 567.1849 (-0.1763 
ppm). λmax (H2O) 275nm. 1H NMR (400 MHz, D4-MeOD): δ (ppm) 6.04-6.06 (1H, d, J 6.39, 
H1’), 4.66-4.69 (1H, ap t, J 5.8, H2’), 4.53-4.55 (1H, dd, J 5.1 and 3.0, H3’), 4.42-4.45 (1H, dd, 
J 7.6 and 4.6, SCH2CH), 4.16-4.21 (2H, q, J 7.1, OCH2CH3), 4.10-4.12 (1H, dd, J 3.2, H4’), 
3.86-3.90 (1H, dd, J 12,3 and 3.0, H5’), 3.75-3.79 (1H, dd, J 12.3 and 3.8, H5’’), 3.70-3.75 (1H, 
dd, J 13.9 and 4.5, SCH2), 3.44-3.50 (1H, dd, J 14.2 and 8.3, SCH2), 3.43 (3H, s, 2’OCH3), 
1.40 (9H, s, C(CH3)3), 1.26-1.30 (3H, t, J 7.1, OCH2CH3). 13C NMR (100 MHz, MeOD): 170.47 
(COOEt), 156.94 (COOtBu), 156.04 (C6), 153.44 (C2), 152.26 (C4), 143.95 (C8),117.66 (C5), 
87.87 (C3’), 86.71 (C1’), 81.05 (C2’), 79.33 (C(CH3)3), 69.61 (C4’), 62.36 (C5’), 61.36 
(OCH2CH3), 57.41 (2’OCH3), 53.69 (SCH2CH),35.11 (SCH2),27.24 (C(CH3)3), 13.05 
(OCH2CH3). 
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8-Oxo-2’-O-methylguanosine (33)272 
 
Sodium benzylate was prepared by addition of sodium (6mg) to a stirred freshly distilled benzyl 
alcohol (0.21ml, 17.25mmol) at 60°C in an inert atmosphere until the solution was 
homogeneous. To the solution was added anhydrous DMSO (1ml) and 8-bromo-2’-O-
methylguanosine (23, 60mg, 0.16mmol) in anhydrous DMSO (1.5ml) and the mixture was 
heated at 65°C for 18 hours and then cooled to room temperature. The solvent was removed 
in vacuo and the crude residue was purified by flash column chromatography (10% MeOH, 
90% DCM, 0.01% Et3N) to give 8-benzyloxy-2’-O-methlguanosine. The white solid (30mg) 
dissolved in MeOH (3ml) was treated with 1M HCl (0.3ml) and allowed to stir for 1 hour. 
Removal of the solvents in vacuo followed by trituration of the residue with CHCl3/EtOAc 
afforded the title compound as a pale yellow solid (21mg, 42%). HRMS (ES+) (m/z): 336.0922 
([M+Na]+); C11H15N5O6Na requires 336.0920 (+0.5951 ppm). λmax (H2O) 248 and 290nm. 1H 
NMR (400 MHz, D4-MeOD): δ (ppm) 5.89-5.90 (1H, d, J 5.7, H1’), 4.56-4.59 (1H, ap t, J 5.4, 
H2’), 4.50-4.52 (1H, dd, J 5.2 and 3.7, H3’), 4.01-4.04 (1H, ap q, J 3.6, H4’), 3.82-3.86 (1H, dd, 
J 12.2 and 2.8, H5’), 3.70-3.73 (1H, dd, J 12.2 and 3.9, H5’’), 3.45 (3H, s, 2’OCH3). 13C NMR 
(100 MHz, MeOD): δ (ppm) 153.47 (C4), 152.50 (C6), 152.30 (C8), 147.47 (C4), 99.46 (C5), 
85.66 (C1’), 84.79 (C2’), 80.69 (C3’), 69.76 (C4’), 62.36 (C5’), 57.28 (2’OCH3). 
 
7.3.1 Oligodeoxynucleotide Reactions 
Site 1, adduct 1 
 
To a solution of the site 1 oligodeoxynucleotide (3.1 OD units) dissolved in distilled H2O 
(100µl) was added 1M TRIS.HCl (10µl) and 0.26M glutathione (15µl). The resulting mixture 
was stirred at 37°C for 18 hours during which time the solution changed from yellow to 
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colourless. Monitoring the progress of the reaction and purification of product was carried out 
by RP-HPLC. The composition of the eluent was controlled by the control method 0-65 as 
shown in Figure 7.3 (page 140). Eluted compounds were detected by UV absorbance at both 
254 and 350nm. 
 
Site 1, adduct 2 
 
To a solution of the site 1 oligodeoxynucleotide (3.1 OD units) dissolved in distilled H2O 
(100µl) was added 1M TRIS.HCl (10µl) and 3’,6’-dihydroxy-3-oxo-N-(2-sulfanylethyl)-3H-
spiro[2-benzofuran-1,9’-xanthene]-5(6)-carboxamide (26, 1.7mg). The resulting mixture was 
stirred at 37°C for 24 hours during which time the progress of the reaction was monitored by 
RP-HPLC. Purification of the product by RP-HPLC using control method 0-65 (page 140) 
afforded the title compound. 
 
Site 1, adduct 3 
 
To a solution of the site 1 oligodeoxynucleotide (3.1 OD units) dissolved in distilled H2O 
(100µl) was added 1M TRIS.HCl (10µl) and ethyl N-(tert-butoxycarbonyl)cysteinate (30, 
0.80mg, 100eq). The resulting mixture was stirred at 37°C for 6 hours during which time the 
progress of the reaction was monitored by RP-HPLC. Purification by RP-HPLC using control 
method 0-65 (page 140) afforded the title compound. 
 
Site 2, adduct 3 
 
To a solution of the site 2 oligodeoxynucleotide (5.0 OD units) dissolved in distilled H2O 
(100µl) was added 1M TRIS.HCl (10µl) and ethyl N-(tert-butoxycarbonyl)cysteinate (30, 
0.34mg, 100eq). The resulting mixture was stirred at 37°C for 11 hours during which time the 
Chapter 7  Experimental 
179 
 
progress of the reaction was monitored by RP-HPLC. Purification by RP-HPLC using control 
method 0-65 (page 140) afforded the title compound. 
 
Site 3, adduct 3 
 
To a solution the site 3 oligodeoxynucleotide (2.9 OD units) dissolved in distilled H2O (100µl) 
was added 1M TRIS.HCl (10µl) and ethyl N-(tert-butoxycarbonyl)cysteinate (30, 0.28mg, 
100eq). The resulting mixture was stirred at 37°C for 11 hours during which time the progress 
of the reaction was monitored by RP-HPLC. Purification by RP-HPLC using control method 0-
65 (page 140) afforded the title compound. 
7.3.2 Oligonucleotide reactions characterization 
The RP-HPLC analysis obtained for all oligodeoxynucleotide reactions is shown in Table 7.9 
 HPLC analysis (Control method 0-65) 
Oligodeoxynucleotide reactions Retention time (minutes) 
Starting material Product Starting Material  Product  
Site 1 Site 1, adduct 1 12.32 11.46 
Site 1 Site 1, adduct 2 11.55 18.63 
Site 1 Site 1, adduct 3 12.55 14.78 
Site 2 Site 2, adduct 3 12.52 13.74 
Site 3 Site 3, adduct 3 12.82 14.13 
Table 7.9: HPLC retention times corresponding to the starting materials and products from all 
oligodeoxynucleotide reactions. 
The UV analysis obtained for the purified oligodeoxynucleotide reaction products is shown in 
Table 7.10. 
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 UV analysis 
Product  OD260 units ε (260nm) Conc. in 1ml H2O (μM) 
Site 1, adduct 1 0.057 122100 0.47 
Site 1, adduct 2 0.022 122100 0.18 
Site 1, adduct 3 2.79 122100 22.05 
Site 2, adduct 3 0.67 361200 1.82 
Site 3, adduct 3 1.06 254400 4.17 
Table 7.10: Data obtained from UV analysis of the oligodeoxynucleotide reaction products. 
Table 7.11 shows the theoretical and experimental molecular weights recorded for all of the 
oligodeoxynucleotide reaction products 
 
Mass spectrometry analysis 
Product  Charge Theoretical mass Experimental mass 
Site 1, adduct 1 -3 1435.9145 1435.8939 
Site 1, adduct 2 -6 738.7889 738.7769 
Site 1, adduct 3 -3 1416.5937 1416.5312 
Site 2, adduct 3 nd nd nd 
Site 3, adduct 3 nd nd nd 
Table 7.11: Theoretical and experimental molecular weights for all of the products of the 
oligodeoxynucleotide reactions. Note nd = not determined. 
The [M-nH]n- peaks were then used to give experimental average masses for the parent ions of 
each oligodeoxynucleotide product. 
 Average molecular weight (Parent ion) 
Product  Theoretical mass Experimental mass Error (ppm) 
Site 1, adduct 1 4310.7670 4310.7052 -14.3047 
Site 1, adduct 2 4438.7810 4438.7090 -16.1618 
Site 1, adduct 3 4250.7996 4250.6850 -44.1360 
Site 2, adduct 3 nd nd nd 
Site 3, adduct 3 nd nd nd 
Table 7.12: Theoretical and experimental average molecular weights corresponding to the parent free acid 
of each oligodeoxynucleotide product. Note nd = not determined. 
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7.3.3 Enzymatic digestion  
The site 1 oligodeoxynucleotide (1 OD unit), phosphodiesterase I from Crotalus atrox (10mg, 
0.1U) and aqueous bovine intestinal alkaline phosphatase (2 μl, 40 U) were dissolved in 0.1 M 
TRIS.HCl pH 8.5 (100 μl total volume) and incubated at 37°C for 2 hours. The mixture was 
diluted with water (100 μl) and the protein precipitated with ice cold ethanol (100 μl) prior to 
centrifugation. The supernatant was concentrated in vacuo and dissolved in 0.1 M TEAB (100 
μl) prior to analysis by RP-HPLC.  
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7.4 Experimental procedures for results and discussion 4 
General method for the Yoshikawa phosphorylation302  
The pre-dried nucleoside (0.22mmol) was placed in a dried 2-neck flask, and dissolved in 
trimethylphosphate (2.0 mL). The solution was cooled to 0°C before dropwise addition of POCl3 
(30 microlitres, 0.33 mmol). The reaction mixture was stirred for 90 minutes during which time 
the progress was monitored by IE-HPLC (Control method IE 0-100, page 142). A suspension 
of tri-N-butylammonium pyrophosphate in anhydrous DMF (0.5M, 2ml) and tributylamine (0.16 
mL) was added. After 40 min, the reaction mixture was combined with TEAB (0.1M, 20 mL). 
The composition of the reaction mixture was then analysed by IE-HPLC (Table 7.13 and 7.14). 
Compound Retention time (minutes) Conversion (%) 
Guanosine monophosphate (34) 4.71 68 
8-Bromoguanosine monophosphate (38) 5.37 43 
8-Nitroguanosine monophosphate (40) 4.17 50 
Table 7.13: Showing the nucleoside monophosphates prepared together with their retention times and 
percentage conversions as determined by HPLC. 
Compound Retention time (minutes) Conversion (%) 
Guanosine triphosphate (35) 10.88 40 
8-Bromoguanosine triphosphate (39) 11.15 23 
Table 7.14: Showing the nucleoside triphosphates prepared together with their retention times and 
percentage conversions as determined by HPLC. 
 
N2-Dimethoxytrityl-8-nitroguanosine (36) 
 
N2-Dimethoxytrityl-8-nitro-2’,3’,5’-tri-O-acetylguanosine (13, 0.37g, 0.5mmol) was dissolved in 
NH3 (7M) in MeOH (5ml) and the solution was stirred in a sealed vessel for 36 hours. The 
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reaction mixture was then concentrated in vacuo. Purification by flash column chromatography 
(30% EtOAc, 70% DCM - 60% EtOAc, 40% DCM) gave the desired product as a yellow solid 
(0.20g, 65%). HRMS (ES+) (m/z): 653.1956 ([M+Na]+); C31H30N6O9Na requires 653.1972 (-
2.4495 ppm). 1H NMR (400 MHz, D6-DMSO): δ (ppm) 7.17-7.32 (9H, m, DMT Ar-H), 6.84-6.86 
(4H, m, DMT CHCOCH3), 5.94-5.95 (1H, d, J 5.0, H1’), 3.99-4.03 (1H, dd, J 6.3 and 5.1, H2’), 
3.76 (6H, s, Ar-OCH3), 3.64-3.69 (1H, J 10.5, 6.6 and 4.6, H4’), 3.51-3.54 (1H, ap t, J 6.1, H3’), 
3.25-3.31 (2H, m, H5’). 13C NMR (100 MHz, DMSO): δ (ppm) 160.14 (Ar-C), 158.94 (C4), 
154.33 (C6), 152.20 (C8), 146.00 (C2), 145.74 (Ar-C), 137.76 (Ar-C), 137.57 (Ar-C), 131.10 
(Ar-C), 131.06 (Ar-C), 129.75 (Ar-C), 129.15 (Ar-C), 128.26 (Ar-C), 116.17 (C5), 114.41 (Ar-C), 
91.99 (C1’), 86.10 (C4’), 72.03 (NHC), 71.15 (C2’), 70.99 (C3’), 63.73 (C5’), 55.75 (Ar-C). 
 
8-Bromoguanosine (37) 
 
To a solution of guanosine (5.00g, 17.65mmol) suspended in distilled H2O (30ml) was added 
aliquots of saturated bromine water (ca. 60ml) with vigorous stirring. Once the solution was 
permanently yellow, the mixture was filtered and washed with cold iPrOH, before drying in a 
vacuum dessicator for 12 hours, to yield the product as a pale orange solid (6.39g, 77%). 
HRMS (ES+) (m/z): 383.9924 and 385.9915 ([M+Na]+); C10H12N5O5NaBr requires 383.9919 
and 385.9899 (+1.3021 and +4.1452 ppm). 1H NMR (400MHz, D6-DMSO): δ (ppm) 10.84 (1H, 
s, NH), 6.52 (2H, br s, NH2), 5.68-5.70 (1H, d, J 6.4, H1’), 5.48-5.45 (1H, d, J 6.2, 2’OH), 5.11-
5.13 (1H, d, J 5.2, 3’OH), 4.99-5.04 (1H, dd, J 11.9 and 6.1, H2’), 4.93-4.96 (1H, dd ,J 6.4 and 
5.7, 5’OH), 4.12-4.16 (1H, ddd, J 8.6, 5.1 and 3.6, H3’), 3.84-3.88 (1H, ddd, J 8.6, 5.2 and 3.9, 
H4’), 3.63-3.69 (1H, ddd, J 11.8, 5.2 and 4.9 H5’), 3.49-3.55 (1H, ddd, J 12.0, 6.0 and 5.8, 
H5’’). 13C NMR (100 MHz, DMSO): δ (ppm) 154.86 (C6), 153.66 (C2), 151.94 (C4), 121.55 
(C5), 117.63 (C8), 90.02 (C1’), 86.22 (C4’), 70.87 (C3’), 70.65 (C2’), 62.36 (C5’). 
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5’-tert-Butyldimethylsilylguanosine (41) 
 
To a stirred solution of guanosine (5.00g, 17.7mmol) in anhydrous DMF (50ml) was added 
imidazole (2.40g, 35.3mmol) and TBDMSCl (5.32g, 35.3mmol). The reaction was stirred at 
room temperature under an atmosphere of N2 for 18 hours before being cooled to 0°C and 
quenched with ice cold H2O. The resulting precipitate was then filtered and washed with H2O 
(50ml) and acetone (50ml) to afford the title compound as a white solid (4.98g, 71%). HRMS 
(ES+) (m/z): 420.1680 ([M+Na]+); C16H27N5O5SiNa requires 420.1679 (+0.2380 ppm). 1H NMR 
(400 MHz, D6-DMSO): δ (ppm) 10.66 (1H, br s, NH), 7.85 (1H, s, H8), 6.51 (2H, br s, NH2), 
5.70-5.71 (1H, d, J 5.4, H1’), 5.49-5.50 (1H, d, J 5.7, 2’OH), 5.17-5.19 (1H, d, J 4.8, 3’OH), 
4.31-4.35 (1H, dd, J 10.4 and 5.3, H2’), 4.07-4.11 (1H, dd, J 8.7 and 4.4, H3’), 3.88-3.90 (1H, 
dd, J 7.8 and 3.9, H4’), 3.78-3.82 (1H ,dd, J 11.4 and 3.7, H5’), 3.69-3.73 (1H, dd, J 11.4 and 
4.1, H5’’), 0.87 (9H, s, C(CH3)3), 0.04 (6H, s, Si(CH3)2). 13C NMR (100 MHz, DMSO): δ (ppm) 
156.77 (C6), 153.76 (C2), 151.38 (C4), 134.91 (C8), 116.57 (C5), 86.72 (C1’), 84.33 (C4’), 
73.85 (C2’), 69.99 (C3’), 63.03 (C5’), 25.87 (C(CH3)3), 18.08 (C(CH3)3), -5.39 (SiCH3), -5.44 
(SiCH3). 
 
5’-tert-butyldimethylsilyl-2’-3’-di-O-acetylguanosine (42) 
 
Acetic anhydride (2.08ml, 22.0mmol) was added dropwise to an ice cooled mixture of 5’-tert-
butyldimethylsilylguanosine (41, 4.39g, 11.0mmol), triethylamine (6.16ml, 44.2mmol) and 
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DMAP (0.135g, 1.10mmol) in MeCN (50ml). The reaction mixture was then allowed to warm to 
room temperature. There was complete solubilisation when the reaction had gone to 
completion. The reaction was quenched with MeOH and the solvent removed in vacuo. The 
residue was then re-dissolved in DCM (50ml) and washed with H2O (3 x 50ml) before drying 
over MgSO4, filtering and concentrated to yield the product as a white solid (5.02g, 94%). 
HRMS (ES+) (m/z): 504.1907 ([M+Na]+); C20H31N5O7SiNa requires 504.1890 (+3.3718 ppm). 
1H NMR (400 MHz, D6-DMSO): δ (ppm) 10.74 (1H, br s, NH), 7.84 (1H, s, H8), 6.58 (2H, br s, 
NH2), 5.97-5.99 (1H, d, J 7.1, H1’), 5.66-5.69 (1H, dd, J 7.1 and 5.5, H2’), 5.40-5.42 (1H, dd, J 
5.4 and 2.6, H3’), 4.20-4.21 (1H, dd, J 6.2 and 3.4, H4’), 3.83-3.85 (2H, m, H5’), 2.11 (3H, s, 
COCH3), 2.00 (3H, s, COCH3), 0.88 (9H, s, C(CH3)3), 0.07 (6H, s, Si(CH3)2). 13C NMR (100 
MHz, DMSO): δ (ppm) 169.52 (CO), 169.27 (CO), 156.66 (C6), 154.06 (C2), 151.36 (C4), 
134.38 (C8), 116.56 (C5), 83.38 (C1’), 82.87 (C4’), 72.25 (C2’), 70.94 (C3’), 62.90 (C5’), 25.76 
(C(CH3)3), 20.47 (COCH3), 20.18 (COCH3), 17.98 (C(CH3)3), -5.53 (SiCH3), -5.58 (SiCH3). 
 
5’-tert-Butyldimethylsilyl-8-bromoguanosine (43) 
 
To a solution of 8-bromoguanosine (37, 10.80g, 29.8mmol) in anhydrous DMF (60ml) was 
added imidazole (4.06g, 59.6mmol) and TBDMSCl (8.98g, 59.6mmol). The reaction was stirred 
at room temperature under an atmosphere of N2 until the reaction reached completion (18 
hours) before being cooled to 0°C and quenched with ice cold H2O. The resulting precipitate 
was then washed with H2O (100ml) and acetone (100ml) to afford the title compound as a pale 
orange solid (11.79g, 83%). HRMS (ES+) (m/z): 498.0786 and 500.0768 ([M+Na]+); 
C16H26N5O5NaSiBr requires 498.0784 and 500.0764 (+0.4015 and +0.7999 ppm). 1H NMR 
(400 MHz, D6-DMSO): δ (ppm) 10.83 (1H, s, NH), 6.56 (2H, br s, NH2), 5.70-5.71(1H, d, J 5.7, 
H1), 5.53 (1H, d, J 5.9, 2’OH), 5.08-5.10 (1H, d, J 5.8, 3’OH), 5.06-5.08 (1H, dd, J 5.7, H2’) 
4.24 (1H, dd, J 9.8 and 5.1, H4’), 3.81-3.86 (2H, m, H4’ and H5’), 3.71-3.76 (1H, dd, J 12.4 and 
7.7, H5’’), 0.84 (9H, s, SiC(CH3)3), 0.00 (3H, s, SiCH3), -0.01 (3H, s, SiCH3). 13C NMR (100 
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MHz, DMSO): δ (ppm) 155.86 (C6), 153.84 (C2), 152.65 (C4), 121.24 (C8), 117.16 (C5), 90.17 
(C1’), 85.25 (C4’), 70.57 (C2’), 70.31 (C3’), 63.77 (C5’), 26.14 (SiC(CH3)3), 18.34 (SiC(CH3)3), -
4.96 (SiCH3), -5.01 (SiCH3). 
 
5’-tert-Butyldimethylsilyl-2’-3’-di-O-acetyl-8-bromoguanosine (44) 
 
Acetic anhydride (2.08ml, 22.0mmol) was added dropwise to an ice cooled mixture of 5’-tert-
butyldimethylsilyl-8-bromoguanosine (43, 4.39g, 11.0mmol), triethylamine (6.16ml, 44.2mmol) 
and DMAP (0.135g, 1.10mmol) in MeCN (50ml). The reaction mixture was then allowed to 
warm to room temperature. There was complete solubilisation when the reaction had gone to 
completion. The reaction was quenched with MeOH and the solvent removed in vacuo. The 
residue was then redissolved in DCM (50ml) and washed with H2O (3 x 50ml) before drying 
over MgSO4, filtering and concentrated to yield the product as a white solid (5.02g, 94%). 
HRMS (ES+) (m/z): 582.1003 and 584.0950 ([M+Na]+); C20H30N5O7BrSiNa requires 582.0996 
and 584.0975 (+1.2025 and -4.2801 ppm). 1H NMR (400 MHz, D6-DMSO): δ (ppm) 10.95 (1H, 
br s, NH), 6.56 (2H, br s, NH2), 6.14-6.17 (1H, dd, J 6.1 and 5.0, H2’), 5.88-5.89 (1H, d, J 4.9, 
H1’), 5.58-5.62 (1H, ap t, J 5.9, H3’), 4.11-4.15 (1H, dd, J 10.2 and 5.5, H4’), 3.81-3.91 (2H, m, 
H5’), 2.10 (3H, s, COCH3), 2.05 (3H, s, COCH3), 0.80 (9H, s, SiC(CH3)3), -0.04 (6H, s, 2 x 
SiCH3). 13C NMR (100 MHz, DMSO); δ (ppm) 169.41 (CO), 169.36 (CO), 155.47 (C6), 153.75 
(C2), 152.06 (C4), 120.10 (C8), 117.16 (C5), 87.17 (C1’), 82.26 (C4’), 70.86 (C2’), 69.89 (C3’), 
62.48 (C5’), 25.67 (SiC(CH3)3), 20.34 (COCH3), 20.24 (COCH3), 17.90 (SiC(CH3)3), -5.52 
(Si(CH3)2).  
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N2-Dimethoxytrityl-5’-tert-butyldimethylsilyl-2’-3’-di-O-acetal-8-bromoguanosine (45) 
 
5’-tert-Butyldimethylsilyl-2’-3’-di-O-acetyl-8-bromoguanosine (44, 3.34g, 5.96mmol) was co-
evaporated to dryness with anhydrous pyridine before re-dissolving in anhydrous pyridine 
(25ml). 4,4’-Dimethoxytrityl chloride (3.03g, 8.94mmol) was added slowly over 5 minutes to the 
stirred solution of the nucleoside under an atmosphere of N2. The reaction was warmed to 
room temperature and stirred for 18 hours. The solution was concentrated in vacuo and the 
resulting orange residue was partitioned between DCM and H2O. The organic extracts were 
then washed with NaHCO3, dried under MgSO4, filtered and concentrated to give the crude 
product as an orange solid. Purification by flash column chromatography eluting 2% MeOH in 
DCM yielded the title compound as a white solid (4.36g, 84%). HRMS (ES-) (m/z): 860.2345 
and 862.2327 ([M-H]-); C41H47N5O9BrSi requires 860.2326 and 862.2306 (+2.2087 and 
+2.4355 ppm). 1H NMR (400 MHz, D6-DMSO): δ (ppm) 7.77 (1H, br s, NH), 7.12-7.36 (9H, m, 
DMT Ar-H), 6.83-6.86 (4H, m, CHCOCH3), 6.76-6.78 (1H, m, H1’), 5.38-5.42 (2H, m, H2’ and 
H3’), 4.88-4.92 (1H, m, H4’), 3.84-3.88 (1H, dd, J 10.8 and 5.3, H5’), 3.71 (6H, s, Ar-OCH3), 
3.64-3.66 (1H, d, J 5.1, H5’’), 2.05 (3H, s, COCH3), 1.89 (3H, s, COCH3), 0.84 (9H, s, C(CH3)3), 
0.00 (6H, s, Si(CH3)2). 13C NMR (100 MHz, DMSO): δ (ppm) 168.97 (CO), 168.79 (CO). 157.76 
(Ar-C), 157.77 (Ar-C), 155.11 (C6), 151.52 (C2), 151.23 (C4), 144.59 (Ar-C), 135.29 (Ar-C), 
129.63 (Ar-C), 129.59 (Ar-C), 128.26 (Ar-C), 127.83 (Ar-C), 127.66 (Ar-C), 126.54 (Ar-C), 
120.87 (C8), 117.39 (C5), 112.96 (Ar-C), 113.19 (Ar-C), 112.92 (Ar-C), 87.18 (C1’), 81.23 
(C4’), 69.67 (NHC), 69.36 (C2’), 69.24 (C3’), 62.36 (C5’), 54.93 (Ar-C), 54.91 (Ar-C), 25.64 
(SiC(CH3)3), 20.14 (COCH3), 19.90 (COCH3), 17.85 (SiC(CH3)3), -5.45 (SiCH3), -5.51 (SiCH3). 
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